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Abstract 
 
Microdeletions and microduplications at the chromosomic locus ch15q11.2 have been linked to 
an increased risk of developing several psychiatric and neurodevelopmental conditions. Abnormal 
expression levels of CYFIP1, one of the genes within this region, have been shown by several 
studies to cause alterations to the morphology and physiology of neuronal cells. However, despite 
its specific expression in progenitors of the developing cortex, little is known about the role played 
by CYFIP1 in neural development. 
This thesis presents an investigation of the biological mechanisms, through which CYFIP1 affects 
cortex development in vitro using human embryonic stem cells (hESCs). To this end, lines of hESCs 
either expressing a CYFIP1 transgene (CYFIP1tg) or harbouring a loss-of-function deletion 
(CYFIP1ko) were derived to mimic increased and decreased level of CYFIP1 expression, 
respectively, and differentiated into cortical glutamatergic neurons. Disruptions to the normal 
levels of CYFIP1 resulted into abnormal formation of neural rosettes and altered kinetics of 
neuronal differentiation. Importantly, CYFIP1 overexpression seemed to promote self-renewal of 
the progenitor pool, while loss of this gene had an opposite effect. 
Whole-genome transcriptomic analysis revealed the dysregulation of numerous pathways, 
including WNT signalling, cell adhesion and mitochondria metabolism. In line with this, the 
expression levels of N-Cadherin and the phosphorylation pattern of β-Catenin suggested that the 
signalling axis involving these two proteins is altered in CYFIP1tg and CYFIP1ko cortical 
progenitors. Moreover, pharmacological inhibition of WNT and AKT, which mediate this signalling, 
was able to rescue the excessive proliferation of NPCs associated with CYFIP1 overexpression. 
Finally, the presence of altered mitochondrial dynamics in CYFIP1tg and CYFIP1ko NPCs and 
neurons was validated using a high-content screening system. 
These data demonstrate that CYFIP1 plays a role in the regulation of cortex development and, 
consequently, in the clinical manifestations associated with 15q11.2 CNVs. Furthermore, they 
strengthen the hypothesis of a developmental origin for psychiatric conditions like schizophrenia 
and autism spectrum disorders.  
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1 Introduction 
 
Psychiatric disorders such as autism spectrum disorders (ASD) and schizophrenia (SZ) are common 
conditions that, combined, are estimated to affect more than 1% of the population worldwide 
(Baxter et al., 2015; Saha et al., 2005 and WHO.int). Many people affected by these disorders 
require long-term care and represent a high economic burden for society (Buescher et al., 2014; 
Chong et al., 2016).  
SZ usually becomes manifest post-puberty and is characterised by a combination of symptoms 
that are classified into “positive”, such as hallucinations and delusions, “negative”, such as apathy 
and lack of speech, and “cognitive”, which include defects of working memory, attention and 
verbal abilities (Patel et al., 2014). ASD are a group of heterogeneous conditions that usually arise 
during early childhood and are defined by the presence of some common aspects, such as 
restrictive and repetitive behaviours and deficits in social interaction and communication 
(Fakhoury, 2015).  
Both SZ and ASD arise from a combination of genetic and environmental factors. The last few 
years have seen the identification of hundreds of chromosomic loci responsible for an increased 
risk of developing these conditions. However, the way in which genetic mutations contribute to 
the disease pathology and, ultimately, the cellular mechanisms underlying these conditions are 
still largely unknown. To date, this represents perhaps the biggest obstacle to the development 
of new therapies. In vitro models in the form of human pluripotent stem cells (hPSCs)-derived 
neurons represent a promising approach to investigate the function of disease-risk genes and can 
also provide a platform for drug development studies.  
1.1 Relevance of Ch15q11.2 CNVs in the context of psychiatric disorders 
1.1.1 Genetics of psychiatric disorders: an overview 
Twin and adoption studies have been fundamental to understand the contribution of genetic and 
environmental factors to the aetiology of psychiatric disorders. The environmental factors most 
commonly associated with SZ are birth or residence in urban areas, season of birth, usually linked 
to a higher risk of pre-natal infections, starvation, obstetric complications, and advanced paternal 
age (Gejman et al., 2011). However, all these factors seem to have a relatively small effect 
compared to the influence of genetics.  
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Heritability, a parameter used to estimate how much of the variability of a phenotypic trait is due 
to the genetic variability in a given population, is estimated to be above 80% for SZ (Sullivan, 
2005). In fact, monozygotic twins have a higher concordance rate than dizygotic twins and the risk 
of SZ in the offspring of schizophrenic parents is the same whether they are raised by their 
biological or adoptive unaffected parents (Gejman et al., 2011).  Similarly, several studies 
estimated ASD heritability between 50% and 90% and the most commonly implicated 
environmental factors include prenatal viral infection and exposure to toxins, advanced paternal 
and maternal age and prenatal and perinatal stress (Freitag et al., 2010; Grabrucker, 2013; Kim & 
Leventhal, 2015). 
The first attempts to discover the genetic causes of SZ and ASD were represented by linkage and 
candidate gene studies. Linkage studies are based on the concept that alleles close together are 
transmitted together, as a unit, through meiosis (Lander & Kruglyak, 1995). Thus, they were used 
to map chromosomal regions that follow the same inheritance pattern between affected family 
members. In the context of SZ, some of the most significant chromosomic regions that emerged 
from these studies are represented by 1q21-22 (Brzustowicz et al., 2000; Rosa et al., 2002) and 
6p24-p22 (Moises et al., 1995; Schwab et al., 2000; Straub, 1995). Examples of loci associated to 
ASD by at least two independent linkage studies are represented by 3p25 (Lauritsen et al., 1999; 
McCauley et al., 2005; Ylisaukko-Oja et al., 2006) and 7q35 (Alarcón et al., 2008; Alarcón et al., 
2002; Ylisaukko-Oja et al., 2006). 
The candidate gene approach is a hypothesis-driven method, which aims to test if the frequency 
of a specific allele/haplotype of a gene of interest is higher in affected than unaffected subjects 
(Kwon & Goate, 2000). Well known candidate genes include Neuregulin 1 (NRG1) (Stefansson et 
al., 2002), Disrupted in schizophrenia 1 (DISC1) (Blackwood et al., 2001) and Dysbindin (DTNBP1) 
(Straub et al., 2002) for SZ and the oxytocin receptor (OXTR) (Wu et al., 2005), Contactin-
associated protein-like 2 (CNTNAP2)(Arking et al., 2008) and Reelin (RELN) (Persico et al., 2001) 
for ASD.   
Several more chromosomic loci and genes were identified by these early genetic studies, but most 
of them were found difficult to reproduce. Two reasons for this could be the small effect of the 
genetic variants analysed and the small sample size (Farrell et al., 2015; Freitag et al., 2010). 
Indeed, linkage studies had been successful in identifying the cause of disorders following a 
Mendelian pattern of inheritance, such as mutations of presenilin 1 in Alzheimer’s disease, but it 
is now known that most psychiatric disorders are likely caused by several common genetic 
variations with different degrees of penetrance (George-hyslop, 2000; Schellenberg et al., 1992; 
Sherrington et al., 1995).  
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More significant advances have been achieved in recent years thanks to the rapid evolution of 
new high-throughput microarray platforms and the formation of large scientific consortia. This 
has facilitated efficient processing of the genetic information of large cohorts of patients and 
controls. Genome-wide association studies (GWAS), analysis of chromosomic copy number 
variations (CNVs) and exome sequencing are the new techniques that significantly contributed to 
such advances. 
 
(I) GWAS 
GWAS are based on the analysis of markers across the whole genome to determine if some 
genetic variations are more abundant in individuals affected by a disease than the unaffected 
subject population. A genetic marker associated with the disease can represent in itself a 
causative variant, or it can be in linkage disequilibrium (LD) with the causative variant (Bush & 
Moore, 2012). This approach is hypothesis-independent and has led to the identification of many 
common variants, in the form of single nucleotide polymorphisms (SNPs) or chromosomic copy 
number variations (CNVs) (McCarroll, 2008).  
SNPs are single base substitutions, which are relatively common in the genome (~1 every 300 
bases) and within populations (>5%) (Schwab & Wildenauer, 2013). Overall it is estimated that 
each SNP associated with a psychiatric disorder is responsible for a small contribution towards 
the total genetic risk (Gejman et al., 2011; Yoo, 2015). Table 1.1 contains a list of genes in which 
SNPs for ASDs and SZ have been confirmed by more than one study. 
 
Table 1.1 Genes in which GWAS have reported the presence of risk variants linked to ASD or SZ. 
Disorder 
Gene 
symbol 
Gene name References 
ASD CDH9 Cadherin 9 (Ma et al., 2009; Wang et al., 2009) 
ASD CDH10 Cadherin 10 (Ma et al., 2009; Wang et al., 2009) 
ASD CNTNAP2 
Contactin-associated protein-
like 2 
(Anney et al., 2012; Arking et al., 
2008) 
ASD JARID2 
Jumonji and AT-Rich Interaction 
Domain Containing 2 
( Liu et al., 2015; Weiss, Arking et al., 
2009) 
ASD MACROD2 
MACRO Domain-Containing 
Protein 2 
(Anney et al., 2010, 2012; Vieland et 
al., 2017) 
ASD SEMA5A Semaphorin 3A (Vieland, 2017; Weiss et al., 2009) 
SZ AKT3 AKT Serine/Threonine Kinase 3 (Ripke et al., 2013, 2014) 
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SZ ARL3 
ADP Ribosylation Factor Like 
GTPase 3 
(Ripke et al., 2014; H. Yu et al., 2016) 
SZ AS3MT Arsenite Methyltransferase (Ripke et al., 2014; H. Yu et al., 2016) 
SZ CACNA1C 
Calcium Voltage-Gated Channel 
Subunit Alpha1C 
(Purcell et al., 2009; Ripke et al., 
2013, 2014) 
SZ CNNM2 
Cyclin And CBS Domain Divalent 
Metal Cation Transport 
Mediator 2 
(Ripke et al., 2011, 2014) 
SZ CSMD1 
CUB And Sushi Multiple 
Domains 1 
(Ripke et al., 2011, 2014) 
SZ CSMD2 
CUB And Sushi Multiple 
Domains 2 
(Ripke et al., 2014; H. Yu et al., 2016) 
SZ ITIH3 
Inter-Alpha-Trypsin Inhibitor 
Heavy Chain 3 
(Ripke et al., 2013, 2014) 
SZ MAD1L1 
MAD1 Mitotic Arrest Deficient 
Like 1 
(Ripke et al., 2013, 2014) 
SZ MIR137 MicroRNA 137 (Ripke et al., 2011, 2013) 
SZ NRGN2 Neurogranin 
(Ripke et al., 2014; Stefansson et al., 
2009) 
SZ NT5C2 5'-Nucleotidase, Cytosolic II (Ripke et al., 2011, 2014) 
SZ PCGEM1 
PCGEM1, Prostate-Specific 
Transcript (Non-Protein Coding) 
(Ripke et al., 2011, 2014) 
SZ TCF4 Transcription Factor 4 
(Ripke et al., 2011, 2014; Stefansson 
et al., 2009) 
SZ TSNARE1 T-SNARE Domain Containing 1 (Ripke et al., 2013, 2014) 
SZ VRK2 Vaccinia Related Kinase 2 (Ripke et al., 2014; H. Yu et al., 2016) 
SZ ZNF804A Zinc Finger Protein 804A 
(O’Donovan et al., 2008; Ripke et al., 
2014; Steinberg et al., 2011; 
Williams et al., 2011) 
 ASD, autism spectrum disorder; SZ, schizophrenia. 
 
 
CNVs are DNA segments of at least 1kb that are found deleted or duplicated in different genomes 
(Hosak, 2013). They can be inherited or they can be the result of de novo mutations, as they 
originate through several mutational mechanisms, mainly non-allelic homologous recombination 
between regions containing low-copy repeats (Gu, Zhang, Lupski, 2008). These chromosomic 
rearrangements are very frequent in the genome and contribute to human genomic variation 
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(Itsara et al., 2009). Interestingly, several studies on both SZ and ASD reported a higher frequency 
of de novo CNVs in the genome of affected individuals than in the control population 
(International Schizophrenia Consortium, 2008; Marshall et al., 2008a; Sebat et al., 2010; Xu et 
al., 2008). These findings suggest that genomic instability may be contributing to the pathology of 
these disorders.   
CNVs affect the expression level of the genes located in the deleted or duplicated regions. A 
popular interpretation of the link between this mechanism and psychiatric disorders is that CNVs 
alter the tightly regulated expression of dosage-sensitive genes important in neural development 
(Hosak, 2013; Tam et al., 2009). In agreement with this, it has been demonstrated that pathogenic 
CNVs are enriched for genes classified as ohnologs, when compared with CNVs identified in the 
general population. Ohnologs are duplicated genes originated by whole genome duplication 
events during vertebrate evolution. Many of them are developmental genes and members of 
protein complexes that are known to be highly dosage-sensitive (McLysaght et al., 2014). The 
effects of such changes in gene dosage are very variable, as several CNVs are associated with more 
than one disorder and can be also present, at lower frequency, in healthy control populations 
(Malhotra & Sebat, 2012). The most characterised CNVs associated to date with SZ and/or ASD 
are listed in Table 1.2 
 
 
Table 1.2 CNVs increasing risk for ASD and/or SZ 
CNV Disorder(s) References 
1q21.1 del/dup ASD/SZ 
(Bucan et al., 2009; Kirov et al., 2014a; Levinson et al., 
2011; Pinto et al., 2010a; Rees et al., 2014; Sanders et al., 
2011; Stefansson et al., 2008; Vacic et al., 2011a) 
2p16.3 del  ASD/SZ 
(Bremer et al., 2011; Glessner et al., 2009a; Kirov et al., 
2014b; Pinto et al., 2010b; Rees et al., 2014) 
3q29 del ASD/SZ 
(Kirov et al., 2014b; Levinson et al., 2011; Mulle et al., 
2010; Pinto et al., 2010b; Rees et al., 2014; Sanders et al., 
2011; Vacic et al., 2011b) 
15q11.2 del/dup ASD/SZ 
(Kirov et al., 2009, 2014b; Rees et al., 2014; Stefansson et 
al., 2008; Tam et al., 2010) 
15q11.2-13.1 dup ASD/SZ 
(Christian et al., 2008; Glessner et al., 2009b; Marshall et 
al., 2008a; Pinto et al., 2010b; Sanders et al., 2011; Vacic 
et al., 2011b) 
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15q13.3 del ASD/SZ 
(Bremer et al., 2011; Kirov et al., 2014b; Levinson et al., 
2011; Pinto et al., 2010b; Rees et al., 2014; Sanders et al., 
2011; Stefansson et al., 2008; The International 
Schizophrenia Consortium, 2008; Vacic et al., 2011b) 
16p13.11 dup ASD/SZ 
(Ingason et al., 2011; Kirov et al., 2014b; Pinto et al., 
2010b; Rees et al., 2014; Sanders et al., 2011; Vacic et al., 
2011b) 
16p11.2 del/dup ASD/SZ 
(Bremer et al., 2011; Glessner et al., 2009b; Kirov et al., 
2014b; Levinson et al., 2011; Marshall et al., 2008b; 
McCarthy et al., 2009; Pinto et al., 2010b; Rees et al., 2014; 
Sanders et al., 2011) 
17p12 del ASD/SZ 
(Kirov et al., 2009, 2014b; Pinto et al., 2010b; Rees et al., 
2014; Sanders et al., 2011; Vacic et al., 2011b) 
22q11.2 del/dup ASD/SZ 
(Bremer et al., 2011; Glessner et al., 2009b; Kirov et al., 
2014b; Marshall et al., 2008b; Pinto et al., 2010b; Rees et 
al., 2014; Sanders et al., 2011; Stefansson et al., 2008; The 
International Schizophrenia Consortium, 2008; Vacic et al., 
2011b) 
ASD, autism spectrum disorder; SZ, schizophrenia; del, deletion; dup, duplication. 
 
(II) Exome sequencing 
GWAS studies are, by definition, limited to the identification of common SNPs and CNVs and may 
therefore fail to identify highly penetrant mutations that occur at a lower frequency in a 
population, due to the decreased reproductive fecundity of the affected individuals (Power et al., 
2013). Because of the large effect size of such rare variants, they are likely to be easier in their 
functional interpretation, providing an important contribution to the understanding of the 
disorders with which they are associated (Gratten, 2016).  
The identification of rare genetic mutations requires the application of DNA sequencing 
technologies, such as whole-exome sequencing (WES). This type of analysis can be performed on 
case-parents trios, to investigate the effect of de novo mutations, or on cohorts of cases and 
controls. WES is still an emerging approach in the field of psychiatric disorders, likely because of 
its relatively high cost compared to older technologies. For the same reason, the studies published 
so far were conducted on small samples (Kato, 2015; Sener, Canatan, & Ozkul, 2016). 
So far in the context of SZ, the application of WES has not strongly implicated any individual genes, 
with the exception of SET Domain Containing 1A (SETD1A) (Singh et al., 2016). However, several 
studies have reported that rare (1:10000) and ultra-rare (1:100000) variants disrupting protein-
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coding genes are present at a higher frequency in SZ cases than in controls and that they are 
particularly enriched in specific gene sets, such as voltage-gated calcium channels and synaptic 
proteins (Genovese et al., 2016; Purcell et al., 2014).  A higher frequency of gene-disrupting 
mutations in cases versus controls has also been reported by WES studies for ASDs (Iossifov et al., 
2012).  The sequencing studies on ASDs present in the literature are several, but they are all based 
on a maximum of a few hundred individuals. Nonetheless, some potential causative genes appear 
in more than one study. Some of these are Forkhead box protein P1 (FOXP1), a transcription factor 
involved in  gene expression regulation during brain development (Egawa et al., 2015; O’Roak et 
al., 2011), Glutamate receptor, ionotropic, N-methyl D-aspartate 2B (GRIN2B), and Sodium 
voltage-gated channel alpha subunit 1 and 2 (SCN1A and 2A). Disruption of these genes is also 
associated with epilepsy (Codina-Solà et al., 2015; O’Roak et al., 2011; Roak et al., 2012; Sanders 
et al., 2013). 
At present, WES appears to be a promising approach to complement the large number of GWAS 
data already published, but bigger sample sizes are needed to identify significant rare variants 
with more confidence.  
Finally, it is important to mention that autistic behaviour is also one of the clinical manifestations 
of several genetic syndromes listed in Table 3. Such disorders have a known high-penetrant 
genetic cause and their pathology involves several organs. Generally, typical manifestations 
include dysmorphic features, metabolic dysfunctions, intellectual disability and seizures 
(Caglayan, 2010; Sztainberg & Zoghbi, 2016). However, these syndromes account for only a small 
proportion (5-7%) of the total ASDs cases (Schaaf & Zoghbi, 2011).   
 
Table 1.3 Monogenic syndromes associated with ASD (table based on Caglayan et al 2010 and 
Sztainberg and Zoghbi 2016) 
Syndrome Genetic mutation Main phenotypes 
Fragile X syndrome 
Silencing of FMR1 
gene by CGG triplet 
expansion  
Large head, protruding ears, macro-orchidism, 
aversion to social interaction, developmental 
delay, ID, ASD.  
FXS accounts for 1-3% of total autism cases  
Rett syndrome 
LOF mutation of 
MECP2 
Microcephaly, cognitive and motor 
impairment, epilepsy, ASD 
Tuberous sclerosis 
complex 
LOF mutation of 
TSC1 or TSC2 
Tumours in multiple organs, ID, ADHD, 
epilepsy, ASD  
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ASD, autism spectrum disorder; LOF, loss of function; ID, intellectual disability; ADHD, attention deficit 
hyperactivity disorder; FMR1, fragile X mental retardation protein 1; FXS, Fragile x syndrome; MECP2, 
methyl-CpG-binding protein 2; TSC1, tuberous-sclerosis 1 (hamartin); TSC2, tuberous sclerosis 2 (tuberin); 
NF1, neurofibromin; CACNA1C, Calcium Voltage-Gated Channel Subunit Alpha1 C; DHCR7, 7-
Dehydrocholesterol Reductase; SHANK3, SH3 And Multiple Ankyrin Repeat Domains 3. 
 
In conclusion, SZ and ASDs are characterised by high phenotypic variability and complex genetic 
architecture, which includes common, rare and de novo risk variants.  For this reason, the 
identification of the genetic causes underlying these diseases remains a challenge. Nevertheless, 
recent advances in genetic technologies have provided a long list of genetic variants associated 
with such psychiatric disorders. Research into the genes affected by such mutations and the 
biological pathways on which they converge can provide important insight into the mechanism 
underlying psychiatric disorders.  
1.1.2 The Ch15q11.2 locus 
CNVs in the long arm of chromosome 15 are estimated to be present at a frequency above 0.3% 
in the general population (Grozeva et al., 2012). Several low copy DNA repeat clusters (also called 
duplicons), containing pseudogenes, are present in this area. Misalignment of these sequences 
Neurofibromatosis 1 LOF mutation of NF1  
Multiple fibromas, macrocephaly, ID, 
developmental delay, ADHD, epilepsy, ASD 
Timothy syndrome 
Missense mutation 
in CACNA1C 
Congenital heart disorders, 
immunodeficiency, syndactyly, developmental 
delay, ID, ASD 
Smith-Lemli-Opitz 
syndrome 
LOF mutation DHCR7 Microcephaly, developmental delay, ID, ASD  
15q duplication 
syndrome 
15q11-q13 
duplication 
Hypotonia motor/cognitive/language delays, 
epilepsy, ASD 
Prader-Willi syndrome 
15q11-q13 deletion 
(paternal allele) 
Hyperphagia, obesity, small hands and feet, 
hypogonadism, obsessive compulsive 
behaviour, ASD 
Angelman syndrome 
15q11-q13 deletion 
(maternal allele) 
Facial dysmorphism, developmental delay, 
learning and speech impairments, ASD  
DiGeorge syndrome 22q11.2 deletion 
Facial dysmorphism, multiple organs 
abnormalities, developemtnal delay, mental 
illnesses including ASD 
Phelan-McDermid 
syndrome 
22q13.3 deletion 
(SHANK3 gene) 
Elongated head, ID, speech and motor delay, 
impulsivity, epilepsy, ASD  
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during meiosis can be responsible for non-allelic homologous recombination and, consequently, 
the formation of chromosomal abnormalities (Locke et al., 2004). Five breakpoints (BPs) have 
been characterised in the proximal region of the long arm of chromosome 15. Deletions and 
duplications in this chromosomic region can involve different combinations of these BPs (Butler, 
2017). 
Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are two genetic imprinting disorders. 
They are characterised by neurodevelopmental phenotypes of variable severity and are caused 
by a deletion of the paternal copy of the 15q11-13 region for PWS, or the maternal one for AS 
(Butler, 2017; Nicholls & Knepper, 2001). The deletion is classified as type I when it occurs 
between BP1 and BP3 (6.6 Mb), or type II if it involves BP2 and BP3 (5.3 Mb) (Butler et al., 2008) 
(See fig. 1.1). Individuals with type I deletion have been found to have more severe intellectual 
and behavioural deficits, suggesting the presence of some dosage-sensitive genes in this region 
that play an important role in neurodevelopment (Butler et al., 2004). The region between BP1 
and BP2 spans approximately 500 Mb and encompasses four non-imprinted genes, which are 
NIPA1 (non-imprinted in Prader-Willi and Angelman syndrome 1), NIPA2, CYFIP1 (cytoplasmic 
FMRP-interacting protein 1) and TUBGP5 (tubulin gamma complex associated protein 5) (Chai et 
al., 2003). 
 
Figure 1.1 Scheme of the 15q11-13 chromosomic locus.   
Genes located between BPs 1 and 5 are shown in green when non-imprinted, genes expressed only from 
paternal allele (PWS critical region) are in blue and genes expressed only from maternal allele (AS critical 
region) in red. This image is taken from Butler’s review on 15q11.2 microdeletion syndrome (Butler 2017). 
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NIPA1 encodes for a magnesium (Mg++) transporter that is widely and highly expressed in the 
developing and adult brain (Goytain et al., 2007; van der Zwaag et al., 2010). Mutations in this 
gene are known to cause hereditary spastic paraplegia (Fink, 2003). 
NIPA2 also encodes a highly selective Mg++ transporter that is expressed in several organs 
including the brain, but is particularly abundant in placenta and kidneys (Chai et al., 2003; Goytain 
et al., 2008). Several studies have implicated a role for NIPA2 mutations in the aetiology of 
childhood absence epilepsy (Jiang et al., 2012, 2014; Xie et al., 2014). 
TUBGCP5 is part of the gamma-tubulin complex required for microtubules nucleation at the 
centrosome (Murphy et al., 2001). Its expression can be detected in many tissues of both mouse 
and human. In the brain, it is particularly high in subthalamic nuclei, a region important in the 
neurobiology of ADHD and obsessive-compulsive disorder (OCD) (Brem et al., 2014; Chai et al., 
2003; Doornbos et al., 2009).  
CYFIP1 is a cytoplasmic protein which is ubiquitously expressed in many organs and participates 
in two multi-protein complexes (Chai et al., 2003). It binds to FMRP to regulate mRNA translation 
and is part of the WAVE regulatory complex (WRC) (Abekhoukh & Bardoni, 2014; De Rubeis & 
Bagni, 2010; Napoli et al., 2008).  Its association with FMRP, the protein mutated in the FXS (see 
paragraph 1.1), makes CYFIP1 a highly likely candidate to explain the psychiatric phenotypes 
linked to 15q11.2 chromosomic abnormalities. Its expression and biological function have been 
the object of numerous studies, which will be reviewed later in this chapter.  
Besides modulating the severity of PWS and AS phenotypes, CNVs involving the region between 
BP1 and BP2 of chromosome 15 are also known to increase risk for neurodevelopmental and 
psychiatric conditions. The first study reporting the association between neurological disorders 
and 15q11.2 microdeletion was published in 2007 (Murthy et al., 2007). Since then, many 
additional cases have been reported. The clinical phenotypes most frequently present in 15q11.2 
deletion carriers include developmental delay and psychiatric disorders, including ASD and SZ. 
Other neurological problems, such as seizures, have also been described (Abdelmoity et al., 2012; 
Burnside et al., 2011; Cafferkey et al., 2014; Doornbos et al., 2009; Jerkovich & Butler, 2014; 
Madrigal et al., 2012; Picinelli et al., 2016; Vanlerberghe et al., 2015; von der Lippe et al., 2011). 
Clinical reports of 15q11.2 microduplications are less abundant in the literature. Patients usually 
present with developmental delay and autistic features. In addition, dysmorphic features, motor 
coordination issues and seizures were also reported in a few cases (Burnside et al., 2011; Picinelli 
et al., 2016; van der Zwaag et al., 2010).  
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The association between 15q11.2 CNVs and psychiatric disorders has been further strengthened 
by the results of several GWAS. In fact, 15q11.2 microdeletion or duplications are reportedly 
found at a frequency of 0.55-0.82% in SZ cases and of above 0.8% in ASD ones, while only 0.2-
0.4% control individuals have been found to carry such mutations (Kirov et al., 2009, 2014a; Rees 
et al., 2014; Stefansson et al., 2008). Data on inheritability are scarce for 15q11.2 duplications, 
but, in the context of deletions, it has been reported that most patients inherit the mutation from 
an unaffected parent (51%), while 5 to 22% of cases represent de novo CNVs (Butler, 2017; 
Cafferkey et al., 2014).  
The frequency of 15q11.2 deletions and duplications observed in control populations provides 
proof for incomplete penetrance and it has been proposed that other mutations in interacting 
genes or pathways may play an important role in determining the clinical phenotype (Butler, 
2017). Figures on penetrance are variable and incomplete, however two studies report similar 
values for the risk of SZ and ASD combined, associated with the microdeletion (10 and 13%) (Kirov 
et al., 2014a; Rosenfeld et al., 2013). Only one study investigates the effect of microdeletion and 
microduplication on ASD alone, reporting an estimated penetrance of 1.3% and 1.8% respectively 
(Chaste et al., 2014).  Despite the incomplete penetrance for psychiatric disorders, 15q11.2 
deletions have been recently shown to also impact the brain structure and IQ of control 
individuals, who often present with dyslexia and/or dyscalculia (Stefansson et al., 2014). 
Considering all the data presented above, it can be concluded that some of the genes located 
between BP1 and BP2 on chromosome 15 have an important role in brain development and 
neuronal function and that an incorrect expression level of such genes significantly increases the 
risk of developing ASD or SZ.  The next section reviews the existing literature on CYFIP1, which is 
considered, from a neurodevelopmental perspective, the most promising candidate gene 
encoded in the 15q11.2 chromosomic locus. 
1.2 CYFIP1 biology 
CYFIP1 (also known as p140Sra-1) is an evolutionarily conserved gene that was named as 
“cytoplasmic FMRP-interacting protein 1” by Schenck and colleagues in 2001 (Schenck et al., 
2001). In this study, the authors employed a yeast two-hybrid system to screen a mouse 
embryonic library for proteins binding to the N-terminus of FMRP. This led to the characterisation 
of two proteins, named CYFIP1 and CYFIP2. The latter is also able to bind the FMRP-related 
proteins FXR1P/2P, whereas CYFIP1 interacts only with FMRP. The two CYFIP proteins share ~88% 
homology (Schenck et al., 2001). 
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However, prior to this study, CYFIP1 had already been identified as a target of Rac1 small GTPase, 
named p140Sra-1 (Kobayashi et al., 1998), and CYFIP2 was already known as PIRI121 (Saller et al., 
1999).  Around the time they were established as FMRP binding partners, both CYFIP1/Sra-1 and 
CYFIP2/PIRI121 were also characterised as being associated with WAVE (WASP (Wiskott–Aldrich 
syndrome protein)-family verprolin homologous protein) proteins in the formation of the WAVE 
regulatory complex (WRC), which controls cytoskeleton dynamics (Eden et al., 2002; Steffen et al., 
2004). 
The interest on CYFIP1 as a potential risk gene for psychiatric disorders is therefore explained by 
its participation to these two fundamental cellular functions, the regulation of mRNA translation 
with the FMRP and the control of actin polymerisation as part of the WRC.     
1.2.1 Role of Cyfip1 in the WRC 
The WRC is a hetero-pentameric complex, which controls actin polymerisation by the Arp2/3, a 
process fundamental for cell adhesion, cell migration, vesicle trafficking and neurite extension 
(Takenawa & Suetsugu, 2007). Its components include WAVE1/2/3, ABI (Ableson interacting 
protein), NAP (NCK-associated proteins), CYFIP1/2 and HSPC300 (hematopoietic stem progenitor 
cell 300) (Chen et al., 2010). 
WAVE proteins are characterised by the presence of a VCA (Verprolin-homology, Central and 
Acidic regions) domain, which binds to Arp2/3 and G-actin monomers to guide actin 
polymerisation (Mendoza, 2013). The resolution of the WRC structure suggested a possible 
mechanism for the regulation of this multi-protein complex. It was proposed that the WRC is 
constitutively inactive, with the VCA occupied by CYFIP1/2, preventing its interaction with Arp2/3.  
Several processes requiring cytoskeletal rearrangements, such as the extension of lamellipodia, 
stimulate Rac1 activation, which can induce CYFIP1/2 release from the VCA (Chen et al., 2010). 
Cooperatively with Rac1, negatively charged phospholipids also participate in WRC activation, 
recruiting the complex to the cell membrane. Such a step is necessary to initiate the formation of 
cell protrusions or lamellipodia and can also facilitate WRC oligomerisation, which significantly 
enhances its activity (Oikawa et al., 2004; Padrick et al., 2008). 
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Figure 1.2 CYFIP proteins participation in the regulation of actin polymerisation by the WRC.  
(A) Schematic illustrating the WRC subunits forming an inactive complex. In this state, the WAVE proteins 
are associated with CYFIP, ABI2, NAP and HSPC300. (B) Activation of Rac signalling destabilises the 
interaction between WAVE and CYFIP, resulting into its dissociation, together with ABI2 and NAP (from 
Abekhoukh and Bardoni, 2014). 
 
1.2.2 Role of Cyfip1 in the regulation of mRNA translation 
Together with their role within the WAVE complex, CYFIP1/2 are known to interact with FMRP at 
the same domain this protein uses for dimerization with other FXR proteins (Schenck et al., 2001). 
This suggests that CYFIP1/2 have the ability to modify FMRP function, but the consequences of 
this interaction have not been entirely elucidated.  
FMRP is a ubiquitously expressed mRNA-binding protein which is particularly enriched in neuronal 
dendrites. It is believed that FMRP acts primarily as a translational repressor, but it is also involved 
in the regulation of localisation and stability of mRNA (Fernández, Rajan, & Bagni, 2013). Several 
studies conducted in neuronal cells identified over a thousand putative FMRP mRNA targets 
(Brown et al., 2001; Chen et al., 2003; Darnell et al., 2011). Importantly, a significant proportion 
of these overlaps with ASD risk genes reported by GWAS studies, while only a smaller fraction is 
represented by mood disorders- and SZ-related genes (Fernández et al., 2013). This evidence 
further strengthens the link between FMRP and ASD and provides important support to the 
hypothesis of an existing shared mechanism across psychiatric disorders. 
In the context of mRNA translation, CYFIP1 has been proposed to be part of a complex that binds 
and controls mRNA translation, interacting with both FMRP and the initiation factor 4E, eIF4E. 
According to this model, CYFIP1 is recruited by FMRP onto specific mRNAs to act as a 4E-BP (4E-
binding protein), blocking the initiation of translation (Napoli et al., 2008; Richter & Sonenberg, 
2005). In Cap-dependent translation, the start of this process requires the association between 
the initiation factors eIF4A-eIF4E-eIF4G (named eIF4F as a complex) and the 5’m7G cap of mRNA 
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molecules. 4E-BPs interfere with eIF4E-eIF4G interaction, keeping the translation inhibited 
(Richter & Sonenberg, 2005).  
 
 
Figure 1.3 Scheme of the proposed Cap-dependent translation mechanism involving CYFIP1. 
The translation of mRNAs is inhibited by the FMRP/CYFIP1 complex, which prevents binding of the eIF4E to 
the PABP. Synaptic stimulation requires mRNA translation at the spine level and, therefore, induces the 
release of FMRP and CYFIP1 from the translation complex. At the same time, the association between eIF4E, 
eIF4G and PABP allows the initiation of translation.  (from Napoli et al., 2008) 
 
In an attempt to find a single mechanism explaining CYFIP1 participation in actin polymerisation 
and protein synthesis, it has been suggested that cellular signals, converging on Rac1 stimulation 
of CYFIP1, trigger a conformational change that induces CYFIP1 release from the complex with 
FMRP and eIF4E and its recruitment to the WRC (DeRubeis et al., 2013). The authors designed two 
mutant forms of CYFIP1 to specifically inhibit its interaction with the WRC or eIF4E and transfected 
each isoform separately in primary neurons, where CYFIP1 had been knocked-down. Transfection 
of the first isoform was able to restore normal actin levels, while the second only rescued the 
translation of some known FMRP targets (DeRubeis et al., 2013). However, the interpretation of 
these results is in conflict with the numerous studies reporting CYFIP1 inhibitory role towards 
actin polymerisation, within the WRC (see previous paragraph). One explanation is that the 
mechanism regulating the distribution of the CYFIP1 protein pool between the two complexes 
could be more complicated than previously believed. Indeed, it has been recently shown that 
MNKs (Map kinase-interacting kinases) are also involved in the control of translation initiation in 
neuronal cells and that, by phosphorylating eIF4E, they induce its release from CYFIP1 (Genheden 
et al., 2015). It is therefore possible that even more proteins are involved in modulating CYFIP1 
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activity in the context of actin polymerisation and protein synthesis and that future studies will 
eventually clarify the mechanism. 
1.2.3 Expression pattern of CYFIP1 
There is little data on CYFIP1 expression pattern, as it has been investigated by very few studies. 
In situ hybridisation analysis by van der Zwaag et al. showed that Cyfip1 is expressed in the mouse 
brain as early as E12 (van der Zwaag et al., 2010). At this stage, the expression level appears to be 
enriched in the ventricular zone (VZ) of the forebrain, an observation in agreement also with data 
from the Eurexpress database (Eurexpress.org). Cyfip1 expression is maintained throughout 
embryonic development up to day E18.5, with strong signal still present in the VZ and cortical 
plate (CP) of the forebrain. In the adult, Cyfip1 was found in the olfactory bulb, the hippocampus 
and the cerebellum. 
Support that Cyfip1 protein is present in the developing cortex was recently provided by Yoon and 
colleague (Yoon et al., 2014). The authors showed specific localisation of Cyfip1 in the ventricular 
surface of the radial glia cells facing the VZ, co-localising with N-Cadherin and β-Catenin, and lower 
expression levels in the intermediate zone (IZ). However, in contrast to what had been previously 
reported by in situ studies, Cyfip1 protein did not appear to be expressed in the CP (van der Zwaag 
et al., 2010; Yoon et al., 2014).  
      
 
Figure 1.4 Cyfip1 expression in the mouse developing brain.  
(A) In situ hybridisation for Cyfip1 in E14.5 mouse embryo (from Eurexpress.org). (B) Specific localisation of 
Cyfip1 in VZ cells of E15.5 mouse forebrain (from Yoon et al 2014). 
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1.2.4 In vivo and in vitro studies on Cyfip1 alterations in neuronal cells  
The known association between abnormal CYFIP1 levels and the increased risk of acquiring 
developmental psychiatric disorders has driven research into modelling the consequences of such 
alterations, using genetically modified mice and rodent or human cultured cells.  
Pathania and colleagues demonstrated that Cyfip1 is essential for embryonic development, as 
Cyfip1 -/- mouse embryos are detectable only until day E8.5 (Pathania et al., 2014). They also 
showed that, in primary cultures of mature mouse hippocampal neurons, Cyfip1 is enriched at 
excitatory synapses and that haploinsufficiency and overexpression of this gene have opposite 
effects on dendritic complexity. More precisely, low levels of Cyfip1 decrease dendritic branching, 
while high levels lead to a more complex dendritic arborisation.  Spine maturation is also affected 
by such alterations (Pathania et al., 2014).  
The disruption of normal dendritic outgrowth by CYFIP1 overexpression was also reported in 
human neuroblastoma cells SY5Y and in cortical cells of transgenic mice by Oguro-Ando and 
colleagues (Oguro-Ando et al., 2014). According to their results, high CYFIP1 dosage causes a 
reduction in neurite length, but also a significant increase in branch number and cell size, in both 
models. With the support of a microarray analysis on E15 cortex of wild type (WT) and transgenic 
mice, the authors proposed mTOR upregulation as the disrupted pathway at the origin of the 
phenotype observed. This hypothesis was confirmed treating mouse neuronal progenitors with 
the mTOR inhibitor rapamycin, which rescued the morphological defects caused by Cyfip1 
overexpression (Oguro-Ando et al., 2014).  
The disruption of physiological CYFIP1 levels has been investigated also in human PSCs-based in 
vitro models. A transcriptomic analysis of CYFIP1-knock down (KD) against control iPSCs-derived 
neural progenitor cells (NPCs) revealed that many of the differentially expressed genes were 
related to cytoskeletal remodelling and cell cycle (Nebel et al., 2016). In agreement with 
cytoskeletal dysregulation, CYFIP1KD NPCs had lower levels of WAVE protein, lower levels of F-
Actin and bigger nuclei, but not significantly bigger cell size (Nebel et al., 2016). 
However, CYFIP1 is only one of the four genes affected by 15q11.2 deletions and duplications (see 
paragraph 1.1.2). As discussed in the next paragraph, iPSCs represent a useful tool to model CNVs 
encompassing several genes and they have also been used in the context of 15q11.2 deletions.  
Yoon and colleagues used iPSCs from three deletion-carriers and five controls to demonstrate that 
the self-organisation of NPCs into neural rosettes, a stage mimicking the neural tube formation 
during in vivo embryonic development, was compromised by the deletion (Yoon et al., 2014). The 
expression pattern of the adhesion proteins marking the rosettes lumen was disrupted and this 
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defect seemed specifically due to the reduction in CYFIP1 levels. Indeed, it could be reproduced 
by transfecting short hairpin RNA (shRNA) targeting CYFIP1 in control cells and it could be rescued 
by increasing CYFIP1 expression in cells carrying the CNV. Significant reduction of WAVE2 protein 
was also observed in both 15q11.2-deleted and CYFIP1KD NPCs. The authors confirmed the 
importance of CYFIP1 in the maintenance of the correct polarity for cortical progenitors with in 
utero electroporation experiments, in which they demonstrated that the correct level of Cyfip1 is 
necessary for the proper placement of radial glial cells (RGCs) and the correct distribution of 
neurons across the cortical layers (Yoon et al., 2014). 
In another study, Das and colleagues used iPSCs from two deletion carriers and one control to 
show that the mRNA levels for CYFIP1, NIPA1, NIPA2 and TUBGCP5 were reduced in pluripotent 
cells and neurons carrying the deletion (Das et al., 2015). In addition, they report that the 
morphology of mature neurons derived from the two patients suggested the presence of dendritic 
spine alterations, but no quantitative analysis was reported for this aspect (Das et al., 2015).  
To date, only these three studies have used PSCs to investigate the significance of 15q11.2 CNVs 
and, in particular CYFIP1, in human neuronal cells (Das et al., 2015; Nebel et al., 2016; Yoon et al., 
2014). However, all of them represent loss-of-function models. The derivation of iPSCs from 
duplication carriers, or the development of hPSCs-based models mimicking an increase of CYFIP1 
or other 15q11.2 genes, have not been reported. 
In the next paragraph, I review the use of human PSCs to model developmental psychiatric 
disorders. This topic was also the subject of a review published in the Brain Pathology journal, as 
part of a mini-symposium on “Using iPSCs to understand human neurological disease: potential 
and limitations” (Tamburini & Li, 2017). The content of this review is reported in the next 
paragraph with minor modifications.  
1.3  The use of human Pluripotent Stem Cells for in vitro modelling of 
neurodevelopmental psychiatric disorders 
Neurodevelopmental disorders are a group of conditions typically manifest early in life and are 
characterised by developmental deficits that produce impairments of personal, social, academic 
or occupational functioning. Neurodevelopmental (or neuropsychiatric) conditions include autism 
spectrum disorders, intellectual disabilities, schizophrenia and bipolar disorder, and have a 
substantial genetic component (Beneyto & Lewis, 2011; Cristino et al., 2014; O’Shea & McInnis, 
2016; Ziats & Rennert, 2016).  
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For a long time, psychiatric research mainly relied on post-mortem studies and animal models. 
The first approach has the major limitation of representing the end-stage of the disease, without 
being informative about its origin and pathological progression. Moreover, changes observed in 
post-mortem tissues may be secondary effects of a patient’s prolonged use of medications. 
Animal models, predominantly rodents, are available for several psychiatric disorders, especially 
autism spectrum disorders and schizophrenia, but they have so far failed to show significant  
predictive validity for drug discovery (Markou et al., 2009; Pratt et al., 2012). This may be due to 
the inability of model organisms to represent unique higher human functions and consequently, 
to recapitulate all the symptoms characterising a particular disorder (Nestler & Hyman, 2010). For 
example, despite the numerous rodent models available for schizophrenia, these are mostly 
representative of the psychotic aspects of the disease, but do not reliably reproduce the cognitive 
and negative symptoms, such as impaired working memory, anhedonia and social withdrawal 
(Jones, Watson & Fone, 2011). In the case of bipolar disorder, there are no animal models 
available to represent both the manic and depressive extremes characterising the disorder 
(O’Shea & McInnis, 2016). 
In just a decade from the derivation of the first line (Takahashi et al., 2007; Takahashi & Yamanaka, 
2006), induced pluripotent stem cells (iPSCs) have become a fundamental tool for modelling 
human development and diseases, as well as for drug discovery. Like their mouse counterparts, 
human iPSCs are believed to have the same self-renewal and pluripotency properties of human 
embryonic stem cells (hESCs), but are derived (reprogrammed) from somatic cells, such as skin 
fibroblasts (Takahashi et al., 2007), keratinocytes (Aasen et al., 2008), dental pulp (Tamaoki et al., 
2010; Yan et al., 2010) or blood (Loh et al., 2009). The reprogramming is achieved by forcing the 
expression of key pluripotency genes such as OCT4, SOX2, c-MYC and KLF4 in somatic cells, where 
the reprogramming factors start a self-regulatory loop that initiates and maintains pluripotency 
(Masui et al., 2007; Pan et al. , 2006). Expression of these reprogramming factors can be induced 
via viral transduction (Ban et al., 2011; Park, 2008), transfection of polycistronic plasmids 
(Montserrat et al., 2011), mRNAs (Warren et al., 2010) or direct delivery of recombinant proteins 
(Hongyan et al., 2009). Moreover, treatment with specific combinations of small molecules has 
been shown to greatly increase the reprogramming efficiency (Huangfu et al., 2008; Yan Shi et al., 
2008).  
The use of adult somatic cells as starting material means that iPSCs are free from the ethical 
concerns that surround the use of hESCs, and that they can be derived from individuals carrying 
genetic variants that predispose to an increased risk of human diseases. Working on iPSCs, and 
PSCs in general, has become increasingly important in psychiatric research thanks to the ability to 
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study the consequences of a large number of disease-associated mutations in the phenotypically 
relevant cell types. This is playing an important role in advancing our understanding of the cellular 
mechanisms underlying psychiatric disorders and reinforcing the hypothesis of their 
developmental origin. 
1.3.1 Generation of disease relevant neuronal cell types from human PSCs 
The brain contains thousands of neuronal types that differ in terms of neurotransmitter identity, 
electrophysiological properties and afferent/efferent connectivity (Nelson, Sugino & Hempel, 
2006).  Different neurological diseases often exhibit pathologies specific to certain brain regions 
and/or cell types. This means that the possibility of observing and, therefore, being able to correct 
a specific phenotype, is strictly dependent on the presence of the appropriate neuronal type in 
the system used. Therefore, an important consideration in modelling human neurological diseases 
is the generation of neural cell types targeted by the disease of interest.  
A number of neuronal cell types have been implicated in psychiatric disorders:  cortical projection 
neurons (Donegan & Lodge, 2016), inhibitory interneurons (Donegan & Lodge, 2016; Lewis et al., 
2012), hippocampal neurons (Frey et al., 2007), dopaminergic neurons (Donegan & Lodge, 2016) 
and striatal medium spiny neurons (Fuccillo, 2016; Simpson, Kellendonk & Kandel, 2010).  
Protocols to generate these neuronal types have been developed and are reviewed in this 
paragraph. Many lines of evidence demonstrate that in vitro PSC differentiation, to a large extent, 
mimics vertebrate development. In the context of neuronal conversion, PSCs firstly exit the 
pluripotent state and acquire a neuroectoderm fate.  Therefore, the majority of neuronal 
differentiation protocols start with the induction of a specific regional neuroepithelial phenotype 
(region-specific progenitors) from which the target cells arise. This is mostly achieved by artificially 
recapitulating the signalling environment that the region-specific progenitors normally 
experience in vivo, by adding an appropriate combination of ‘inductive’ molecules. The aim is to 
induce a cascade of transcription resembling normal development, leading to the expression of a 
combinatorial set of transcription factors characteristic to the desired neural progenitor 
phenotype. 
Currently, a popular method for generating neural cells  from hPSCs is via monolayer 
differentiation protocol by dual SMAD inhibition (Chambers et al., 2009). Normal central nervous 
system development follows an anterior first - posterior later temporal fashion. As such, the first 
neuroepithelial cells generated from PSCs exhibit features of forebrain regional identity. These 
anterior progenitors readily mature into neurons with predominantly cortical glutamatergic 
identity (Boissart et al., 2013; Espuny-Camacho et al., 2013; Shi et al. , 2012). Cell types of all 
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cortical layers appear in a sequence reminiscent of in vivo corticogenesis, from deep layers to 
superficial ones. The efficiency of this approach was shown to be very high, with glutamatergic 
neurons accounting for 80% to nearly 100% of the cells in culture.  
The specification of the other neuronal fates requires the use of additional morphogens to mimic 
the in vivo environment of the corresponding brain region. For example, the derivation of 
GABAergic interneurons requires the activation of sonic hedgehog (SHH) signalling (Y. Liu, Liu, et 
al., 2013; Y. Liu, Weick, et al., 2013), in some cases combined with WNT inhibition (Maroof et al., 
2013; Nicholas et al., 2013), to induce the medial ganglionic eminence (MGE) fate demonstrated 
by the expression of transcription factor NKX2.1. However, despite the induction of a high 
percentage of NKX2.1+ MGE-like progenitors, efficient generation of mature interneurons, 
including the two major subtypes, somatostatin (SST) and parvalbumin (PV), have so far proved 
challenging. On the other hand, caudal ganglionic eminence (CGE)-derived interneurons 
expressing calretinin have been derived with a higher efficiency (>70%), by exposing late neural 
progenitors to activin A, a member of the TGF-β superfamily (Cambray et al., 2012).  
When applied to forebrain neural progenitors at an earlier time window, activin A induces the 
specification of a lateral ganglionic eminence (LGE) fate, leading to the production of 40-50% of 
medium spiny neurons (Arber et al., 2015).  Other strategies for deriving this type of neurons rely 
on the use of SHH, alone or in combination with WNT inhibition (X.-J. Li et al., 2009; L. Ma et al., 
2012; Nicoleau et al., 2013), in a similar way to MGE protocols. Dopaminergic neurons, which are 
born in the ventral midbrain, can be differentiated from hPSCs by exposing the neural precursors 
to different combinations of WNT agonists with SHH (Denham et al., 2012; Kirkeby et al., 2012; 
Kriks et al., 2011) or FGF8 (Xi et al., 2012). In addition, FGF signalling blockade using a ERK/MEK 
inhibitor on exit of pluripotency, followed by addition of SHH and FGF8 has also been reported to 
induce authentic midbrain dopamine neurons (Jaeger et al., 2011). The yield of tyrosine 
hydroxylase positive cells is elevated in all these cases, reaching above 80%. Finally, only one 
protocol has been reported so far for the production of hippocampal neurons (Yu et al., 2014). 
For these cells, the application of WNT3a and BDNF to dorsal forebrain progenitors seems to be 
essential to induce the expression of PROX1, a marker for dentate gyrus hippocampal neurons.  
Monolayer differentiation has proved itself a highly efficient and reliable paradigm for generating 
a number of neuronal types.  Indeed, monolayer based forebrain glutamatergic neuron 
differentiation has been the platform of choice for the majority of disease modelling papers 
published so far (Brennand et al., 2015; Brennand et al., 2011; Chen et al., 2014; Griesi-Oliveira et 
al., 2014; Kim, Hysolli & Park, 2011;  Marchetto et al., 2010; Robicsek et al., 2013; Shcheglovitov 
et al., 2013a; Srikanth et al., 2015; Wen et al., 2014b; Yoon et al., 2014). However, the monolayer 
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culture system has limitations in visualising potential alterations in the cytoarchitecture of the 
derived ‘brain tissue’. This shortcoming can be overcome, to a certain extent, by differentiating 
PSCs in 3 dimensional (3D) structures called organoids (Lancaster & Knoblich, 2014; Mariani et al., 
2012; Qian et al., 2016), although at the expense of higher variability, both within and between 
organoids, and in different preparations. To date, only Mariani and colleagues have used 
telencephalic organoids for analysing the developmental abnormalities with iPSCs derived from  
patients with idiopathic autism (Mariani et al., 2015).  
The generation of ‘induced neurons’ (iNs) by direct reprogramming represents an alternative to 
conventional PSC neural differentiation. iNs are produced by forcing the expression of a defined 
set of transcription factors crucial for the acquisition of neuronal fate in somatic cells or PSCs 
(Ambasudhan et al., 2011; W. Hu et al., 2015; Ladewig et al., 2012; Pang et al., 2011; A. S. Yoo et 
al., 2011). iN protocols for the generation of specific neuronal types have also been published 
(Caiazzo et al., 2011; Colasante et al., 2015; Pfisterer et al., 2011; Sun et al., 2016; Victor et al., 
2014; Z. Xu et al., 2016). However, the iN approach may not be suitable for modelling diseases 
where pathogenesis occurs at neural progenitor stage, because it bypasses the process of neural 
progenitor specification, proliferation and differentiation choice towards distinct neuronal and 
glial fates.  Moreover, in contrast to hPSC neural differentiation, the number of iNs that can be 
generated from the donor somatic cells is limited due to the restricted proliferative capacity of 
somatic cells prior to senescence. These shortcomings combined may explain why there are no 
studies published to date using iN technology to model psychiatric disorders. 
1.3.2 Current status of iPSCs-based research for psychiatric disorders 
Brain imaging studies have demonstrated changes in the anatomy and neuronal activity in 
patients suffering from psychiatric disorders, while post-mortem studies have revealed aberrant 
cellular morphology (Black et al., 2004; Dinstein et al., 2011; Hutsler & Zhang, 2010; Whitfield-
Gabrieli et al., 2009). The iPSC technology has provided an invaluable tool to investigate the 
cellular basis of such alterations and elucidate the molecular pathways that may be targeted for 
drug discovery.  
The first proof-of-principle study using iPSCs was published by Brennand and colleagues in 2011 
(Brennand et al., 2011). The authors reported that neurons derived from schizophrenic patients’ 
iPSCs differ from those of the controls in neuronal connectivity, morphology and gene expression. 
This work was followed by several other schizophrenic iPSC studies reporting the emergence of 
earlier developmental abnormalities. 
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Robicsek and colleagues differentiated schizophrenia and control iPSCs into glutamatergic and 
dopaminergic neurons and found defects in the maturation of both cell types, with the dopamine 
lineage more severely affected (Robicsek et al., 2013). The authors also reported differences in 
mitochondrial distribution and function. This aspect of the phenotype was more pronounced in 
dopaminergic progenitors than the glutamatergic cells. This could suggest the presence of a higher 
vulnerability for dopamine cells to oxidative stress, but it could also reflect, at least in part, their 
extremely impaired maturation. Together with alterations of mitochondrial membrane potential 
and neuronal morphology, other defects often reported in neuronal cells from schizophrenic 
patients iPSCs are relative to WNT signalling and migration (K. Brennand et al., 2015; Topol et al., 
2015) (see also Table 1). 
All the studies listed above were based on heterogeneous cohorts of schizophrenic patients, 
selected only on the basis of their diagnosis, without knowledge of their genetic risk variants. This 
probably played a significant part in the high experimental variability evident in some of the 
results. 
It is known that schizophrenia has a strong genetic component, with rare Copy Number Variations 
(CNVs) significantly increasing the risk of developing this disorder (reviewed by Kirov (Kirov, 
2015)). Stratifying patients based on the presence of specific genetic mutations could help to 
reduce the degree of variability associated with iPSC work and discover new mechanisms that 
otherwise may be masked by the heterogeneity of the patients’ samples.  Wen and colleagues 
took the genetics orientated approach by analysing the effect of Disrupted In SChizophrenia 1 
(DISC1) mutations, which are known to co-segregate with major psychiatric illnesses (Millar et al., 
2000; Wen et al., 2014b). iPSCs lines were derived from two patients carrying the same frameshift 
mutation in the DISC1 gene and three unaffected individuals. The authors reported altered 
morphology and electrophysiological properties in DISC1 neurons, as well as the expression of 
genes related to synaptic transmission, neural development and major mental disorders. They 
also established the causality between DISC1 mutations and the changes observed by repeating 
some of the analysis in several isogenic cell lines. These were derived by correcting the DISC1 
mutation in one of the mutant lines and by introducing the same frameshift deletion present in 
patients in two control lines. Both synaptic and vesicular release properties were restored to 
normal levels in the cell line in which the DISC1 gene sequence had been corrected, while the 
control lines carrying DISC1 deletion recapitulated the original mutant phenotype. However, the 
majority of CNVs associated to psychiatric disorders contain multiple genes. This genetic feature 
makes iPSC modelling particularly advantageous over the generation of animal models. 
Microdeletion of the 15q11.2 locus has been reported by several studies as an important risk 
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factor for schizophrenia (Stefansson et al., 2008; The International Schizophrenia Consortium, 
2008). Yoon and colleagues demonstrated that iPSCs derived from 15q11.2 deletion carriers had 
significant defects in neural rosette formation (Yoon et al., 2014). The 15q11.2 region contains 
four genes, CYFIP1 was proposed to be the likely responsible gene for the observed phenotypes. 
Indeed, increasing CYFIP1 expression by lentiviral transduction in differentiating 15q11.2del iPSCs 
rescued the abnormal expression of apical polarity markers, while reduction of CYFIP1 expression 
by shRNA in a control line mimicked the phenotype observed in the deleted progenitors. The 
authors extended their quest into CYFIP1 function by shRNA knockdown of Cyfip1 in mouse 
embryos via in utero electroporation, which resulted in incorrect localisation of radial glia cells 
and nascent neurons. However, the consequences of CYFIP1 disruption in post-mitotic neurons 
were not explored.  
As for autism spectrum disorders, in vitro modelling was first applied to syndromic autism, such 
as Rett syndrome (RTT) and Phelan-McDermid syndrome (PMDS). RTT syndrome is one of the 
most common causes of mental retardation mainly affecting girls and is caused by mutations of 
the methyl CpG binding protein 2 (MECP2) (Amir et al., 1999). iPSCs-based investigations into RTT 
reported defects in neuronal maturation in patients’ cells (K. Y. Kim et al., 2011; M. C. N. 
Marchetto et al., 2010) (See also Table 1). In particular, Marchetto and colleagues demonstrated 
the presence of morphological alterations and reduced number of glutamatergic synapses in RTT 
neurons (M. C. N. Marchetto et al., 2010). This defect could be rescued by IGF1, a neurotrophic 
factor capable of promoting synaptogenesis. The same group subsequently reported the 
involvement of MeCP2 in regulating the expression of TRPC6, one of the genes disrupted by a 
translocation recently found in an autistic patient (Griesi-Oliveira et al., 2014).  
Similar cellular phenotypes were reported in in vitro models of PMDS. Shcheglovitov and 
colleagues investigated the cellular phenotypes of iPSCs-derived neurons from two patients 
carrying heterozygous deletion of chromosome 22q13.3, the mutation responsible for PMDS 
(Shcheglovitov et al., 2013b). Cortical neurons derived from these iPSCs displayed impaired 
excitatory synaptic transmission, while the properties of their inhibitory synapses were not 
affected. These deficits could be either rescued by increasing the expression of SHANK3, a gene 
included in the deleted locus, or by IGF1 treatment, which did not affect SHANK3 levels. 
Taking a different approach, Mariani and colleagues derived iPSCs from four probands with 
idiopathic autism, carrying no known genetic mutation previously associated with autism 
spectrum disorders, and unaffected family members (Mariani et al., 2015). Transcriptomic 
analysis of telencephalic organoids derived from patients and control cells revealed many 
differentially expressed genes, mainly relative to cell fate, proliferation, axonal guidance, synaptic 
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function and ion channels. Consistently with these results, probands’ cells showed dysregulated 
cell cycle and overproduction of inhibitory neurons, a phenotype that could be rescued by 
attenuating FOXG1 levels. 
In the context of bipolar disorder, after performing a microarray analysis of iPSC-derived neurons 
from three patients and three controls, Chen and colleagues found a similar alteration in the 
expression of transcription factors regulating dorso-ventral telencepahlic patterning (Chen et al., 
2014). These results, however, do not significantly overlap with those from Mertens et al, the only 
other publication employing iPSCs for bipolar disorder modelling to date (Mertens et al., 2015). 
Their work, based on hippocampal neurons derived from bipolar patients, showed that the 
hyperexcitability and abnormal mitochondria size of these cells could be rescued by lithium 
treatment, while alteration of mitochondrial membrane potential could not be improved. 
In the interest of space, table 1.4 summarises the above works together with additional studies 
not individually discussed in this mini review. It is evident that differences exist between studies 
within the context of the same disorder. These discrepancies may attribute to different 
differentiation protocols, culture systems and analysis methods. Nevertheless, some common 
themes emerge from these studies. In general, genes involved in nervous system development 
are reported to be affected by many studies and, in line with this, several phenotypes are already 
present at the neural progenitor stage. In particular, altered WNT signalling and mitochondria 
dysfunction seem to be frequently reported in patient-derived cells (K. Brennand et al., 2015; K. 
J. Brennand et al., 2011; Mertens et al., 2015; Robicsek et al., 2013; Srikanth et al., 2015; Topol et 
al., 2015; P. Wang, Lin, et al., 2015). They may represent shared mechanisms in the aetiology of 
neurodevelopmental psychiatric disorders. 
1.3.3 CRISPR-based genome editing as a powerful alternative to model 
neurodevelopmental disorders 
iPSCs represent a virtually unlimited and bankable source of patient-specific cells that can be 
differentiated into many disease-relevant neuronal types. Therefore, they allow the investigation 
of cellular phenotypes in cohorts of patients sharing a specific genetic mutation or the same 
clinical manifestation with unknown genetic background. This is particularly advantageous in the 
context of those disorders for which a genetic cause has not been identified, such as idiopathic 
autism cases (Ardhanareeswaran, Coppola & Vaccarino, 2015). However, iPSC-based studies can 
suffer from high variability due to differences in the genetic background of different patients, 
reprogramming methods and culture conditions (Sandoe & Eggan, 2013). Working with 
genetically modified hESCs or a well characterised reference line of hiPSCs and their isogenic 
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controls can represent an alternative to the use of patient iPSCs. This strategy will avoid the 
variability linked to the different genetic backgrounds of distinct patient iPSC lines and reduce the 
necessary work load of studying multiple patient iPSC lines required for identifying true 
phenotype and establish causality. 
The CRISPR (Clusters of Regularly Interspaced Short Palindromic Repeats)/Cas9 technology allows 
genome editing more easily and efficiently than traditional gene targeting via Homologous 
Recombination (Cong et al., 2013; Ding et al., 2013; Mali et al., 2013; Ran, Hsu, Wright, & 
Agarwala, 2013). CRISPR/Cas9 is a type II CRISPR system (reviewed by Makarova et al., 2011), 
which is naturally present in many bacteria as an immunity mechanism to protect them against 
foreign DNA (Gasiunas et al., 2012; Jinek et al., 2012). It consists of the Cas9 nuclease and a guide 
RNA (gRNA), a chimeric RNA molecule combining a CRISPR RNA (crRNA) and a transactivating RNA 
(tracrRNA), which together direct the Cas9 to cleave the target DNA sequence. This mechanism 
also requires the presence of a protospacer adjacent motif (PAM) upstream of the binding region 
(Jinek et al., 2012). As a genome editing tool, CRISPR/Cas9 can be used to target virtually any 
genomic sequence next to a PAM site, by simply designing appropriate gRNAs. The generation of 
a double strand break (DSB) by the Cas9 induces cellular DNA repair mechanisms, like non-
homologous ends joining (NHEJ), which is likely to introduce indels disrupting the targeted DNA 
sequence, or homology-directed repair (HDR), if a donor construct is present. This system has 
been optimised for its application to human cells, including hPSCs, by transfecting a single or 
multiple vectors to co-express the Cas9 nuclease and the gRNAs (Cho et al., 2013; Cong et al., 
2013; Jinek et al., 2013; Mali et al., 2013). As an alternative to the generation of a DSB by the wild-
type Cas9 enzyme, a mutated nickase version has also been developed, to facilitate HDR and 
reduce off-target mutations (Cong et al., 2013). Delivery of the CRISPR/Cas9 components via 
lentiviruses (Shalem et al., 2014; X. Wang et al., 2015), or adenoviruses (Maggio et al., 2014), has 
also shown a high efficiency in targeting the human genome. To further improve the flexibility and 
rapidity of genome editing in hPSCs, Danwei Huangfu’s group developed the iCRISPR platform, 
consisting of hESCs lines with doxycycline-inducible Cas9 expression (indicated as iCas9) (González 
et al., 2014). Transfection of iCas9 cells with gRNAs, derived via in vitro transcription, lead to over 
40% efficiency for single gene targeting or around 10% for triple gene targeting.  
Genome editing technologies are evolving fast and, as previously discussed, they represent a valid 
alternative to the use of iPSCs, because of the reduced variability associated with the use of 
isogenic cell lines. Alternatively, CRISPR/Cas9 could also be used to correct a specific genetic 
mutation in patient-derived cells. In this case, the rescue of the phenotype would provide the 
definitive proof of the connection between disease and genotype. When investigating the effects 
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of CNVs including several genes, the creation of isogenic models would be excessively time 
consuming, but it should at least be considered to confirm the causality link between the gene(s) 
of interest within a CNV and the phenotype observed in differentiated iPSCs. In conclusion, the 
careful planning of in vitro modelling experiments and parallel use of engineered hESCs and iPSCs, 
allows the generation of very elegant systems for the investigation of the cellular pathology 
underlying complex neurodevelopmental disorders. 
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Disease Genotype Cellular model Findings Reference 
Schizophrenia Mixed 
iPSCs from 5 patients and 6 
controls 
Differentiation to predominantly 
glutamatergic neurons 
Differences in neuronal connectivity, morphology and gene 
expression (glutamate, cAMP and WNT signalling, synaptic 
connection and long-term potentiation). 
(Brennand et al., 
2011) 
Schizophrenia Mixed 
iPSCs from 3 patients and 2 control 
individuals 
Differentiation to dopaminergic 
(DA) and cortical glutamatergic fate 
Defective differentiation to DA fate (lower TH expression, 
reduced number and length of neurites) 
Impaired maturation towards cortical glutamatergic fate 
(lower expression of synaptic markers) 
Mitochondrial abnormalities 
(Robicsek et al., 
2013) 
Schizophrenia Mixed 
iPSCs from 4 affected patients and 
6 controls 
Differentiation to neural progenitor 
cells (NPCs) 
Many differences in gene and protein expression (mainly 
relative to synapses, cellular adhesion and oxidative stress)  
Aberrant migration and increased oxidative stress in SZ NPCs 
(Brennand et al., 
2015) 
Schizophrenia Mixed 
iPSCs from 4 affected patients and 
6 controls 
Differentiation to NPCs 
Increased canonical WNT signalling in SZ cells  
No differences in migration 
(Topol et al., 2015) 
Schizophrenia 
Frameshift 
deletion in 
DISC1 gene 
iPSCs from 2 deletion carriers and 3 
controls 
Differentiation to forebrain 
neurons 
Morphological, electrophysiological and synaptic defects in 
DISC1-mutant neurons 
Phenotype rescued after correction of DISC1 mutation in 
patients’ cells 
Phenotype mimicked in control cells after introduction of 
DISC1 mutation 
(Wen et al., 
2014a) 
Schizophrenia 
15q11.2 
deletion 
iPSCs from 3 deletion carriers and 3 
control individuals 
Differentiation to NPCs 
Disrupted expression of apical adhesion proteins and 
formation of neural rosettes 
Phenotype rescued by lentiviral transduction to increase 
CYFIP1 expression 
(Yoon et al., 2014) 
Table 1.4 List of publications on iPSCs-based models of neurodevelopmental psychiatric disorders published to date. 
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Reduction of CYFIP1 level by shRNA recapitulated the 
phenotype 
Schizophrenia 
22q11.2 
deletion 
iPSCs from 6 deletion carriers and 6 
control individuals 
Embryonic bodies (EBs)-based 
differentiation to a mixed 
population of excitatory and 
inhibitory neurons 
Altered expression of miRNA regulating genes associated to 
psychiatric disorders  
(Zhao et al., 2015) 
Schizophrenia 
22q11.2 
deletion 
IPSCs from 8 deletion carriers and 7 
controls 
Differentiation to a mixed 
population of excitatory and 
inhibitory neurons 
Differentially expressed genes linked to cell cycle, cell survival 
and apoptosis and MAPK pathway 
(Lin et al., 2016) 
Syndromic 
Autism (Rett 
syndrome) 
MeCP2 
mutations 
iPSCs from 4 RTT patients and 6 
healthy controls 
Embryoid bodies (EBs)-based 
differentiation to a mixed 
population of excitatory and 
inhibitory neurons 
Reduced number of glutamatergic synapses, fewer spines and 
smaller soma in RTT neurons 
Synaptic defects rescued by IGF1 treatment 
(Marchetto et al., 
2010) 
Syndromic 
Autism (Rett 
syndrome) 
MeCP2 
mutations 
iPSCs from 5 RTT patients and 4 WT 
PSCs lines (3 iPSCs and HUES1) 
 
Impaired neuronal maturation of RTT iPSCs (lower TuJ and 
sodium channels expression) 
 (Kim et al., 2011) 
Syndromic 
Autism 
(Phelan-
McDermid 
syndrome) 
22q11.3 
deletion 
iPSCs from 2 patients and 3 control 
PSCs lines (2 iPSCs and HUES9) 
Differentiation to cortical neurons 
Altered excitatory post-synaptic transmission (reduced 
amplitude and frequency of excitatory post-synaptic currents, 
EPSCs)  
Inhibitory synaptic transmission unaffected 
Synaptic deficits restored to control levels by lentiviral 
transduction increasing SHANK3 expression, or IGF1 
treatment 
(Shcheglovitov et 
al., 2013a) 
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Syndromic 
Autism 
15q11-13 
duplication 
15q11-13 
deletion 
(Angelman 
syndrome ,AS) 
iPSCs from 4 duplication carriers, 1 
AS patient and 1 control 
Embryonic bodies (EBs)-based 
differentiation to a mixed 
population of excitatory and 
inhibitory neurons 
Altered level of transcripts related to neuronal 
differentiation, cell cycle and protein catabolism 
Several autism and epilepsy candidate genes amongst the 
differentially expressed genes 
(Germain et al., 
2014) 
Syndromic 
Autism 
(Fragile X 
Syndrome) 
FMR1 gene 
silencing 
caused by 
CGG 
expansion 
iPSCs from 3 patients and 2 hESCs 
control lines (H9 and HUES13) 
Cortical glutamatergic neurons 
differentiation 
Morphological abnormalities 
Reduced ability to fire trains of action potentials 
Abnormal synaptogenesis 
(Telias et al., 2015) 
Autism 
Spectrum 
Disorder 
Translocation 
in 3p21 and 
11q22 
chromosomes 
(Disruption of 
VPRBP and 
TRPC6 genes 
respectively) 
iPSCs from one patient and 2 
control lines (one iPSCs and 1 
HUES6) 
Differentiation to forebrain NPCs 
and neurons 
Differentially expressed genes relative to nervous system 
development and function (several CREB-target genes) 
Alterations of Ca++ influx, morphology and synapses 
Normal phenotype restored by lentiviral-mediated WT TRPC6 
expression or hyperforin (TRPC6 agonist) treatment 
Involvement of MeCP2 in TRPC6 regulation 
(Griesi-Oliveira et 
al., 2014) 
Autism 
Spectrum 
Disorder 
Mixed 
iPSCs from 4 patients and 8 
unaffected first-degree family 
members 
Differentiation to cerebral 
organoids 
Altered expression of genes involved in cell fate, proliferation, 
axonal guidance, synaptic function and ion channels 
Faster proliferation of ASD iPSCs and NPCs 
Overproduction of GABAergic neuros 
Phenotype rescued by reduction of FOXG1 level via shRNA 
(Mariani et al., 
2015)  
Autism 
Spectrum 
Disorder 
Mixed  
IPSCs from 8 patients with early 
brain overgrowth and 5 controls 
Differentiation to forebrain 
excitatory and inhibitory neurons 
Faster proliferation (altered β-catenin/BRN2 signalling) 
Reduced synaptogenesis and network activity 
(Marchetto et al., 
2016) 
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Bipolar 
Disorder 
Mixed 
iPSCs from 3 patients and 3 
controls 
Differentiation to forebrain 
neurons 
Dysregulated expression of several transcripts regulating 
dorso-ventral telencepahlic patterning, calcium signalling and 
miRNAs processing 
(Chen et al., 2014) 
Bipolar 
Disorder 
Mixed 
iPSCs from 6 patients and 4 
controls 
Differentiation to hippocampal 
dentate gyrus neurons 
Upregulation of mitochondrial genes, higher mitochondrial 
membrane potential and smaller mitochondria size in BD 
neurons 
Hyperexcitability of BD neurons (higher Na+ activation, 
increased action potential firing and amplitude) 
Mitochondrial and electrophysiological changes rescued by 
lithium (Li) treatment in neurons derived from Li-responsive 
patients 
(Mertens et al., 
2015) 
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1.4 Cortex development 
The cerebral cortex is considered to be the most complex structure of the human brain, which 
regulates its highest functions, such as consciousness and perception of reality, making it 
particularly relevant in the context of psychiatric disorders (Frith & Dolan, 1996). For this reason 
and because differentiation protocols for PSCs towards this fate are well characterised and 
reproducible, this approach is the most used in in vitro models of psychiatric disorders (see 
paragraph 1.3). The correct analysis and interpretation of the cellular phenotypes observed during 
the application of such protocols depends on a deep understanding of the corresponding in vivo 
process.  
Most of our knowledge about in embryonic cortical development derives from mouse studies, 
thanks to the availability of tissue and the ease of deriving mutant animals to study the function of 
specific genes. The following paragraphs describe embryonic cortex development primarily in the 
mouse model. Human data are included where important differences between the two models 
need to be highlighted.  
1.4.1 Early corticogenesis: progenitor subtypes and characteristics 
The most abundant class of neurons found in the cerebral cortex is represented by excitatory 
pyramidal neurons (~85%), which originate from the embryonic dorsal telencephalon, the rostral-
most region of the neural tube. GABAergic interneurons (INs), which migrate into the cortex from 
the MGE, in the ventral telencephalon, constitute the remaining 15-20% (Marín & Müller, 2014).  
The term corticogenesis is mainly used to indicate the generation of pyramidal neurons from 
progenitors located in the VZ and subventricular zone (SVZ), which together represent the 
proliferative area adjacent to the ventricles in the dorsal telencephalon (Fig. 5) (Tiberi, 
Vanderhaeghen & van den Ameele, 2012). The tissue forming the wall of the neural tube, where 
neurogenesis occurs, is characterised by an intrinsic polarity, with the side facing the ventricle 
defined as apical and the one in contact with the basal lamina (or pial surface) defined as the basal 
side (Fig. 5) (Taverna, Götz & Huttner, 2014). 
The first type of progenitors to arise early in development are neuroepithelial cells (NEs). These are 
bipolar cells that contact both apical and basal surfaces. The apical side is marked by the presence 
of tight junctions and a primary cilium, which detect signals present in the cerebrospinal fluid (CSF) 
filling the ventricle (Laguesse, Peyre & Nguyen, 2014). Signalling molecules in the CSF include 
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Fibroblast Growth Factors (FGF), Insulin-like Growth Factor (IGF), Sonic Hedgehog (SHH), Bone 
Morphogenetic Proteins (BMPs), Retinoic Acid (RA) and WNT (Taverna et al., 2014).  
NEs undergo a first phase of symmetric divisions to amplify the initial progenitor pool and later, 
with the onset of neurogenesis (~E12), switch to asymmetric divisions. The proliferation of this 
progenitor pool is characterised by a mechanism defined as Interkinetic Nuclear Migration (INM), 
which indicates the migration of the cell soma between the apical and basal side of the VZ at 
different phases of the cell cycle. Briefly, cell division during the M phase happens in contact with 
the apical surface, while other phases happen during migration towards the basal side (G1), while 
the nucleus is localised at the basal side of the VZ (S phase) or during migration from the basal to 
the apical side (G2). This mechanism, which allows all NEs to remain in contact with the apical 
surface, and to simultaneously migrate away from it at different times, leads to formation of what 
is defined as a pseudostratified epithelium (Fig 51a) (Taverna & Huttner, 2010). 
With the switch to asymmetric division, NEs undergo several changes, resulting in transformation 
into radial glia cells (RGCs). RGCs maintain some similarities to NEs, such as the extension of a 
primary cilium into the ventricle and the mechanism of INM (Laguesse et al., 2014). However, 
important differences include the loss of tight junctions, which are substituted by adherent 
junctions, and the expression of a different set of markers, including Paired box 6 (Pax6), Brain Lipid-
Binding Protein (BLBP), Vimentin (VIM) and Nestin (Feng et al., 1994; Götz et al., 1998; Laguesse et 
al., 2014).  
The adherent junctions, found at the apical surface, are marked by the presence of N-Cadherin 
(NCAD or CDH2) and Zona-Occludens 1 (ZO-1). Cadherins are transmembrane proteins which carry 
out, with their extracellular domain, calcium-dependent homofilic interactions, while, at the 
intracellular level, they recruit complexes of α/β-catenin. Catenin proteins mediate the interaction 
between Cadherins and the actin cytoskeleton, which is represented by a “belt” of F-Actin lining 
the apical surface of these cells (Suzuki & Takeichi, 2008; Thumkeo et al., 2011).  
The apical domain of RGCs is a fundamental signalling centre in the regulation of the balance 
between proliferation and differentiation of the cells occupying the VZ. The key signalling pathways 
active in this area include Wnt/β-Catenin, Notch, Fgf and Shh, all supporting the proliferation of the 
progenitor pool (Tiberi et al., 2012). Perturbation of the elements located at the apical surface of 
RGCs has deleterious consequences on the balance between self-renewal and differentiation of this 
class of progenitors. For instance, the interaction between Ncad and β-catenin contributes to 
regulating the pool of free β-catenin that can migrate into the nucleus and activate transcription 
(Taverna et al., 2014). It has been demonstrated that in vivo knock-down of Ncad in mouse cortical 
progenitors at E13.5, causes premature differentiation and migration away from the VZ (Zhang et 
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al., 2010). In addition to this, overexpression of a constitutively active form of β-catenin in mouse 
neural precursors causes abnormally enlarged brains due to the over-proliferation of neuronal 
progenitors (Chenn & Walsh, 2002).  However, a similar hyperactivation of the WNT pathway in 
basal progenitors has been reported to promote neuronal differentiation by activating the 
proneuronal gene Neurogenin 2 (NGN2), suggesting that most of these mechanisms are stage-
specific (Hirabayashi et al., 2004).  
Other proteins recruited to the apical domain and involved in signalling mechanisms include the 
atypical Protein Kinase C (aPKC) and Par complexes (Costa et al., 2007; Insolera, Chen & Shi, 2011). 
In particular, the level of Par3 in daughter cells regulates asymmetric division through a Notch-
mediated mechanism (Bultje et al., 2009).  Because of the connection between apical adhesion 
molecules and F-actin fibres, cytoskeleton dynamics are also involved in regulating RGCs behaviour. 
Indeed, conditional KO mouse models for RhoA and cdc42, two GTPase proteins participating in the 
control of actin polymerisation, showed alterations in RGC self-renewal (Cappello et al., 2006, 
2012). 
Asymmetric divisions of RGCs give rise to intermediate progenitors (IPs), another class of cortical 
progenitor cells, which are localised in the SVZ, and are characterised by a multipolar morphology 
and expression of the transcription factor Tbr2 (Englund, 2005). In mouse, these cells divide one or 
two times before undergoing the last terminal neurogenic division (Noctor et al., 2004). In humans 
and other gyrencephalic species, IPs can undergo more symmetric divisions, contributing to the 
expansion of the progenitor pool (Betizeau et al., 2013).  The primate SVZ is significantly thicker and 
can be subdivided into “inner” SVZ (ISVZ), containing TBR2+ cells, and “outer” SVZ, containing 
another type of progenitors defined as outer radial glia cells (oRGCs). Such cells are derived from 
apical RGCs by asymmetric division and are highly proliferative, generating more oRGCs, IPs or 
neurons directly (Betizeau et al., 2013). ORGCs possess a basal, but not an apical, fibre and express 
some pan-radial glia genes, such as VIM and HES1, and some unique markers, such as ITGB5, HOPX 
and TNC, which were recently identified. Moreover, the proliferation of this class of progenitors 
seems to be regulated by LIF/STAT signalling (Pollen et al., 2015). The expansion of the oSVZ is 
considered the most important event in the evolution of the neocortex (Dehay, Kennedy & Kosik, 
2015). 
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Figure 1.5 Scheme of cortical neurogenesis.  
(a) Interkinetic Nuclear Migration (INM) in ventricular zone (VZ) cells. (b) Neurogenic steps and progenitors 
subtypes in the mouse developing cortex. (c) Diversity of cortical progenitors in the human foetal cortex at 
approximately 15 weeks post-conception (PCW) (From Jiang and Nardelli 2016). 
 
1.4.2  Formation of the cortical layers 
Before the generation of neurons that will occupy the cortical plate (CP, layers I to V), Reelin+ Cajal-
Retzius cells appear close to the pial surface, in the so-called marginal zone (MZ). These early-born 
neurons are primarily generated in the cortical hem and septum and, in humans, can also originate 
from NE cells. A clear population of MZ cells is already present at gestational week (GW) 9 in the 
human developing cortex  (Bystron, Blakemore & Rakic, 2008). Cajal-Retzius cells secrete Reelin, a 
large glycoprotein, which provides fundamental signalling for the correct formation of the cortical 
layers (Frotscher, 1998). 
Cortical neurons of layers I to V are generated either directly from RGCs in the VZ or indirectly from 
intermediate progenitors in the SVZ. This happens via an asymmetric division, giving rise to a 
progenitor still capable of self-renewal and a cell destined to terminal differentiation, or via a 
symmetric neurogenic division (Noctor et al., 2004). Newly-born neurons migrate to the CP by 
somal translocation or locomotion. The first process happens when the cell extends a basal process 
and the cell body can move basally within it. In the second case, the neuron develops a short leading 
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process in the direction of the pial surface, but not attached to it, and the whole cell moves in that 
direction (Nadarajah et al., 2001).  
The formation of cortical layers happens in an inside-out manner, with early-born neurons 
populating the deep layers and late-born ones migrating past them to settle in more superficial 
positions. As soon as they leave the cell-cycle, the expression of specific transcription factors acts 
on post-mitotic neurons to specify their identity (Greig, Woodworth et al., 2013). This process is 
summarised in figure 1.6.  
Briefly, layer VI cortico-thalamic projection neurons are characterised by the expression of T-box 
brain protein 1 (Tbr1), a transcription factor that was demonstrated to be fundamental in the 
development of this class of neurons and that acts mainly by repressing FEZ Family Zinc Finger 2 
(Fezf2), which is in turn essential for specification of layer V sub-cerebral projection neurons (Chen 
et al., 2005; Mckenna et al., 2011). A typical marker of layer V neurons, named COUP-TF-interaction 
protein 2 (Ctip2) acts downstream of Fezf2 to regulate the extension of axonal projections to 
subcortical targets and determines in this way the acquisition of the correct fate (Chen et al., 2008). 
Layers II and III are primarily formed by neurons that project to other cortical structures, including 
callosal projection neurons, the axons of which extend across the corpus callosum into the 
contralateral hemisphere. The expression of the special AT-rich sequence binding protein 2, Satb2, 
which represses Ctip2, is essential for specifying the identity of this class of neuronal cells and for 
the development of their axonal projections towards the appropriate targets (Alcamo et al., 2008; 
Britanova et al., 2008). Satb2 is also weakly expressed by layer IV granular neurons, which project 
mostly locally (Alcamo et al., 2008; Britanova et al., 2008). They have been shown to derive from a 
population of SVZ progenitors labelled by Svet1 (Subventricular tag 1), and to be characterised also 
by the expression of the two homologues of the Drosophila homeobox Cut gene (Cux1/2) (Nieto et 
al., 2004; Tarabykin et al., 2001). Cux1/2 are specifically found in all upper-layer neurons, including 
Satb2+ layer II/III (Nieto et al., 2004).  
The specification of the various projection neuron subtypes happens in parallel to other processes, 
such as the specialisation of the different cortical areas and the generation and migration of 
inhibitory interneurons. Although very important in the context of cortex development, these 
events are not essential for the understanding and interpretation of the results presented in this 
thesis and, therefore, they are not reviewed in this chapter. 
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Figure 1.6 Schematic representation of cortical layer formation during mouse corticogenesis. 
 Neurons of all six cortical layers are generated sequentially, starting from E11.5. Cajal-Retzius (CR) cells are 
the first ones to appear and populate the top layer of the developing cortex. Subplate neurons (SPN) represent 
the first group of neurons to be generated from radial glia (RG) cells. They are followed by cortico-thalamic 
projection neurons (CThPN), subcortical projection neurons (SCPN), granular neurons (GN) and callosal 
projection neurons (CPN), in this order. At the end of corticogenesis, the remaining progenitors switch to the 
generation of astrocytes and oligodendrocytes (from Greig, Woodworth et al 2013). 
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1.5 Aims of the project 
Deletions and duplications of the 15q11.2 locus are known risk factors of psychiatric disorders and 
CYFIP1 is one of the four genes encoded in this region. In neuronal cells, CYFIP1 contributes to the 
regulation of actin polymerisation and mRNA translation in association with FMRP, the protein 
which mutation causes FXS. Because of this, CYFIP1 is considered the strongest candidate to be 
responsible for the development of psychiatric phenotypes in 15q11.2 CNVs carriers. 
The overall aim of this thesis is to investigate how altered levels of CYFIP1 affect cortical 
development of hPSCs, an aspect that may underpin its contribution to the phenotypes associated 
with 15q11.2 CNVs. To achieve this, I aim to generate hESCs lines with increased CYFIP1 expression 
and derive CYFIP1-knock out stem cells using CRISPR/Cas9. The parallel characterisation of these 
cell lines during cortical differentiation protocols will allow to uncover the mechanisms in which 
CYFIP1 is involved and, with the help of RNA-sequencing, those biological pathways that are 
specifically altered by changes in the expression of this gene. Manipulation of these pathways will 
be used to try and reverse the phenotypes associated to CYFIP1 alterations. 
Together with the derivation of hESCs with modified CYFIP1 levels, I will also derive iPSCs from some 
15q11.2 CNVs carriers recruited during the time of my project. Such iPSCs lines will be used to 
characterise the expression of the genes encoded in this locus during human cortical 
differentiation. This would help to understand if, together with CYFIP1, any of the other 15q11.2 
genes may be involved in the regulation of brain development.   
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2 Methods and materials  
2.1 Cell culture 
2.1.1 hESC culture 
The cell lines used in this study were H7 (wicell.org), iCas9 (González et al., 2014), their engineered 
derivatives, CYFIP1tg and CYFIP1ko, as well as iPSC lines derived from 15q11.2 deletion carriers. 
Human ESCs were maintained in mTesR1 or TesR-E8 media (STEMCELL technologies) under 
standard culture conditions (37˚C, 5% CO2) in 6 well-plates coated with Matrigel® (Corning, VWR). 
mTesR1 was used during critical steps, such as sub-cloning of genetically modified cells, or recovery 
after thawing or transfection. 
The cells were passaged every 3-4 days, when 70-90% confluent. Briefly, stem cells were washed 
once with DPBS and incubated in 0.02% EDTA (Sigma) for about 3 minutes at 37˚C. After removing 
EDTA, cells were dissociated into small clumps in fresh medium and were then seeded into a new 
plate. Usually, H7 and H9-iCas9 were split at ratios between 1:3 and 1:5. 
For freezing, approximately 1-2x106 cells were dissociated with EDTA as described above, 
centrifuged at 200g for 5 minutes and resuspended in 1ml of cold hESC medium with 10% DMSO 
(Sigma). Cryo-vials containing the cell suspension were transferred in an appropriate freezing 
container, placed at -80˚C, to achieve 1˚C/min cooling rate. Once frozen, cryo-vials were transferred 
to nitrogen tanks. 
For thawing, cryo-vials were placed in a water bath at 37˚C, to make this process as quick as 
possible. The thawed cell suspension was then transferred to 10 ml of pre-warmed hESC medium 
and centrifuged at 200g for 5 minutes. Finally, the cell pellet was resuspended in hESC medium and 
plated. 
2.1.2 Monolayer differentiation into cortical glutamatergic neurons 
The cortical pyramidal neurons differentiation protocol used for the experiments presented in this 
thesis is an adapted version of previously published ones (Espuny-Camacho et al., 2013; Kirwan et 
al., 2015; Yichen Shi et al., 2012). An outline of the procedure is shown in Figure 2.1. 
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Figure 2.1 Monolayer differentiation of hESCs into cortical pyramidal neurons. The timing for both 
parental lines is shown in grey, while the substrate and the type of media used at each stage are shown in 
blue and purple, respectively.   
 
Initially, stem cells were plated on Growth Factor Reduced Matrigel (Corning, VWR) and kept in 
hESCs medium until 80-90% confluent. The day when hESCs medium was switched to neural 
induction medium was set as day 0. The composition of all media used in differentiation 
experiments are listed in Table 2.1.  The timing of neuronal induction and maturation for H7 and 
iCas9 cells is remarkably different. Therefore, based on previous work of our group, the 
differentiation protocol was adapted accordingly. The cells were kept in neural induction medium 
until day 8 for the iCas9 line and day 12 for the H7, when LDN and SB were removed. 
Two days before the end of neural induction, the cells were split at a 2:3 ratio on fibronectin-coated 
plates. Coating with fibronectin (Millipore) was performed incubating a solution of 15μg/ml at 37˚C 
for at least 1 hour. For the splitting, the cells were first pre-treated with 100μM ROCK inhibitor (Y-
27632, STEMCELL Technologies), for 1 hour to prevent cell death. Then they were incubated in EDTA 
for 3 minutes and manually dissociated in N2B27 medium, using a 2ml serological pipette, keeping 
large cell clumps. These were carefully resuspended in the appropriate amount of neural induction 
medium and seeded in a new plate. 
After 8-10 days, the neural progenitors that form the differentiating cultures at this stage, were 
split again, at a ratio of 1:4, on Poly-D-Lysin/Laminin-coated plates. This coating was performed 
incubating first a solution of 10 μg/ml of Poly-D-Lysin (Sigma) for 30 minutes at room temperature. 
This was followed by 3 washes with DPBS and an overnight incubation at 37˚C with a 10μg/ml 
laminin solution (Sigma). A few days after this second passage, when cells displayed a clear neuronal 
morphology, the media is switched to N2B27, in which the B27 supplement contains vitamin A, to 
promote maturation. Throughout the whole differentiation protocol, cells were fed every other 
day. 
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Table 2.1 composition of media used for monolayer differentiation 
Media Composition 
N2B27 (without vitamin A) 
2:1 DMEM-F12 and Neurobasal, 
1x N2, 1x B27 without vitamin A, 2Mm Pen/Strep-Glutamine, 
0.1 mM Beta-Mercapto-Ethanol 
(All from Thermo Fisher) 
Neural induction medium 
N2B27 without vitamin A, 10μM SB-431542 (TOCRIS), 100nM 
LDN-193189 (TOCRIS) 
N2B27 (with vitamin A) 
2:1 DMEM-F12 and Neurobasal, 
1x N2, 1x B27 without vitamin A, 2Mm Pen/Strep-Glutamine, 
0.1 mM Beta-Mercapto-Ethanol 
(All from Thermo Fisher) 
 
2.1.3 hESC differentiation into brain organoids 
Human ESCs were differentiated into brain organoids according to the protocol published by 
Lancaster and Knoblich (Lancaster & Knoblich, 2014). Briefly, 9000 cells per well were seeded in U-
bottom ultra-low attachment 96w-plates to form embryoid bodies (EBs). EBs were fed every other 
day until 500-600 μm in diameter, when they were transferred to bacterial dishes in neural 
induction medium. After 4-5 days, the EBs showing a radially organised neuroepithelium were 
embedded in Matrigel droplets and cultured in differentiation medium. After a few days, when the 
embedded organoids started showing neuroepithelial buds, they were transferred to a spinning 
bioreactor in differentiation medium containing B27 with vitamin A and cultured in constant 
agitation until the time chosen for analysis. The composition of all media is listed in Table 2.2. 
Table 2.2 composition of media used for organoids differentiation 
Media Composition 
EBs medium 
DMEM-F12, KOSR (1:5), FBS (1:30, Biosera), 1x Pen/Strep-
Glutamine, 1x NEAA, bFGF (4ng/ml, PeproTech) and ROCK 
inhibitor (50mM, STEMCELL Technologies) 
Neural induction medium 
DMEM-F12, N2 supplement (1x), Pen-Strep-Glutamine (1x), 
NEAA (1x) and heparin (1μg/ml). 
Differentiation medium 
1:1 DMEM-F12 and Neurobasal, 0.5x N2, 0.5x B27 (with or 
without vitamin A), 1x Pen-Strep-Glutamine and 1x NEAA 
(All reagents from Thermo Fisher, unless otherwise stated) 
 
2.1.4 Other chemicals used in differentiation experiments 
For the experiment aimed at rescuing the neurogenesis phenotype in CYFIP1tg cells (Chapter 5.2.2), 
neural progenitors were treated for three days with XAV939 (1μM, TOCRIS), API2 (1μM, TOCRIS) or 
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an antibody blocking N-Cadherin function (ACAM GC-4, Sigma). An equivalent amount of DMSO 
(Sigma) was also added to the cultures as vehicle.  
2.2 Fibroblast and keratinocytes reprogramming into iPSCs  
The acquisition of primary tissue was performed in collaboration with the National Centre for 
Mental Health, with ethical approval from the Cardiff University Research Tissue Bank 
(11/WA/0255). Human dermal fibroblasts and keratinocytes were collected, cultured and 
reprogrammed by Dr. Craig Joyce. The reprogramming was carried out using the CytoTune®-iPS 2.0 
Sendai Reprogramming Kit (Thermo Fisher). Briefly, somatic cells from an early passage and at 
about 80% of confluency, were transduced with the appropriate amount of virus, according to 
manufacturer instructions. A week after transduction, the cells were re-plated on Matrigel-coated 
plates and, 24 hours later, their culture media was replaced with stem cells media. During the 
following 2 weeks, the media was replaced daily and the cultures were monitored for the 
appearance of iPSCs colonies. When they reached the appropriate size, these were manually 
picked, expanded and banked as described above. This part of the work was done in conjunction 
with Craig Joyce (NMHRI technician). 
2.3 Molecular cloning for CYFIP1-overexpression vector 
For the generation of the CYFIP1-overexpression vector, the full length open reading frame (ORF) 
of the human CYFIP1 gene was cut out of a commercial expression vector (Origene, SC100426) and 
cloned downstream of the CAG promoter in a pCAG-IRES-GFP plasmid available in the lab. To this 
end, the Origene plasmid was digested with the restriction enzyme NotI (New England Biolab, NEB) 
and run on a 2% agarose gel, to isolate the DNA band corresponding to CYFIP1 (4400 pb) from the 
backbone. The band corresponding to the CYFIP1 ORF was then cut and purified using the ISOLATE 
II PCR and Gel Kit (Bioline). At the same time, NotI was used to cut also the pCAG-IRES-PAC vector 
at the level of the insertion site, just downstream of the CAG promoter. This cut vector was then 
combined with a 3-fold molar excess of insert, the purified CYFIP1 ORF, for the ligation reaction. 
This was performed at room temperature, following the Quick ligation Kit (NEB) protocol. An aliquot 
of 5 µl from the ligation reaction was used to transform chemically competent cells 5-alpha F'Iq 
Competent E.coli (NEB) according to manufacturer’s instructions. Transformed bacteria were 
plated on LB agar plates containing ampicillin and incubated overnight at 37°C. On the following 
day, 10-20 miniprep reactions were set up from single ampicillin-resistant colonies. These were left 
to grow overnight in LB media, in constant agitation, at 37°C. The next day, the plasmid DNA was 
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extracted using QIAprep Spin Miniprep Kit (Qiagen) and screened with BglII and PvuI (both NEB) to 
reveal the presence and orientation of the insert. A representative image of the digested CYFIP1-
overexpression (pCAG-hCYFIP1-IRES-PAC) vector can be found in Chapter 3 (Fig. 3.1). All digestions 
were performed in the recommended buffers, at 37°C, for at least 1 hour.  
2.4 CRISPR/Cas9 targeting: gRNA design and synthesis 
Guide-RNAs (gRNAs) targeting the first exon of CYFIP1 were designed using DNA2.0, now ATUM 
(www.atum.bio) and the online CRISPR Design tool from the Massachusetts Institute of Technology 
(www.crispr.mit.edu). Three sequences were chosen based on the off-targets scores given by both 
online tools.  The gRNAs were then generated via in vitro transcription. To this purpose, a single-
strand DNA oligo containing a T7 promoter followed by a 20 nucleotides-long guide sequence and 
the tracr-RNA, was synthetized by Sigma (Fig. 2.1 A). This single-strand construct was used as 
template for PCR using a primer complementary to the T7 region and one complementary to the 
last 20 nucleotides of the tracr-RNA sequence (Fig. 2.1 A, red arrows). The resulting double stranded 
DNA amplicon was converted into RNA using the MEGAshortscript T7 kit for in vitro transcription 
(Thermo Fisher), to produce an RNA molecule composed by guide sequence and tracrRNA in a 5’ to 
3’ order. The yield was determined by running 2 µl of the in vitro transcription reaction on a 2% TBE 
gel (Fig. 2.1 B), while the remaining product was purified using the MEGAclear Kit (Thermo Fisher), 
to obtain the gRNAs ready for transfection. 
 
Figure 2.2 Generation of gRNAs. 
(A) Nucleotide sequence of one of the DNA oligo used as template for in vitro transcription. The T7 promoter 
sequence is shown in green, the guide RNA in black and the tracrRNA sequence in blue. Red arrows represent 
the primers used for PCR amplification of the ssDNA oligo. (B) RNA gel showing the products of in vitro 
transcription with three different guide sequences.  
 
2.5 Transfection of hESCs 
2.5.1 Nucleofection 
Nuleofection was used to deliver the pCAG-hCYFIP1-IRES-PAC plasmid (see paragraph 2.2) into H7 
hESCs, to derive CYFIP1-Overexpressing (CYFIP1tg) cells (see also Chapter 3). For the transfection, 
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the Lonza 4D-Nucleofector® and the P3 Primary Cell 4D-Nucleofector® X Kit were used, according 
to manufacturer’s instructions. For one nucleofection, about 2x106 H7 hESCs were dissociated with 
Gentle Cell Dissociation Reagent (STEMCELL Technologies) for 10 minutes and spun down in stem 
cells medium. The cell pellet was resuspended in 100 µl of P3 buffer together with 2 µg of plasmid 
DNA and placed into an electroporation cuvette. The CB-150 program, pre-installed in the 4D-
Nucleofector, was applied to deliver the plasmid. Immediately after this step, the cells were re-
plated in hESCs medium, supplemented with 100μM Y-27632, and left to recover for 2 days. After 
this time, puromycin selection (1μg/ml) was applied for ten days, until a few colonies of cells with 
stable expression of the transgene remained and grew to a suitable size to be manually picked. 
2.5.2 RNA transfection 
RNA transfection was carried out to deliver gRNAs into iCas9 hESCs for the derivation of the 
CYFIP1ko line (see also Chapter 3). The Lipofectamine® RNAiMAX transfection reagent (Thermo 
Fisher) was used for this purpose. Following the product protocol, 1μl of Lipofectamine and the 
appropriate amount of RNA were diluted into two separate aliquots of stem cell medium (250μl 
each, for one well of a 6 well-plate). These were then combined and incubated at room temperature 
for 20 minutes, to allow the formation of RNA-Lipofectamine complexes. After this time, such 
complexes were added dropwise to two wells of ~50% confluent iCas9 cells. The final concentration 
of RNA in the well was of 10 nM for the fluorescent Alexa555-Block iT RNA control (Thermo Fisher) 
and 20 nM for the guide RNAs used for CYFIP1-targeting.  
2.6 Gene expression analysis  
2.6.1 RNA extraction 
RNA was isolated from cultured cells using a phenol/chloroform extraction protocol. Firstly, 
cultured cells from one well of a 12-well plate were washed once with PBS and lysed in 1 ml of 
TRIzol® (Thermo Fisher). Cell lysates from the same experiment were stored at -80°C until all the 
samples, from multiple cell lines and/or multiple time points, were collected. Biological duplicates 
for each sample of each experiment, were taken.  
The extraction was performed following the manufacturer’s protocol. Briefly, the samples were 
thawed and 200 µl of chloroform were added to each of them. The samples were then shaken and 
centrifuged at 12,000g for 15 minutes to allow the separation of the mixture into a lower red 
phenol-chloroform phase, a white interphase, and a colourless upper aqueous phase. The RNA-
containing aqueous phase was transferred to a new tube, mixed with 500 µl isopropanol and left 
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to stand for 5 minutes at room temperature. The RNA was precipitated by centrifuging the samples 
at 12,000g for 10 minutes. The supernatant was discarded and the pellet washed in 75% ethanol. 
The RNA was pelleted again by centrifugation at 7,500g for 5 minutes. After removing ethanol RNA 
samples were air dried and resuspended in DEPC-treated bi-distilled water (ddH2O). All 
centrifugation steps were performed at 4°C. The RNA concentration was measured using a 
BioSpectometer (Eppendorf). 
2.6.2 DNase treatment 
RNA was treated with the TURBO DNA-free kit (Thermo Fisher) to remove any presence of 
contaminant DNA that could compromise the qPCR analysis. For each sample, 10 µg of RNA were 
diluted with nuclease-free water to a final volume of 17 µl, to which 2 µl TURBO DNase 10x buffer 
and 1 µl TURBO DNase were added. The samples were incubated at 37°C for 30 minutes. After this 
time, 2 µl of DNase inactivation reagent were added to stop the reaction and incubated for 5 
minutes at room temperature. Finally, the samples were centrifuged for 1.5 minutes at 10,000g to 
pellet the DNase enzyme and inactivation reagent and the supernatant, containing DNA-free RNA, 
was transferred to a new clean tube. At the end of the DNase treatment the RNA concentration 
was re-measured. 
2.6.3 Reverse transcription 
The qScript cDNA Supermix (Quantabio) was used for reverse transcription. Following the 
manufacturer protocol, 1 µg of RNA for each sample was diluted in DEPC-treated ddH2O up to a 
volume of 16 µl, which was combined with 4 µl of 5X Supermix. Samples were placed in a T100 
Thermal Cycler (Biorad) and the recommended program was run (25°C for 5 minutes, 42°C for 60 
minutes and 85°C for 5 minutes). The resulting cDNA was diluted 1:10 with ddH2O and stored at -
20 °C. 
2.6.4 qPCR 
Quantitative PCR (qPCR) was used to quantify transcripts of interest using fluorescent dsDNA-
binding dye and measuring its signal as the specific sequence of interest is amplified during the 
reaction. For this process, each sample was run as a triplicate. Firstly, a mastermix containing 10 µl 
of 2X PerfeCTa SYBR Green SuperMix (Quantabio), 2μl of primers (from a 10 µM stock) for the gene 
of interest and 6 µl of ddH2O was prepared for each well of 96-well plate needed for the analysis. 
A volume of 18 µl of this mastermix was pipetted into each well together with 2μl of the cDNA 
solution of the appropriate sample. The qPCR reaction was run on a Bio-Rad CFX Connect Real-Time 
System. The program used included an initial incubation at 95°C for 4 mins, followed by 40 cycles 
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of 94°C for 30 secs, 60°C for 15 secs and 72°C for 30 secs. A melting curve was also generated to 
check for the specificity of the product at the end of the run. The data were analysed on Microsoft 
Excel using the ΔΔCT method for relative quantification (Livak & Schmittgen, 2001; Pfaffl, 2001). 
Table 2.3 Primers used for qPCR 
Gene Fw sequence (5’-3’) Rev sequence (5’-3’) 
IRES CCACCATATTGCCGTCTT GAGGAACTGCTTCCTTCA 
CYFIP1 GAAAACCGTGGAGGTTCTGGA GCTCAATGGCATTTCTCTGGAAG 
NIPA1 TGGGCGCCCTTGGAGTA TGCCCAAGATGTTGAGCTTTT 
NIPA2 GGCCAACTTCGCTGCGTAT GGCACTTACTAGCACGCTGAGA 
TBGCP5 TGTTTTACTTTTTGGTGAACTGGTTAG TGAGCAACTGTGTCTTGTTCATGT 
GAPDH ATGACATCAAGAAGGTGGTG CATACCAGGAAATGAGCTTG 
18S rRNA GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
(NIPA1, NIPA2 and TUBGCP5 primers were published by Picinelli et al., 2016) 
 
2.7 Genotyping 
2.7.1 Genomic DNA extraction 
Cultured cells were washed once with PBS and incubated at 37°C overnight in lysis buffer (10 mM 
Tris-pH8.0-, 50 mM EDTA, 100 mM NaCl, 0.5% SDS) supplemented with 0.5mg/ml of Proteinase K 
(all components from Sigma). The following day the lysis buffer was mixed with an equal volume of 
isopropanol and the DNA was precipitated at 15,000g for 20 minutes. The resulting pellet was 
washed with 70% ethanol, air-dried and resuspended in an appropriate amount of ddH2O. DNA 
concentration was measured with a Biospectrometre (Eppendorf). 
2.7.2 PCR and DNA electrophoresis 
PCR was used for the screening of CYFIP1-targeted clones. Each PCR reaction included about 100ng 
of template genomic DNA, 10µl of 5X MyTaq Buffer, 1 µl of MyTaq Polymerase (Bioline), 2 µl of 
primers from a 20µM stock and ddH2O up to 50μl. Usually, 30 amplification cycles were performed 
in a T100 Thermal Cycler (BioRad). Each cycle included 15 seconds of denaturation at 95°C, 15 
seconds of annealing at 55-57°C and 10-20 seconds of extension at 72°C. The annealing 
temperature and length of the extension interval were optimised for each pair of primers. Finally, 
5 µl of the final PCR product were run on agarose gel (1 to 4% agarose, according to the size of the 
PCR amplicon). 
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Table 2.4 Primers used for genotyping of CYFIP1 locus 
Gene Fw sequence (5’-3’) Rev sequence (5’-3’) Product length 
CYFIP1 ATGTGTTGTTCCAGCCCAGG CATCATGTGGGGTCGGAGC 190bp 
CYFIP1 CCCTGAGAGAGACACGCAAC CCTCACTGCATAGTCTATTGGGA 557bp 
 
2.7.3 Surveyor assay 
The Surveyor assay allows the quantification of the targeting efficiency in a pool of transfected cells 
using the activity of the Surveyor Nuclease, which recognizes and cleaves mismatches caused by 
small indels in a DNA fragment. The Surveyor® Mutation Detection Kit (Integrated DNA 
Technologies) was used for this purpose. 
Following the manufacturer protocol, a PCR product derived from a pool of targeted cells was 
placed in the T100 Thermal Cycler (Biorad) to undergo a cycle of denaturation and re-annealing 
(95°C for 10 minutes, ramp down to 85°C at -2°C /s; ramp down to 25°C at -0.1°C /s; hold at 4°C). 
This allows the formation of heteroduplexes between the different DNA molecules within the PCR 
mixture, which was then mixed with MgCl2 (1:10) and SURVEYOR Enhancer S (1µl). The reaction 
was split in two equal parts, of which only one was treated with SURVEYOR Nuclease S (1µl), while 
the other was used as “non-treated” control. Both aliquots were incubated at 42°C for 60 minutes 
and then mixed with Stop Solution (1:10). Finally, reactions were run on a 4% agarose gel and 
imaged. The intensity of the bands, measured by ImageJ, was used to calculate the targeting 
efficiency according to the formula below (Ran et al., 2013).  
%indels= 100 x (1 – (1- fraction cleaved)1/2) 
2.7.4 PCR cloning and sequencing analysis  
Candidate CYFIP1 mutant hESC lines identified by PCR were selected for sequencing to verify the 
presence of indels and out-of-frame mutations. To this end, the targeted locus was amplified with 
a pair of primers producing a 600 bp product followed by cloning into the pGEM-T vector (Promega) 
following the manufacturer’s protocol. A ligation containing pGEM-T Easy vector (1µl), 2X reaction 
buffer (5µl), T4 DNA ligase (1µl) and purified PCR product (3µl) was set up and incubated for 1 hour 
at room temperature. A volume of 2 µl from this reaction was used to transform competent cells 
(NEB® 5-alpha F'Iq Competent E. coli) with a heat-shock mediated transformation. The competent 
cells were then plated on LB plates and incubated overnight at 37°C. For each transformation, the 
plasmid DNA was extracted from 10 minipreps as described above (2.3) and EcoRI digestion was 
used to verify the presence of the insert. The plasmids that has successfully incorporated the PCR 
amplicon were sent to GATC Biotec (gatc-biotec.com) for Sanger sequencing. The results were 
analysed with the BioEdit software (www.mbio.ncsu.edu/BioEdit).  Each sequence derived from a 
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targeted clone was aligned with the WT sequence and translated into the predicted protein, to 
characterise the type of mutation generated during the targeting.  
2.8 Western Blotting 
Cultured cells were lysed on ice using RIPA buffer (Abcam) supplemented with a protease and 
phosphatase inhibitors cocktail (Sigma). Cell lysates were centrifuged for 15 minutes at 12000g and 
the resulting supernatant was combined with 1X Bolt®LDS Sample Buffer (Thermo Fisher) and 1X 
Bolt®Sample Reducing Agent (Thermo Fisher) and boiled at 97°C for 5 minutes. Equal amounts of 
proteins for each sample were separated on 4-12% Bolt® Bis-Tris Plus gels (ThermoFisher) and then 
transferred to a PVDF membrane (0.45 µm pore size, Amersham Hybond, GE Healthcare) via 
electro-blotting. The membrane was blocked in 5% BSA (Sigma) in Tris Buffered Saline containing 
0.1% Tween (TBS-T) and incubated with primary antibodies overnight at 4°C. The membrane was 
then washed three times in TBS-T, incubated 1 hour at room temperature with secondary 
antibodies and washed again before imaging. The secondary antibodies used were conjugated to 
horse-radish peroxidase (HRP) (Abcam) or to infra-red dyes (IRDye 800CW or 680RD) (LI-COR). HRP 
secondary antibodies were detected following 5 minutes incubation with the reagent Luminata 
Crescendo HRP substrate (Millipore). Chemiluminescent detection was carried out with a BioRad 
ChemiDoc™ XRS+ system. Alternatively, when IR secondary antibodies were used, the blots were 
imaged with the LI-COR Odyssey CLx system. In both cases, the images were exported to ImageJ for 
quantification. 
Table 2.5 Antibodies used for western blotting 
Target Species Dilution Cat. Number Supplier 
βCAT mouse 1:1000 Sc-7963 Santa Cruz 
βCAT (p-ser33/37) rabbit 1:500 2009 Cell Signalling Technologies 
βCAT (p-Ser552) rabbit 1:500 9566 Cell Signalling Technologies 
CYFIP1 rabbit 1:3000 AB6046 Millipore 
GAPDH mouse 1:10000 AB8245 Abcam 
GAPDH rabbit 1:10000 AB9485 Abcam 
NCAD mouse 1:1000 18-0224 Thermo Fisher 
NIPA1 rabbit 1:500 AB128640 Abcam 
NIPA2 rabbit 1:500 AB84343 Abcam 
TUBGCP5 mouse 1:1000 AB168325 Abcam 
 
 
48 
 
2.9 Immunocytochemistry   
2.9.1 Immunofluorescence staining  
Cultured cells were washed with DPBS and fixed with cold 3.7% PFA for 15 minutes. PFA incubation 
was followed by 3 PBS (Sigma) washes before proceeding with staining. In the case of cerebral 
organoids, fixing was performed in a well of 24-well plate. Here, the desired number of organoids 
was washed with DPBS and incubated in cold 4% PFA for 15 minutes. They were then incubated 
overnight at 4˚C in a 30% sucrose solution in PBS. The organoids were then embedded in a pre-
warmed solution containing 7.5% gelatin (Sigma) and 10% sucrose (Sigma) in PBS. Gelatin blocks 
were cut with a cryostat (Leica) into 13 µm-thick sections and stored at -80˚C.  
For staining, cells or organoids sections were first permeabilised in PBS-T (0.3% Triton-X-100 in PBS) 
for 10 minutes, and then blocked in PBS-T with 2% BSA and 3% donkey serum (Gentaur) for 30 
minutes at room temperature.  Cells or sections were incubated with primary antibodies in blocking 
solution overnight at 4°C. They were then washed 3 times for 10 minutes in PBS-T and AlexaFluor 
secondary antibodies (Thermo Fisher), diluted in PBS-T, were added and incubated for 2 hours at 
room temperature, in the dark. Nuclei were stained with DAPI (Sigma), diluted 1:3000 in PBS. After 
3 more washes with PBS, stained cells or sections were mounted with DAKO fluorescent mounting 
medium and stored at 4°C.  
Table 2.6 Antibodies used for immunofluorescence 
Target Species Dilution Cat. Number Supplier 
CTIP2 Rat 1:500 AB18465 Abcam 
FOXG1 Rabbit 1:1000 AB18259 Abcam (ChIP grade) 
GABA Rabbit 1:1000 A2052 Sigma 
KI67 Mouse 1:1000 550609 BD Pharmigen 
MAP2 Mouse 1:1000 M1406 Sigma 
NCAD Mouse 1:1000 18-0224 Thermo Fisher 
NESTIN Rabbit 1:500 ABD69 Millipore 
NEUN Mouse 1:500 MAB377 Millipore 
NEUN Rabbit 1:500 ABN78 Millipore 
OCT4 Goat 1:500 SC-8629 Santa Cruz 
P27KIP1 Rabbit 1:500 06-445 Upstate (Millipore) 
PAX6 Mouse 1:1000 PAX6 DSHB 
PHH3 Rat 1:1000 641002 Biolegend 
SATB2 Mouse 1:100 AB51502 Abcam 
SSEA3 Rat 1:500 MAB4303 Millipore 
TBR1 Rabbit 1:500 AB31940 Abcam 
TBR2 rabbit 1:500 AB23345 Abcam 
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2.9.2 EdU proliferation assay 
The Click-iT® EdU Alexa Fluor Imaging Kit (Thermo Fisher) was used to measure proliferation of 
neural progenitors at several stages of differentiation. Cultured cells were incubated with EdU 
(1:1000, final concentration 10 µM) in culture media at 37°C, usually for 2 hours, then fixed in PFA, 
as described above. EdU detection was performed by incubating the cells for 20 minutes at room 
temperature in the Click-iT reaction cocktail, prepared as per manufacturer’s protocol. If co-staining 
with other nuclear markers, this step was performed after the incubation with secondary 
antibodies. Finally, EdU detection was followed by nuclei stain with DAPI and mounting, as 
described above.  
2.9.3 Imaging and picture analysis 
Stained cells were imaged using a Leica DM6000B inverted microscope, if fixed on plates, or a Leica 
DMI6000B upright microscope, if fixed on coverslips and mounted on slides. An average of 10 
random fields was acquired for each well or coverslip at a 20x magnification, if intended for 
quantification. Cell counting was performed automatically, using Cell Profiler (cellprofiler.org), for 
DAPI and most nuclear markers. Other measurements, such as number and morphology of neural 
rosettes, were performed manually, using the ImageJ software. Data analysis and representation 
was carried out using Microsoft Excel and R (www.r-project.org). Unless otherwise stated, all the 
immunohistochemistry quantifications were collected from at least two independent experiments, 
with at least two biological replicates for each marker counted.  
2.10 High Content analysis of mitochondria  
2.10.1 Mitotracker staining 
Neuronal cells were seeded, 2 or 3 days before the analysis, in 96 well- plates at a density of 2000 
cells per well. On the day of the analysis, they were incubated with 100 nM Mitotracker 
(ThermoFisher) for 1 hour at 37°C. Cultures were then fixed in PFA and the nuclei were stained with 
DAPI, as described above. The stained cells were preserved in DAKO for a few days at 4 °C. 
2.10.2 Cell Insight CX7 High Content Screening (HCS) platform 
The Cell Insight CX7 HCS platform (ThermoFisher) combines fluorescent microscopy (wide-field or 
confocal), automated image acquisition and quantitative analysis. The Spot Detector application 
allows quantitative analysis of fluorescence punctate stainings and was therefore used for the 
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analysis of Mitotracker-labelled mitochondria. Before running the analysis, the “miniscan” function 
was used to set up and test all the parameters necessary for the assay. These include the 
background removal, thresholding and segmentation for the DAPI staining. The correct 
identification of all the nuclei in each field, also depends on the elimination of DAPI+ “objects” of 
abnormal shape or size, like small debris or clusters of nuclei not correctly segmented. For the 
Mitotracker staining, only background removal and thresholding were applied.  Images were 
acquired using the confocal function. At least 10 fields from about 10 wells for each cell line and 
time point were imaged without changing any of the acquisition and processing settings. 
Quantitative data relative to spot count, intensity and nuclear morphology were exported and 
analysed in Microsoft Excel and R. 
2.11 Flow cytometry analysis 
Flow cytometry was used to evaluate the efficiency of RNA transfection during the generation of 
CYFIP1-tageted cell lines (described in Chapter 3) and to analyse the cell cycle profile after DAPI 
staining (results in Chapter 4). Before the analysis, both transfected (or stained) and non-
transfected (or unstained) cells were dissociated in Accutase (Thermo Fisher) for 10 minutes at 
37°C. When this reagent was removed, the cells were resuspended in cold DPBS and analysed on a 
BD LSR Fortessa cytometer (BD Biosciences). Lasers of the appropriate wavelength were used for 
exciting the samples and gates were set using the unstained samples as negative controls. The 
instrument was set up with the help of Mark Bishop, lab manager for the European Cancer Stem 
Cells Research Institute of Cardiff University. Data were analysed with FlowJo_V10 software. 
2.12 Transcriptome analysis via RNA sequencing (with Daniel Cabezas de la 
Fuente) 
RNA was collected for sequencing at three time points of differentiation, for each cell line, in 
triplicate. The extraction was performed with the PureLink® RNA minikit (Thermofisher), following 
manufacturer’s instructions. RNA quality was checked on an Agilent Bioanalyzer 2100, by the 
Central Biotechnology Services (CBS) facility of Cardiff University. After confirmation that all the 
samples had a RNA Integrity Number (RIN) above 8, proving the absence of degradation, they were 
sent to the Oxford Genomics Centre for library construction and RNA sequencing (RNA-seq) 
(http://www.well.ox.ac.uk/ogc). Here, 1 μg of RNA was used for library construction with a TruSeq 
mRNA Library Preparation kit (Illumina). Paired-end sequencing was performed on an Illumina 
HiSeq 4000 with a depth above 28 million reads per sample.  
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Processing of the raw data, quality control and differential gene expression were performed by 
Daniel Cabezas de la Fuente, with the help of Dr Robert Andrews (Cardiff University Data Clinic) and 
Dr Andrew Pocklington (MRC Centre for Neuropsychiatric Genetics and Genomics). Briefly, the 
FASTQ files generated from the sequencing were trimmed from any residual Illumina adapter 
sequence and from low quality bases, then mapped to the Ensembl human genome GRCh38.84 
(hg38) using STAR (Bolger, Lohse & Usadel, 2014; Dobin et al., 2013). The FastQC software was used 
to perform a quality control of the data (www.bioinformatics.babraham.ac.uk/ projects/fastqc). 
Finally, the expression values for each gene, intended as the number of reads aligning to its 
sequence, were generated using the FeatureCounts software (Liao, Smyth & Shi, 2014).  These 
values were used for differential gene expression analysis. This was performed in R, using the 
Bioconductor package DESeq2 (Anders & Huber, 2010). The Benjamini-Hochberg (BH) correction 
method was applied to control for false discovery rate (Benjamini & Hochberg, 1995). The 
differentially expressed genes (DEGs) resulting from this process were analysed with the 
Bioconductor package ClusterProfiler to identify dysregulated pathways via KEGG gene set 
enrichment analysis (Kanehisa et al., 2012; Yu et al., 2012a). The selection of genes related to a 
specific function was carried out using the R package dplyr (CRAN.R-project.org/package=dplyr). 
With this, the data-frame of DEGs between two cell lines at one time point was cross-compared 
with the desired list of EnrezIDs. Neurogenesis-related transcripts were obtained from the Gene 
Ontology website (geneontology.org) and mitochondria-related transcripts were from the 
MitoCarta2.0 website (broadinstitute.org) (Calvo, Clauser & Mootha, 2016). Graphic representation 
of RNA-seq data was carried out with the R package ggplot2 (CRAN.R-
project.org/package=ggplot2).  
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3 Derivation of hESCs with altered CYFIP1 dosage and iPSCs 
carrying 15q11.2 CNVs 
3.1 Introduction 
Psychiatric disorders are caused by a complex combination of genetic and environmental factors 
(Robinson, Neale & Hyman, 2015; Sullivan, 2005). Many common genetic variants have been 
demonstrated to increase the risk of developing diseases such as ASD and SZ, with variable 
penetrance.  Some of these variants are represented by CNVs, which often include more than one 
gene (Gratten et al., 2014).  
In this context, the use of patient-derived iPSCs represents an advantageous alternative to the 
generation of animal or cellular models carrying mutations in several genes, the generation of which 
would be technically challenging. However, because of the genetic variability between individuals, 
iPSC-based experiments need to include several clonal lines from different patients, in order to 
produce reliable results.  A solution to this problem is represented by working with genetically-
modified hESCs and their parental isogenic line, which are not subject to the same degree of 
variability. This approach also allows to explore the phenotype specifically caused by one gene of 
interest, within a CNV, independently from the other genes in the same region and from the genetic 
background of a patient. Therefore, modified hESCs and patient-derived iPSCs represent two 
complementary aspects, which should both be considered for in vitro disease modelling.   
Since the start of iPSC research, an efficient and popular method for the reprogramming of patients’ 
somatic cells has been the ectopic expression of pluripotency-inducing factors using viral vectors, 
in particular retrovirus (Park, 2008; Takahashi et al., 2007). However, retroviral vectors have been 
demonstrated to be easily silenced, eventually resulting in incomplete reprogramming, and require 
integration into the host genome, leading to the disruption of random genes, with unknown 
consequences (Hu, 2014). 
Sendai virus-based (SeV) vectors have been developed as a safer alternative to express transgenes 
in a variety of host cells and have become an increasingly popular method for iPSC reprogramming. 
This is because SeVs are not pathogenic for humans and do not require integration into the host 
DNA. Moreover, the development of SeV vectors with depletion of fusion proteins and/or 
introduction of temperature-sensitive mutations into key viral proteins has opened the possibility 
of deriving virus-free stably reprogrammed iPSCs from a variety of somatic cells (Ban et al., 2011; 
Fusaki et al., 2009; Nakanishi & Otsu, 2012). These advantages have led our choice of 
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reprogramming system towards a commercially available kit containing SeV-based vectors for the 
delivery of Oct3/4, Sox2, c-Myc and Klf4, which have been successfully used by several published 
studies (Fusaki et al., 2009; MacArthur et al., 2012; Tucker et al., 2013). 
The generation of iPSCs carrying 15q11.2 CNVs is only one of the tools necessary to investigate the 
role played by the genes in this locus, particularly CYFIP1, during brain development. Together with 
patients’ cells, the derivation of isogenic hESC lines carrying CYFIP1 mutations alone is also 
necessary and, because 15q11.2 CNVs can occur as deletions or duplications, hESCs with increased 
and decreased expression of this gene are equally important.  
The overexpression of a gene of interest in hESCs can be challenging, as transgenes tend to be 
silenced over subsequent passaging of undifferentiated cells and also during the course of in vitro 
differentiation (Liew et al., 2007). However, a comparison of several vectors where the expression 
of eGFP (enhanced Green Fluorescent Protein) was driven by different promoters, showed that the 
pCAG promoter allows the generation of hESCs lines with stable transgene expression, maintained 
also in the differentiated progeny (Liew et al., 2007). This promoter is formed by the sequences of 
the cytomegalovirus early enhancer element, the promoter and first exon and intron of the chicken 
β-Actin gene and the splice acceptor site of the rabbit β-Globin gene and appears to be efficient 
also in bicistronic vectors. For instance, transfection of pCAG-GFP-IRES-PURO, where the GFP and 
puromycin-resistance gene (PURO) are linked by an internal ribosomal entry site (IRES), has been 
applied to several hESC lines to derive stably transfected clones, without affecting their 
pluripotency (Braam et al., 2008). Therefore, this approach appears to be promising also for the 
generation of CYFIP1-overexpressing (CYFIP1tg) hESCs.  
Gene targeting in hPSCs has recently become significantly easier by the discovery of the 
CRISPR/Cas9 system and its optimisation for use in mammalian cells. This technique requires the 
construction of plasmids or viral vectors allowing co-expression of the Cas9 and gRNAs into the 
target cells (Cho et al., 2013; Cong et al., 2013; Jinek et al., 2013; Mali et al., 2013). The need for 
several cloning steps can be bypassed using the iCRISPR platform, represented by hESCs containing 
a doxycycline-inducible Cas9 stably integrated in their genome. Once the Cas9 expression is 
induced, the only step required is the transfection of gRNAs, which can be generated by in vitro 
transcription or purchased. This method has been reported to have an efficiency as high as 40% 
(González et al., 2014). For this reason, the iCRISPR platform was chosen for the generation of 
CYFIP1-knockout (CYFIP1ko) hESCs.  
In this chapter, I describe the derivation and validation of CYFIP1tg and CYFIP1ko hESCs and the 
reprogramming of 15q11.2-deleted fibroblasts and keratinocytes into iPSCs. The characterisation 
of these patient-derived lines includes the analysis of protein levels for the four 15q11.2 genes in 
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iPSCs-derived NPCs and neurons, an aspect that has not been reported to date. The generation of 
iPSCs carrying 15q11.2 duplication has not been possible, because no patients with such mutation 
were recruited during my PhD. 
3.2 Results 
3.2.1 Generation of CYFIP1tg hESCs 
(I) Construction of Cyfip1 overexpression vector 
For the generation of CYFIP1tg hESCs, a bicistronic vector containing the CYFIP1 and puromycin 
acetyltransferase (PAC) genes under the control of the pCAG promoter was created (pCAG-hCYFIP1-
IRES-PAC). Such a construct allows high constitutive CYFIP1 expression and provides puromycin 
resistance to all stably transfected cells.  
The full-length human CYFIP1 open reading frame (ORF) was cut out of a commercially available 
expression vector and cloned downstream of the CAG promoter in a pCAG-IRES-PAC plasmid (Fig. 
3.1 A). A digestion with the restriction enzymes PvuI and BglII was performed to confirm the 
presence and orientation of the right insert (Fig. 3.1 B). The plasmid, the digestion of which is shown 
in lane 1, was used for transfection of H7 hESCs. 
 
 
Figure 3.1 CYFIP1-overexpression vector construction.  
(A) Map of CYFIP1-overexpression plasmid and (B) DNA electrophoresis gel showing BglII/PvuI digestion 
pattern of the same plasmid with CYFIP1 insert in the correct orientation (lane 1), in the wrong orientation 
(lane 2) or without insert (lane 3). 
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(II) Isolation of Puromycin-resistant hESCs clones and validation of increased Cyfip1 during 
neuronal differentiation 
The pCAG-Cyfip1-IRES-PAC plasmid was delivered into H7 hESCs via nucleofection, as described in 
Chapter 2. Puromycin selection was applied 48h after transfection and maintained for 10 days. 
During this time, 11 colonies of puromycin-resistant cells emerged and were picked manually and 
expanded as independent clones. RT-qPCR was performed to measure CYFIP1 and IRES mRNA levels 
at the stem cell stage. The results revealed that CYFIP1tg clones #3, #,4 and #5 expressed the 
highest level of CYFIP1transgene (Fig. 3.2 A and B). Despite having the correct ESCs morphology 
(Fig. 3.2 C), cells from clone #4 showed a poor efficiency of differentiation towards the neuronal 
lineage and were discarded from subsequent differentiation experiments. Conversely, CYFIP1tg #3 
and #5 turned efficiently into cortical neurons and, when compared to the parental line H7, 
maintained a higher CYFIP1 expression throughout the whole process, as demonstrated by the 
qPCR and western blot data (Fig. 3.2 E, F).  
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Figure 3.2 Characterisation of CYFIP1tg hESCs.  
RT-qPCR results for IRES (A) and CYFP1 (B) transcripts in all the hESC clones isolated after puromycin selection. 
Quantification data are normalised to GAPDH and 18S rRNA. Expression values are relative to the H7-CTRL, 
taken as 1. Error bars represent SD between 3 technical replicates. (C) Bright field images of three CYFIP1tg 
clones, showing normal hESC-like morphology. Scale bar= 100 μm. (D) RT-qPCR results for CYFIP1 expression 
at different stages of cortical differentiation of CYFIP1tg, clones #3 and #5 (clone numbers defined in A). Data 
are normalised to GAPDH and 18S rRNA. Expression values are relative to the control line at day 5, taken as 
1. Quantification (E) and western blots (F) for CYFIP1 protein during cortical differentiation of CYFIP1tg (#3 
and #5) and CTRL cells. RT-qPCR and western blot data (D and E) represent the mean value ± SD from 4 
independent experiments (N=4, 2 experiments for each CYFIP1tg clone). Data were compared by two-way 
ANOVA, followed by Tukey HSD test (*p<0.05, **p<0.01). 
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3.2.2 CYFIP1 targeting in iCas9 hESCs 
(I) Validation of RNA transfection procedure 
CYFIP1ko hESCs were derived from iCas9 cells, a line of genetically modified pluripotent cells with 
doxycycline-inducible expression of Cas9 nuclease (González et al., 2014). Gene targeting with this 
system requires the transfection of gRNA molecules into the cells, after the induction of Cas9 
expression.  
For this reason, I firstly verified the efficiency of RNA transfection using an Alexa555-conjugated 
RNA molecule delivered into the cells via a lipid-based transfection reagent optimised for RNA 
delivery. Flow-cytometry was used to analyse the population of transfected cells 24 hours later. The 
results showed that over 50% of the cells were fluorescent when compared to the non-transfected 
(negative) control sample (Fig.3.3).  
 
 
Figure 3.3 Validation of RNA transfection method.  
Histograms of FACS analysis showing a control (A) and transfected (B) sample of iCas9 cells. The analysis was 
carried out 24 hours post-transfection. 
 
(II) Transfection and screening of targeted clones 
After confirming the efficiency of the transfection method, iCas9 hESCs were transfected with 
gRNAs targeting the first exon of CYFIP1 (Fig. 3.4 A). The synthesis and transfection of the gRNAs is 
described in Chapter 2.2 and 2.4. Twenty-four hours after transfection, one of the transfected wells 
was used for extraction of the genomic DNA, together with a control (non-transfected) one. A PCR 
reaction was carried out for both samples to amplify the targeted locus and the product was then 
digested with Surveyor nuclease, to evaluate the targeting efficiency. Indel occurrence was 
estimated as explained in Ran et al. and resulted to be about 15% (Ran et al., 2013). A DNA gel 
showing the result of the Surveyor assay is shown in figure 3.4 B. 
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The remaining cells were dissociated, plated at a clonal density (250-500 cells per 6cm dish) and 
left to grow until small colonies emerged. About 100 of these colonies were manually isolated and 
expanded as single clones. Genomic DNA was extracted from some cells of each clone and used for 
PCR screening of the targeted CYFIP1 locus. This process led to the identification of several clones 
carrying insertions and/or deletions (indels) in the region of interest. An example of an agarose gel 
used to analyse the PCR results is shown in figure 3.4 B.  
Sanger sequencing was then used to verify the results of the PCR screening and to determine the 
exact nucleotide sequence of the targeted locus. As shown in figure 3.4 D and E, clones #31, #41 
and #70 had mutations in both alleles, but in the case of #41 and #70, one of the alleles had a 
deletion of 3 and 6 nucleotides respectively, leaving the gene sequence in frame. Other clonal lines 
containing mutations were #53 and #97, with a 1bp insertion in one allele, and #71 and #97, with 
only an in-frame deletion in one allele. Therefore, only clone #31 resulted to be a functional 
homozygous knock-out, with all the others being genetically or functionally heterozygous. Clone 
#31 was used for most of the experiments presented in this thesis and will be referred to as 
CYFIP1ko hereafter.  
(III) Validation of targeted clones 
The CYFIP1ko and two of the heterozygous lines (#41 and #70) were differentiated into cortical 
projection neurons in parallel to the control line to confirm that the mutations introduced did not 
affect the differentiation process in a way that would prevent the use of these mutant lines. During 
this process, proteins were collected from neural progenitors, a stage when CYFIP1 is known to be 
expressed. The results shown in figure 3.4 F and G confirm a significant reduction of CYFIP1 protein 
in all the targeted clones, particularly CYFIP1ko, when compared to the parental line. 
These data confirm that the cell lines generated by CRISPR/Cas9 targeting of CYFIP1 are suitable for 
modelling the effects of a reduction of this gene in human neurons, using in vitro differentiation 
from hESCs. 
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Figure 3.4 Screening and characterisation of CYFIP1-mutant hESCs.  
(A) Scheme of the CYFIP1 gene locus, highlighting the first translated exon (red) and the positions targeted by 
the three guide sequences used. gRNAs are reported with 5’ to 3’ orientation followed by the PAM (blue). (B) 
Surveyor nuclease assay of genomic DNA extracted from an untransfected pool of iCas9 hESCs (lane 1) and a 
well of transfected cells (lane 2). (C) Example of a DNA electrophoresis gel showing PCR products of the 
targeted locus from iCas9 hESCs (lane 1) and three targeted clonal lines where indels are present (lanes 2,3,4). 
(D) Summary of the genotyping results for all the clonal lines containing indels in one or both alleles. (E) Partial 
DNA sequence of CYFIP1 exon 1, in the parental iCas9 line and all the targeted clones where indels were found. 
(F) Western blot for CYFIP1 in CTRL (iCas9), CYFIP1ko (clone#31) and clonal lines #41 and #70 (heterozygous 
mutants).  
 
3.2.3 Derivation of iPSCs from 15q11.2-deleted fibroblasts and keratinocytes 
IPSCs were derived from fibroblasts and keratinocytes of two different patients carrying 15q11.2 
deletions using a commercial Sendai virus-based kit. Briefly, a population of somatic cells was 
transduced with viral vectors to induce the expression of several pluripotency genes (see also 
Chapter 2). Over time, colonies showing ESC-like morphology started to appear. More than 10 
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colonies per patient were isolated and expanded. These were named after the same identification 
number (ID) given to the patient followed by another number indicating the cellular clone.  
Clones EA008.4, EA008.21, EA062.13 and EA062.19 were stained for pluripotency markers and 
differentiated into cortical glutamatergic neurons to verify their ability to generate neurons. During 
this experiment, RNA and proteins were also extracted to quantify the expression levels of the 
deleted genes. In parallel to the patient-derived iPSCs, two control lines from a male and female 
healthy volunteer were also differentiated (CTRL#900 and CTRL#202, respectively). 
The results of the staining for the pluripotency markers SSEA3 and OCT4 for one control line and 
one iPSC clone per patient are shown in Figure 3.5 A. The same figure also demonstrates that both 
patient- and control-derived iPSCs were equally able to generate neuronal cells, as shown by the 
expression of typical neural progenitor (fig. 3.5 B) and post-mitotic neuron markers (fig. 3.5 C).  
 
 
Figure 3.5 Immunofluorescent staining in iPSCs and iPSCs-derived neuronal cultures.  
(A) Undifferentiated iPSCs stained for the pluripotency markers SSEA3 (green) and OCT4 (red). (B) iPSC-derived 
neural progenitors stained for a neuroepithelial marker nestin (green). (C) iPSC-derived neurons stained for 
the neuron-specific cytoskeletal protein MAP2 (green). All nuclei are counterstained with Dapi (blue). Scale 
bars=50 μm. 
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The analysis of the expression levels of the four 15q11.2 genes showed that CYFIP1 mRNA and 
protein were significantly reduced in patient-derived iPSCs compared to controls (fig. 3.6 A and fig. 
3.7 A).  
NIPA1 mRNA levels in patient iPSC-derived neuronal cells appear to be similar to those from the 
controls (fig. 3.6 B). However, the threshold cycles detected by RT-QPCR were all considerably high. 
This could mean the gene is expressed at a very low level, which may compromise the reliability of 
the quantification. In support to this hypothesis, western blot for NIPA1 showed only a very weak 
band at the neuronal stage and seemed almost absent in progenitor cells. Moreover, the intensity 
of NIPA1 bands did not appear to be different between patients and control cells (fig. 3.7 B). 
Interestingly, NIPA2 mRNA was particularly abundant at the NPCs stage and the protein was 
detected only at this time point. In neural progenitors, both the transcript and protein 
quantification showed significant reduction in cells carrying 15q11.2 deletion when compared to 
any of the controls used (fig. 3.6 C and fig. 3.7 C). In neurons, only the two clonal lines from EA062 
had a significant reduction in NIPA2 mRNA (fig. 3.6 C). 
The levels of TUBGCP5 transcript and protein were very variable between lines. Despite an apparent 
reduction in TUBGCP5 mRNA in EA008 progenitors and EA062 neurons, these differences were not 
statistically significant. This was reflected in the protein levels, which were similar in all lines and 
clones, at both differentiation stages (fig. 3.6 D and fig. 3.7 D). 
In conclusion, these data describe the characterisation of iPSCs carrying a 15q11.2 deletion. The 
expression of CYFIP1 and NIPA2 generally correlate with the number of copies of the gene present 
in the genome, both at the mRNA and protein level. On the other hand, the regulation of TUBGCP5 
and NIPA1 expression does not appear to be strictly related to the gene copies carried by an 
individual. However, NIPA1 seems to be present only at a very low level in in vitro differentiated 
post-mitotic neurons. 
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Figure 3.6 RT-qPCR for 15q11.2 genes in iPSCs-derived neuronal cells.  
Data were normalised to GAPDH and ribosomal RNA 18S and expressed relatively to the CTRL#900, taken as 
1, for each time point. Data represent mean ± SD (N=2 independent experiments) and were compared with a 
Two-way ANOVA, followed by Tukey HSD test (* p<0.05, **p<0.01). 
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Figure 3.7 Western blots for 15q11.2 genes in iPSCs-derived neuronal cells. 
The band intensity for each gene was normalised to that of GAPDH from the same membrane. Data represent 
mean ± SD (N=2 independent experiments) and were compared with a Two-way ANOVA, followed by Tukey 
HSD test (* p<0.05, **p<0.01). 
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3.3 Discussion 
This chapter describes the derivation of several hPSCs lines that lay the basis for the study of CYFIP1 
function in human brain development and its contribution to the increased risk for psychiatric 
disorders in 15q11.2 CNVs carriers. 
CYFIP1tg hESCs were derived from H7 hESCs via transfection of a vector where the CYFIP1 gene is 
driven by the CAG promoter. The use of a strong promoter is necessary to drive high level of 
constitutive transgene expression in hESCs, because they tend to be silenced during prolonged 
cultures and differentiation protocols. In agreement with published studies, the CAG promoter 
proved to be efficient in maintaining a high level of CYFIP1 both in stem cells and in differentiated 
neurons (Braam et al., 2008; Liew et al., 2007). Indeed, two of the CYFIP1tg hESCs lines tested, clone 
#3 and #5, were able to successfully differentiate into cortical projection neurons, maintaining a 
higher level of CYFIP1 expression than the parental H7 line, at any of the time points tested.  
However, the stable integration of the CYFIP1-overexpression plasmid in the host’s genome confers 
risk of interrupting important genes, which could affect the pluripotency and/or differentiation of 
the transgenic cells. Despite this, none of the CYFIP1tg hESCs clones showed abnormal morphology 
or behaviour, while the differentiation potential was compromised in only one of the transgenic 
lines (clone #4). Therefore, these two CYFIP1tg lines (#3 and #5) can be considered as a suitable 
gain-of-function model to investigate the consequences of an abnormally high level of CYFIP1 
during human neural development. Moreover, both clones were differentiated in parallel in most 
of the experiments, in particular during the initial stage of the project, to allow a confident 
identification of the cellular phenotypes specifically due to CYFIP1 overexpression. 
Human ESCs modelling the loss of CYFIP1 function were derived from the H9-iCas9 line (González 
et al., 2014), via transfection of gRNAs targeting the first translated exon of CYFIP1. When tested 
with a fluorescent RNA molecule, the transfection method used to deliver the gRNAs showed an 
efficiency comparable to that stated in the original publication on the iCRISPR system (González et 
al., 2014). However, the targeting efficiency reported in the same publication was, on average, 
around 40%, while that observed during CYFIP1 targeting was around 15%. This is not surprising 
and is likely due to the efficiency of the guide sequences chosen and to the genetic region targeted. 
Indeed, the data presented by Gonzalez et al also showed high variability in the percentage of 
mutant clones generated by targeting of different genes, ranging from as low as 20% to as high as 
70%. In addition to this, they also reported the preferential generation of the same non-random 
deletions in several clones, possibly due to microhomology-directed repair caused by the presence 
of small repeated sequences adjacent to the region where the DSB occurs (González et al., 2014). 
65 
 
Non-random deletions were detected also during the generation of CYFIP1-targeted lines. These 
were a 17 nucleotides-deletion present in clone #31 and #41 and a 6 nucleotides deletion present 
in one allele of clones #70, #71 and #107. Despite the efficiency observed being lower than 
expected, it was possible to generate a hESC line carrying a full knock-out of the CYFIP1 gene. 
Inactivation of this gene did not affect the behaviour of the targeted cells and resulted into a strong 
reduction of CYFIP1 protein in the line named CYFIP1ko. Therefore, hESCs from this clonal line 
represent a suitable model to investigate the effects of CYFIP1 loss during cortex development.  
Finally, iPSCs carrying a 15q11.2 deletion were also generated from two patients. Most of the 
interest in this CNV has been so far focused on CYFIP1, because of its functions within neuronal 
cells. The other genes encoded in this region have received little attention and their expression 
pattern has been investigated by just few studies and only at the mRNA level (Das et al., 2015; 
Picinelli et al., 2016; van der Zwaag et al., 2010). To carry out an initial characterisation of the 
patient-derived iPSCs, the expression of all the genes encoded in the 15q11.2 locus at both the 
mRNA and protein levels in two clonal iPSC lines per patient were compared to two control lines 
available in our group. RNA and protein samples were collected at the neural progenitor and 
neuronal stages from cultures differentiating into cortical pyramidal neurons, to carry out the 
analysis in a cell type relevant to neurodevelopmental psychiatric disorders.  
NIPA1 transcripts and protein levels were detected but at a very low level. Neuronal cells derived 
from patients carrying 15q11.2 deletion did not show a significant reduction of NIPA1 mRNA, in 
contrast with data from other studies (Das et al., 2015). NIPA1 protein was difficult to detect by 
western blot and, when present, the bands observed were very weak.  Several different 
combinations of antibodies and protein concentrations were tried to obtain this result. An increase 
in protein or antibody concentration resulted in the appearance of several unspecific bands rather 
than a more intense band of the right molecular weight. On the basis of these preliminary data, a 
small amount of NIPA1 seems to be present only in in vitro-derived cortical neurons and its level at 
this stage does not appear to be specifically linked to the number of NIPA1 copies in the genome. 
TUBGCP5 mRNA and protein were expressed in iPSC-derived neuronal cells at both time points 
tested. However, transcripts levels were very variable between cell lines and especially between 
patients. Also, the lack of one gene copy in 15q11.2-deleted cells did not result in significantly 
reduced protein levels. These results are different from what was expected on the basis of the qPCR 
data published by Das and colleagues (Das et al., 2015). However, the small sample used in that 
study and the high degree of variability observed in the results presented here may explain this 
discrepancy.  
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CYFIP1 mRNA and protein were detected at both the progenitor and neuronal stages and, in 
agreement with published data, loss of a copy of the gene results in significantly reduced expression 
levels for both mRNA and protein (Das et al., 2015; Picinelli et al., 2016).  
Finally, NIPA2 transcript was found at higher levels in progenitors than in neurons in all the lines 
tested. Interestingly, and in line with qPCR data, NIPA2 protein was detected only in neural 
progenitors and seemed to be absent in neurons. Moreover, the presence of 15q11.2 deletion 
significantly affects the expression of this gene, resulting in a clear reduction of its mRNA and 
protein. This is in agreement with published studies reporting that NIPA2 expression is positively 
correlated with the number of copies of the gene (Das et al., 2015; Picinelli et al., 2016; van der 
Zwaag et al., 2010). However, only one of these studies is based on in vitro-derived neurons and 
does not report any indication of the expression trend of NIPA2 mRNA during differentiation, as 
data are normalised to the control line for each time point analysed (Das et al., 2015). This makes 
it impossible to compare the interesting expression pattern observed in this study with any 
published data. NIPA2 specific expression in neural progenitors suggests a role for this gene in the 
developing cortex and opens a question about a possible contribution of NIPA2 to the phenotypes 
observed in 15q11.2 CNVs carriers.  
NIPA2 is a Mg++ transporter, mutations of which have been linked by some studies to an increased 
risk of epilepsy in the Chinese population (Jiang et al., 2012). Few data are available on its function 
in neuronal cells. Xie and colleagues used rat primary foetal neurons to demonstrate that mutations 
of NIPA2 interfere with its correct cellular localisation, lowering intracellular Mg++ and disrupting 
NMDAR currents  (Xie et al., 2014). The presence of NIPA2 in rat foetal cortical neurons seems to 
be in contrast with the impossibility to detect the same protein in in vitro-derived human neurons 
during the experiments presented here. The samples taken for this study are collected from young 
hESCs-derived neurons, which should be comparable to the E16-18 cortical cells used by Xie et al. 
Nevertheless, differences in the model and the maturity of cells could be at the origin of this 
inconsistency.  
Literature on the function of Mg++ transporters in NPCs is scarce. However, Mg++ is a very abundant 
ion in mammalian cells and a few studies linked its concentration to the proliferation and 
differentiation potential of neuronal precursors during adult neurogenesis (Jia et al., 2016; W. Liao 
et al., 2017). In light of these recent data, the investigation of a possible role of NIPA2 in NPCs 
represents an interesting venue for future studies.  
For most of the time spent working on the experiments presented in this thesis, iPSCs from only 
one 15q11.2 deletion carrier were available. Because of this, most of my work was focused on 
CYFIP1tg and CYFIP1ko cells, while work on patients-derived cells is still at a preliminary stage. 
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4 Phenotypic Analysis of CYFIP1tg and CYFIP1ko cells  
4.1 Introduction 
The expression of  Cyfip1  in the neuroepithelial cells facing the ventricle in the developing mouse 
cortex (Yoon et al., 2014 and Eurexpress.org) suggests a role for this gene in cortical development. 
Indeed, Yoon and colleagues demonstrated that knock-down of CYFIP1 in iPSC-derived neural 
progenitors disrupts the formation of neural rosettes, a defect observed also in NPCs carrying 
15q11.2 deletion (Yoon et al., 2014). The same authors also reported that Cyfip1 knock-down during 
mouse embryonic development results in aberrant localisation of radial glial cells and the neurons 
to which they give rise (Yoon et al., 2014). The apical side of neural rosettes is an important source 
of signals regulating the survival and neurogenic potential of the neural progenitors forming these 
structures (Banda et al., 2015; Elkabetz et al., 2008). Therefore, the disruption of the normal rosette 
morphology associated with reduced level of CYFIP1 is likely to impact on the generation of neurons 
at a later stage. However, the consequences of neural rosettes alterations in human neuronal cells 
and the mechanism behind the defects observed were not thoroughly investigated. 
The effects of CYFIP1 reduction in NPCs was analysed also by Nebel et al (Nebel et al., 2016). 
Transfection of shRNAs targeting CYFIP1, followed by RNA sequencing, revealed alterations in genes 
regulating cell cycle, cytoskeletal remodelling and cell adhesion. The differentially expressed genes 
were also enriched for FMRP targets and post-synaptic density (PSD) genes. This study also reported 
differences in the amount of F-Actin and the nuclear and cellular size of CYFIP1-deficient NPCs, but 
the authors did not examine all the cellular functions that appeared to be affected in the 
transcriptomic analysis (e.g. cell cycle) nor did they explore which pathway to manipulate to rescue 
the abnormalities caused by CYFIP1 knock-down (Nebel et al., 2016). 
In addition to 15q11.2 deletions, duplications of the same locus are also associated with psychiatric 
and developmental disorders (Burnside et al., 2011; Picinelli et al., 2016; van der Zwaag et al., 2010). 
Despite this, the investigation of increased CYFIP1 level in human cortical progenitors and neurons 
is still missing.  
In this Chapter, I report the phenotypic analysis of the CYFIP1tg and CYFIP1ko hESCs in cortical 
development in vitro. To this end, CYFIP1tg and CYFIP1ko neuronal cells were compared to their 
respective parental lines at different stages during differentiation and were analysed using several 
approaches. These include assays to evaluate the efficiency of neuronal induction, neural rosette 
formation and generation of neurons of all cortical layers. 
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4.2 Results 
4.2.1 Changes in CYFIP1 level do not affect neuronal induction efficiency 
CYFIP1tg and CYFIP1ko hESCs and their respective parental lines were differentiated to cortical 
pyramidal neurons using a protocol adapted from published studies (Espuny-Camacho et al., 2013; 
Shi et al., 2012). Under our conditions, PSCs differentiate into NPCs in about 18 days for H7 and 
CYFIP1tg cells and in about 12 days in the case of iCAS9 and CYFIP1ko lines. At this time, cells were 
stained for markers of cortical radial glia cells to analyse the efficiency of NPCs production and the 
positional identity of the differentiated cells. As shown in figure 4.1 A and B, virtually all cells in 
CYFIP1tg, CYFIP1ko and control cultures were positive for NESTIN, an intermediate filament widely 
expressed by proliferating cells of the developing central nervous system (Dahlstrand, Lardelli & 
Lendahl, 1995).  A high proportion of cells was also positive for PAX6 and FOXG1, two transcription 
factors expressed in dorsal forebrain progenitors and in all forebrain cells, respectively, (Greig, 
Woodworth et al., 2013), without significant differences between the CYFIP1 engineered and 
control cell lines (Fig.4.1 A-D).  
Moreover, at this stage, the number of cells expressing proliferation markers in CYFIP1tg and 
CYFIP1ko NPCs was also similar to the respective controls. KI67, a protein present during all active 
phases of the cell cycle (Scholzen & Gerdes, 2000), was present in more than 60% of cells for all the 
lines analysed (Fig. 4.2 A-D). Another important parameter in the context of proliferation is the 
incorporation of the thymidine analogue EdU (Salic & Mitchison, 2008). The ratio between EdU and 
KI67 is inversely proportional to the cell cycle length and it is often used as an indirect measure of 
the proliferation rate in cultured cells (Mariani et al., 2015; Qu et al., 2013). Both the number of 
Edu+ cells and the value of the EdU/KI67 ratio were similar for CYFIP1tg, CYFIP1ko and their 
respective isogenic control lines (Fig 4.2 C, D).  
Together these data demonstrate that an altered dosage of CYFIP1 does not affect the efficiency of 
neural induction, nor the positional identity or proliferation of cortical progenitor cells at an early 
stage of PSC differentiation.  
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Figure 4.1 Expression of cortical progenitor markers in CYFIP1tg and CYFIP1ko cultures. 
 Immunofluorescence for PAX6 (red), FOXG1 (green) and Nestin (red) in CYFIP1tg and H7 cultures at day 18 
(A) and in CYFIP1ko and iCas9 cultures at day 14 (B). All nuclei were counterstained with Dapi (blue). Scale 
bars=50 μm. (C) Quantification of cells expressing PAX6 and FOXG1 in CYFIP1tg and H7 NPCs at day 18 of 
differentiation. CYFIP1tg data represent an average of two different clonal lines. (D) Percentage of CYFIP1ko 
and iCas9 NPCs expressing PAX6 and FOXG1 at day 14 of differentiation. Data represent mean ± SD from 4 
independent experiments (2 experiments for both CYFIP1tg clones #3 and #5). All quantification data were 
compared by t-test and no significant differences were found. 
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Figure 4.2 Expression of proliferation markers in CYFIP1tg, CYFIP1ko and control NPCs. 
Immunofluorescence staining for KI67 (green) and Alexa-555 labelling of EdU (red) in day 18 CYFIP1tg and H7 
neural progenitors (A) and in day 14 CYFIP1ko and iCas9 neural progenitors (B). Nuclei are stained with Dapi 
(blue). Scale bars = 50 μm. (C, D) Quantification of KI67+ and EdU+ cells and KI67/EdU ratio in day 18 CYFIP1tg 
and H7 cultures and in day 14 CYFIP1ko and iCas9 cultures, respectively. Data represent mean ± SD from 3 
independent experiments. The CYFIP1tg line used was #5. Data were compared by t-test and no significant 
differences were found. 
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4.2.2 Abnormal levels of CYFIP1 interfere with the self-organising ability of 
cortical progenitors 
Cultures of CYFIP1tg and control progenitors were stained for NCAD (N-CADHERIN or CADHERIN 2), 
a protein that in vivo is localised at the apical surface of cortical progenitors of the VZ and that in 
vitro marks the centre of neural rosettes. These are polarised structures originated, during 
monolayer differentiation, by the self-organisation of neural progenitors around a centre devoid of 
cells (Elkabetz et al., 2008; Miyamoto, Sakane & Hashimoto, 2015).  
At a time when control cultures reached their peak of neural rosette formation, CYFIP1-
overexpressing progenitors formed significantly fewer rosettes (Fig. 4.3 C). Moreover, while NCAD 
staining appeared to exhibit the typical circular expression pattern in H7 control cultures, the 
CYFIP1tg cultures showed irregular NCAD staining, highlighting the aberrant and incomplete 
morphology of a significant proportion of rosettes (Fig 4.3 A and D). The disorganised nature of 
CYFIP1tg neural rosettes was more apparent at a higher magnification (Fig. 4.3 B). Nestin-stained 
CYFIP1tg progenitor cells did not show an apico-basal radial pattern as those in the control rosette 
(Fig. 4.3 B, white arrowhead).   Mitotic phospho-histone H 3 (pHH3)-expressing cells, which in vivo 
are only found adjacent to the ventricle, were correctly positioned around the lumen of neural 
rosettes in control cultures, but not in CYFIP1tg rosettes (Fig. 4.3 B, green arrowhead).  
In order to explore how these cells performed in a more complex system, CYFIP1tg and H7 hESCs 
were differentiated into brain organoids. Following a published protocol, PSCs were cultured in 
suspension to form embryoid bodies-like structures, which were then embedded in Matrigel 
droplets to allow expansion of the neuroepithelial tissue (Lancaster & Knoblich, 2014) (Fig. 4.3 E).  
Around 15 days post-Matrigel embedding, several VZ-like areas were evident in the control line. At 
this time, the thickness and area of each VZ region were measured from the most central section 
showing the widest ventricular area. The thickness was measured by averaging the length of four 
radial segments for each VZ. The area was selected with the free hand tool of ImageJ and calculated 
using the “Measure” function of the same program. The results of this analysis showed that 
CYFIP1tg hESCs-derived organoids had significantly smaller and thinner VZ-like areas than control 
ones, at the same time point (Fig. 4.3 F, G, H).  
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Figure 4.3 Abnormal neural rosettes and VZ-like areas formed by CYFIP1tg neural progenitors. 
(A) Immunostaining for NCAD (red) in control and CYFIP1tg cultures at day 18 of differentiation. Scale 
bars=50μm (B) Immunostaining for Nestin (white) and pHH3 (green). White arrowhead indicates an area of 
disorganised Nestin staining. Green arrowhead indicates a pHH3+ cells not adjacent to the rosette lumen.  
Nuclei were counterstained with Dapi (blue). Scale bars=25μm. (C, D) Quantification of NCAD+ rosettes and 
percentage of incomplete rosettes present in control and CYFIP1tg cultures at day 18 of differentiation. 
Quantification was carried out on two different CYFIP1tg clones each time (N=4, two independent experiments 
for both CYFIP1tg clone #3 and clone #5). (E) Bright field images of brain organoids at day 2 post-seeding and 
day 5 after Matrigel embedding. Scale bars=100μm (F) Immunostaining for NCAD and Nestin on a section of 
a control and a CYFIP1tg organoid at day 15 post-embedding. Nuclei were counterstained with Dapi (blue). 
Scale bars=50μm (G and H) Quantification of thickness and surface area of VZ-like structures in organoids 
derived from H7 and CYFIP1tg cells on day 15 post-embedding (N=3. Four organoids measured for each 
experiment). All data are represented as mean ± SD and were compared with t-test (*p<0.05, **p<0.01, 
***p<0.001).  
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The formation of neural rosettes was analysed also in CYFIP1ko cultures (Fig. 4.4). Following, 
immunostaining for NCAD, no differences were found in the number of rosettes between CYFIP1ko 
and the isogenic control cultures (Fig. 4.4 C). However, the expression pattern of NCAD was found 
to be abnormal in a high proportion of CYFIP1ko rosettes, as it lacked the typical circular 
configuration and, instead, appeared in a disperse pattern. In contrast, neural progenitors derived 
from the control line showed correct radial organisation and circular pattern of NCAD staining (Fig. 
4.4 A, B). Quantification of the proportion of incomplete rosettes over two independent 
experiments confirmed the presence of a significant difference (Fig. 4.4 C). 
Overall, these data indicate that abnormal levels of CYFIP1 impact negatively on the self-
organisation of cortical neural progenitors into correctly polarised structures. 
 
 
Figure 4.4 Disorganised neural rosettes in CYFIP1ko progenitor cultures. 
(A) Immunostaining for NCAD (green) and Nestin (red) in day 14 cultures of NPCs derived from control and 
CYFIP1ko cells. Nuclei are marked by Dapi staining (blue). Scale bars=50μm. (B) High magnification field 
showing one NCAD+ (green) neural rosette for both lines. Nuclei were stained with Dapi (blue). Scale 
bars=25μm. (C, D) Quantification of the number of neural rosettes and percentage of incomplete ones present 
in control (iCas9) and CYFIP1ko cultures at day 14 of in vitro differentiation (N=3). Data from the two cell lines 
are represented as mean ± SD and were compared by t-test (*p<0.05, **p<0.01, ***p<0.001).  
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4.2.3 CYFIP1 overexpression results in prolonged proliferation of the progenitor 
pool 
To investigate whether the disruption to normal rosettes morphology impacts the generation of 
neurons at later stages, the number of PAX6+ progenitors and post-mitotic NEUN+ neurons was 
analysed in H7 and CYFIP1tg cultures during a window of active neurogenesis, between day 30 and 
40 of in vitro differentiation. At both time points the percentage of PAX6+ cells was significantly 
higher in CYFP1tg cultures, while the number of neurons was considerably higher in the control 
population (Fig. 4.5 A, B, D, E).  
A 2-hour EdU incorporation experiment was then performed to quantify the fraction of proliferating 
cells in both CYFIP1tg and control cultures. This experiment confirmed the presence of a larger 
number of actively dividing cells within the CYFIP1-overexpressing population both at day 30 and 
40, with the difference at day 40 being highly significant (Fig. 4.5 F).  EdU incorporation can also be 
used to determine the neurogenic rate of a population of neural progenitors, as EdU is retained by 
the neuronal progeny upon exit from the cell cycle. In this case, an EdU pulse is given to the 
progenitors on a certain day and the percentage of cells co-labelled with EdU and a post-mitotic 
neuronal marker is analysed a few days later (Otani et al., 2016). This approach was used to analyse 
the production of neuronal cells in CYFIP1tg and control cultures. Co-staining for NEUN and EdU 5 
days after the EdU pulse was given revealed a significantly lower proportion of EdU+ NEUN+ cells in 
CYFIP1tg cultures than in the control ones (Fig. 4.5 C and G), suggesting that CYFIP1tg progenitors 
have a higher tendency to proliferate than to undergo terminal differentiation into neurons.  
This was further supported by flow-cytometry analysis of the control and CYFIP1tg cells stained with 
the DNA dye, Dapi. The amount of DNA present is indicative of whether the cell is in the G0/G1, S 
or M phase of the cell cycle (Fig. 4.5 H and I). Such analysis showed that at day 35 the majority of 
control cells had exited the cell cycle, while a significant proportion of CYFIP1tg cells was still in the 
S and M phases (Fig. 4.5 K). However, no significant differences were found when the same analysis 
was performed 1 week earlier (Fig. 4.5 J), confirming that proliferating progenitors behave in similar 
way at early stages of differentiation but persist for longer in CYFIP1tg cultures  
This over-proliferation of CYFIP1tg PAX6+ progenitors was also reflected by the delayed appearance 
of TBR2+ intermediate progenitors and of the typical cortical markers for deep and superficial layers 
(Fig. 4.6). The transcription factors TBR2, TBR1, CTIP2 and SATB2 appear in this order during in vivo 
corticogenesis and this pattern is maintained in in vitro differentiation (Espuny-Camacho et al., 
2013; Yichen Shi et al., 2012).  
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The percentage of TBR2 progenitors was significantly lower in CYFIP1tg cultures than in controls at 
day 30, but no difference was present at days 40 or 50. Both control and CYFIP1tg cultures were 
able to produce all types of pyramidal neurons, but significant differences were present in the 
numbers of TBR1+, CTIP2+ and SATB2+ cells at day 30. There were no differences at later stages, 
which is consistent with a delayed exit from the cell cycle of CYFIP1tg progenitors (Fig. 4.6 C). 
Together, these data provide evidence that CYFIP1 overexpression promotes expansion of the 
progenitor pool, at the expense of delayed neurogenesis, during in vitro cortical differentiation.  
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Figure 4.5 Overproliferation of neural progenitors caused by CYFIP1 overexpression. 
(A, D) Immunofluorescent staining and quantification of PAX6+ cortical progenitors (red) as a percentage of 
the total number of cells, marked by Dapi staining (blue). (B, E) Immunofluorescent staining and quantification 
of NEUN+ post-mitotic neurons (green). Nuclei were counterstained with Dapi (blue). (C) Double staining for 
EdU (red) and NEUN (green), 5 days after EdU incubation (2hours). All scale bars = 50 μm.  (F) Quantification 
of EdU+ cells at day 30 and 40 of differentiation, right after EdU incubation (2hours). (G) Quantification of 
EdU+/NEUN+ cells at day 40 of differentiation, 5 days after EdU incubation (2hours). (H, I) Flow-cytometry 
histogram of Dapi+ cells at day 35 of in vitro differentiation. The intensity of Dapi fluorescence allows to divide 
the cell population into three sub-populations, corresponding to the different cell cycle phases, G0/G1, S and 
M. (J, K) Percentage of cells in the different phases of the cell cycle at day 28 and 35 respectively. Quantitative 
data relative to control and CYFIP1tg lines were compared by t-test (*p<0.05, **p<0.01, ***p<0.001) (N=3, 
all experiments were performed on the CYFIP1tg clone#5).  All data are represented as mean ± SD. 
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Figure 4.6 Delayed appearance of cortical layer markers in CYFIP1t cultures. 
Immunostaining for TBR2, TBR1, CTIP2 and SATB2 in CYFIP1tg and control (H7) cultures at day 30 (A) and 50 
(B) of in vitro-cortical differentiation. Nuclei are labelled by Dapi (blue). Scale bars = 50 μm. (C) Quantification 
of TBR2, TBR1, CTIP2 and SATB2 in CYFIP1tg and control (H7) cultures at day 30, 40 and 50 of differentiation. 
For CYFIP1tg, data represent an average of two different cellular clones (CYFIP1tg clone #3 and clone#5, N=2 
experiments for each clone). The percentage of positive cells in overexpressing and control lines were 
compared using Two-way ANOVA (*p<0.05). Data represent mean ± SD. 
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4.2.4 CYFIP1ko cortical progenitors undergo premature neuronal differentiation 
The analysis of the proliferative behaviour of CYFIP1ko neural progenitors revealed an opposite 
trend to that of the CYFIP1tg cells.  Around day 20, in control iCas9 cultures, a substantial population 
of NEUN+ neurons began to emerge. However, at the same time, CYFIP1ko cultures already 
contained a significantly higher proportion of neurons and, accordingly, a much smaller pool of 
PAX6+ progenitors (Figure 4.7 A-D).  
A pulse-chase EdU incorporation experiment was performed to analyse the neurogenic rate of the 
progenitors present at this stage. EdU was given for 2 hours at day 20 and cells co-labelled for EdU 
and NEUN were quantified 5 days later.  More EdU+ neurons were found in the CYFIP1ko cultures 
than the controls, suggesting that more CYFIP1ko progenitors had given rise to neurons during the 
5 day period (Fig. 4.7 E, F). Consistently with this, the proportion of cells expressing TBR1 and CTIP2 
at day 20 was higher for CYFIP1ko cells than for the parental line. At day 30, more CTIP2+ cells were 
found in CYFIP1ko cultures and SATB2 was also significantly increased. However, by day 40, the 
quantification of these cortical neuronal subtypes did not show any difference (Fig. 4.7 G-I). 
Several cell cycle and proliferation markers were also analysed, to gain a more complete 
understanding of the phenotype caused by CYFIP1 loss.  At day 20, when more neurons are known 
to be present in CYFIP1ko cultures, the number of KI67+ cells, as well as the fraction of proliferating 
cells detected by flow-cytometry, were significantly smaller (Fig. 4.8 A, C). At the same time, a 
higher proportion of neuronal cells were found to be positive for p27KIP1, a cyclin-dependent kinase 
inhibitor, the upregulation of which promotes neuronal differentiation (Nguyen et al., 2006) (Fig. 
4.8 B). 
Overall, these data demonstrate that loss of CYFIP1 is associated with a reduced proliferative ability 
of cortical progenitors, which results in early loss of the self-renewing pool and, ultimately, 
premature neuronal differentiation. 
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Figure 4.7 Increased neurogenic ability of CYFIP1ko cortical progenitors. 
Immunostaining for PAX6 (red) (A) and NEUN (green) (C) in CYFIP1ko and control (iCas9) cultures at day 20 of 
in vitro cortical differentiation. (B, D) Quantification of PAX6+ and NEUN+ cells in CYFIP1ko and control (iCas9) 
cultures at day 20 of differentiation. (E, F) Staining for NEUN (green) and EdU (red) and quantification of 
double-labelled cells at day 25, 5 days after EdU pulse. (G-I) Immunofluorescent staining for TBR1 (green in 
G), CTIP2 (green in H) and SATB2 (red in H) at day 20 and quantification of these markers (I) at day 20, 30 and 
40 of in vitro differentiation. All nuclei are counterstained with Dapi (blue). All Scale bars = 50 μm. 
Quantification data in B, D and F were analysed by t test. Quantification data in I were compared y two-way 
ANOVA (*p<0.05, **p<0.01). All data are represented as mean ± SD and were collected from 3 independent 
experiments. 
80 
 
 
 
Figure 4.8 Reduced proliferation of CYFIP1ko progenitor pool. 
Immunostaining and quantification for KI67 (green in A) and P27kip1 (red in B) in CYFIP1ko and control (iCas9) 
cultures at day 20 of in vitro cortical differentiation. All nuclei are counterstained with Dapi (blue). Scale bars 
= 50 μm. (C) Flow-cytometry histogram of Dapi+ cells at day 20 of in vitro differentiation and quantification of 
the percentage of cells in G0/G1, S and M phases of the cell cycle, on the basis of Dapi content. Data represent 
mean values from 3 independent experiments ± SD. Significant differences were analysed by t-test (*p<0.05, 
**p<0.01). 
 
4.3 Discussion  
Human ESCs with an excess (CYFIP1tg) and a loss of CYFIP1 (CYFIP1ko) were differentiated into 
cortical pyramidal neurons to investigate the consequences of abnormal CYFIP1 levels in the 
context of human cortical development. Neither the overexpression nor the loss of CYFIP1 
appeared to compromise the efficiency of neuronal induction or the specification of the correct 
positional identity of the differentiated cells, as the percentage of neuronal progenitors expressing 
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dorsal telencephalic markers were comparable between both CYFIP1-mutant lines and the 
respective parental controls. 
One hallmark of early stage in vitro cortical differentiation is the appearance of neural rosettes, 
radial arrangements of NPCs with very similar characteristics to the RGCs present in the VZ of the 
embryonic cortex, such as the presence of intracellular nuclear migration (Banda et al., 2015; 
Elkabetz & Studer, 2009; Ziv et al., 2015). Neural rosettes formed by both CYFIP1tg and CYFIP1ko 
NPCs were morphologically different from those formed by controls, suggesting that CYFIP1 is 
fundamental for the self-organisation of NPCs in appropriately polarised structures. The 
differentiation of CYFIP1tg hESCs into a 3D model of cerebral organoids provided further evidence 
towards this conclusion. 
Aberrant neural rosette formation was previously reported by Yoon and colleagues in 15q11.2-
deleted iPSCs and CYFIP1KD cells (Yoon et al., 2014). Notably, the “scattered” expression pattern of 
rosette apical markers described in their study was very similar to that shown here for CYFIP1tg and 
CYFIP1ko NPCs. The same authors also reported that CYFIP1 reduction was associated with a lower 
level of WAVE2 protein, a fundamental component of the WRC, which regulates actin 
polymerisation (Takenawa & Suetsugu, 2007). For this reason, they argued that the destabilisation 
of this complex, caused by low CYFIP1 levels, was the cause of the defective neural rosettes (Yoon 
et al., 2014).  
However, actin is only one of the several proteins present at the apical side of these structures, 
which form closely interconnected system. Of these proteins, NCAD was shown to also be a key 
FMRP target, in a mouse model of FXS, during embryonic cortical development (La Fata et al., 2014). 
Therefore, malfunction of the CYFIP1-FMRP complex could alter the normal levels of NCAD 
translation and result in the formation of faulty apical junctions. Hence, each of these mechanisms, 
or a combination of the two, could explain CYFIP1 contribution to the neural rosette phenotype 
observed.  
Both the signalling molecules present within the rosettes and their cytoarchitectural organisation 
play an important role in the regulation of the neurogenic capabilities of the NPCs forming these 
structures (Banda et al., 2015; Ziv et al., 2015).  Consistent with this, CYFIP1tg and CYFIP1ko cells 
showed differences in their proliferative behaviour and neurogenic rate. EdU incorporation 
experiments and flow cytometry analysis of the cell cycle profile revealed that overexpression of 
CYFIP1 was associated with increased progenitor proliferation accompanied by a delayed 
generation of post-mitotic neurons, while CYFIP1 loss had the opposite effect.  Nonetheless, 
neurons of deep and upper cortical layers were formed by all the cell lines analysed, confirming 
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that the differences observed concerned only the kinetic of differentiation but not the fate of the 
cells generated.  
Importantly, neurogenesis mechanisms have been shown to be affected also in several FXS models. 
Loss of FMRP leads to increased proliferation and neuronal production in Drosophila larvae and 
increased generation of TuJ+ cells was observed in neurospheres derived from Fmr1-/y mouse 
embryos and FXS foetuses (Callan et al., 2010; Castrén et al., 2005). Moreover, loss of Fmr1 was 
shown to impact adult neurogenesis, by increasing proliferation and affecting neuronal 
differentiation and survival (Luo et al., 2010). In this model it was also demonstrated that Cyclin D1, 
CDK4, and GSK3β transcripts are FMRP targets and that Fmr1-/y NPCs have reduced WNT signalling 
levels (Luo et al., 2010). Recently, the correlation between FMRP and GSK3β was confirmed in NPCs 
derived from human FXS iPSCs, but it could not be verified in neurons, leading the authors to 
postulate that this association may be stage and species-specific (Telias et al., 2015). These data 
support the hypothesis that the FMRP-CYFIP1 complex may be controlling the translation of some 
key neurogenesis regulators and be ultimately responsible for the differentiation phenotype 
observed in CYFP1tg and CYFIP1ko cultures.  
Deficits of proliferation and differentiations have been described by several other in vitro models 
of SZ and ASD. For instance, two separate studies on iPSCs derived from individuals with idiopathic 
autism reported enhanced proliferation of neural progenitors, during both monolayer and organoid 
differentiation (Marchetto et al., 2016; Mariani et al., 2015). More specifically, the defects observed 
were relative to a decrease in cell cycle length, which caused a fast expansion of the progenitor 
population. Interestingly, in one of these studies, the increased proliferation was also shown to 
correlate with the degree of macrocephaly present in the donor patients (Marchetto et al., 2016). 
This type of alterations could be relevant in the context of the structural abnormalities observed in 
the brains of patients affected by psychiatric disorders, especially ASD. Indeed, the most commonly 
reported alterations in ASD subjects are larger brain volume and excess of cortical neurons, as well 
as abnormalities in cortical minicolums (Casanova et al., 2006; Courchesne et al., 2011; McKavanagh 
et al., 2015; Sacco et al., 2015). Moreover, mild brain structural abnormalities have been specifically 
reported for 15q11.2 CNV-carriers (Stefansson et al., 2014; Ulfarsson et al., 2017). 
In conclusion, the phenotypes detected in CYFIP1tg and CYFIP1ko neural cells confirm the 
hypothesis of an important role played by CYFIP1 during embryonic cortex development and fit in 
the broader scenario of proliferation and differentiation deficits as a possible common cellular 
pathology of neurodevelopmental psychiatric disorders. 
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5 Molecular basis of CYFIP1tg and CYFIP1ko phenotypes 
5.1 Introduction 
Data presented in the previous chapter showed that the overexpression and loss of CYFIP1 affect 
the formation of neural rosettes and the kinetics of neurogenesis during in vitro cortical 
differentiation. More precisely, increased and decreased levels of CYFIP1 had opposite effects on 
the proliferative and neurogenic ability of the cortical progenitor pool, suggesting that this 
phenotype is specifically caused by CYFIP1 changes. Therefore, investigation of the mechanism 
underlying this defect should provide important insight into the role of CYFIP1 in the context of 
cortex development. 
In vitro, neural rosette NPCs experience very similar signals to those present in the VZ during mouse 
corticogenesis (Banda et al., 2015). A large number of pathways have been implicated in the 
regulation of neuronal differentiation during mouse cortex development.  Of these, Notch and WNT 
pathways have been reported to be linked to CYFIP1 or its partner FMRP in various models.  
The Notch pathway, activated by Delta-like1 ligand (Dll1), is well known for promoting the 
maintenance of radial glia cells (RGCs) in an undifferentiated state. Upon activation, the 
intracellular domain of the Notch receptor is released and translocated to the nucleus to activate 
its target genes, HES1 and HES5 (Androutsellis-Theotokis et al., 2006; Imayoshi et al., 2010; 
Schroeter, Kisslinger & Kopan, 1998). These transcription factors repress the expression of pro-
neural genes and prevent the initiation of neuronal differentiation (Bertrand, Castro & Guillemot, 
2002; Ohtsuka et al., 1999). Pro-neural genes and Dll1 are expressed within the same cells, making 
them able to undergo neuronal differentiation whilst inhibiting the same fate in neighbouring cells, 
in a process known as “lateral inhibition” (Kageyama et al., 2008). Aberrant NOTCH expression was 
detected during in vitro neuronal differentiation of FXS iPSCs (Telias, Segal & Ben-Yosef, 2013). In 
addition, CYFIP1 was shown to be a NOTCH target in human keratinocytes (Dziunycz et al., 2017) .  
WNT signalling also plays a fundamental role in this context, as it regulates both patterning and 
neurogenesis of the developing telencephalon. Here, WNT molecules are expressed in the cortical 
hem and are necessary to maintain the dorsal identity of pallial cells (Backman et al., 2005). In 
addition, WNT has been shown to promote self-renewing symmetric divisions of cortical precursors 
of the VZ and its down-regulation is needed to initiate differentiation (Chenn & Walsh, 2002; Pöschl 
et al., 2013; Woodhead et al.,  2006). Activation of canonical WNT signalling is mediated by 
stabilisation of β-catenin, which would be otherwise degraded by a destruction complex, formed 
by glycogen synthase kinase 3β (GSK-3β), adenomatous polyposis coli (APC), axis inhibition protein 
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(Axin) and serine/threonine kinase casein kinase 1α (CK1α) (Moon et al., 2004). The accumulation 
of active β-catenin in the cytoplasm results in its translocation into the nucleus and the 
transcriptional activation of WNT target genes (Moon et al., 2004). Βeta-Catenin is also a binding 
partner of N-Cadherin (NCAD) and together, they form complexes present at the apical side of the 
VZ, which are also connected to the actin cytoskeleton by α-catenins (Nelson, 2004; Stocker & 
Chenn, 2015). Disruption of this type of complexes has been shown to severely affect the 
differentiation and migration of neural precursors (Stocker & Chenn, 2009; Zhang et al., 2010, 
2013). In addition to these, more signalling pathways contribute to the regulation of cortical 
neurogenesis, making the dissection of the mechanisms affected by CYFIP1 challenging.  
RNA-sequencing (RNA-seq) offers an absolute genome-wide quantification of all transcripts present 
in a sample of cells. This technique overcomes a number of limitations associated with other 
methods of transcriptomic analysis, such as microarrays, which are limited to the detection of 
known sequences and have a lower dynamic range (Wang, Gerstein & Snyder, 2009). RNA-seq was 
used to gain insight into the mechanisms driving the changes in neurogenesis observed in CYFIP1tg 
and CYFIP1ko cells and to allow a broader and unbiased characterisation of the pathways 
dysregulated in these cells. Importantly, this technique is increasingly used to characterise animal 
and cell-based models of ASD and SZ, as well as to analyse patients’ post-mortem brains, in the 
hope of uncovering the complexity underlying these disorders. Therefore, the comparison of the 
RNA-seq results obtained from CYFIP1tg and CYFIP1ko neural cells to existing datasets from ASD 
and SZ models will also allow to explore the presence of shared or convergent mechanisms, 
providing useful insights into the biology of these diseases. 
5.2 Results 
5.2.1 Molecular pathways affected by overexpression and loss of CYFIP1  
RNA-seq was performed on control and modified cells at three stages of differentiation. These were 
a neuroepithelial stage (day 10 for H7 and CYFIP1tg, day 5 for iCas9 and CYFIP1ko lines), a NPC stage 
(day 18 for H7 and CYFIP1tg cells, day 12 for iCas9 and CYFIP1ko) and a neuronal stage (day 45 for 
H7 and CYFIP1tg, day 35 for iCas9 and CYFIP1ko cells). After the necessary quality control steps on 
the raw data (performed by Daniel Cabezas de la Fuente), differential gene expression analysis was 
performed to compare each CYFIP1-modified line to their respective controls, for each time point 
(Anders & Huber, 2010). Differentially expressed genes (DEGs) with an absolute fold change value 
of at least 1.5 were used for KEGG (Kyoto encyclopaedia of genes and genomes) gene set 
enrichment analysis (Kanehisa et al., 2012; Yu et al., 2012). The most significant pathways affected 
in both the overexpression and knock-out datasets are shown in figure 5.1.  
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Firstly, the KEGG analysis revealed that most of the normalised enriched scores (NES) follow 
opposite directions for the overexpression and knock-out data sets. Because of this, these pathways 
can be considered to be specifically affected by changes in CYFIP1 levels, independently of the 
genetic background of the parental lines, the integration site of the overexpression plasmid or the 
effects of off-target mutations.    
Moreover, several of the pathways identified by this approach, such as WNT, PI3K, cell cycle and 
focal adhesion, play an important role in the regulation of neurogenesis. Therefore, they represent 
interesting candidates to investigate in the context of the phenotype presented in Chapter 4.  
Together with these, oxidative phosphorylation, which has been previously reported to be altered 
by several in vitro studies on psychiatric disorders, also appeared to be significantly affected in 
CYFIP1tg and CYFIP1ko cells at all time points (Ebrahimi-Fakhari et al., 2016; Mertens et al., 2015; 
Robicsek et al., 2013). For these reasons, neurogenesis and mitochondria-related genes were 
chosen for follow-up experiments on CYFIP1tg and CYFIP1ko lines.  
The same set of RNA-seq results is also being analysed in depth by Daniel Cabezas de la Fuente, 
another PhD student in our group. His work includes the characterisation of several aspects linked 
to the pathways illustrated in figure 5.1 (e.g. Calcium signalling), as well as the comparison between 
the transcripts altered by CYFIP1 mutations with existing databases of psychiatric disease-risk 
genes.  
 
86 
 
 
Figure 5.1 Biological processes and signalling pathways significantly affected by altered CYFIP1 
levels. 
The bar graph represents the results of KEGG enrichment gene set analysis carried out on the DEGs of each 
modified line compared to the respective parental line, for each time point. Only DEGs with an absolute fold 
change value of 1.5 were used for this analysis. A p value cut-off of 0.05 and a p-adjusted cut-off of 0.1 were 
also set. (NES, normalised enrichment score). This image was provided by Daniel Cabezas de la Fuente. 
 
5.2.2 Mechanisms underlying the neurogenesis phenotype in CYFIP1tg and 
CYFIP1ko neural cells 
(I) Neurogenesis-related genes affected by CYFIP1expression levels 
To gain further insight into the genes responsible for the abnormal neurogenesis in CYFIP1tg and 
CYFIP1ko cells, DEGs associated with the GO (Gene Ontology) term “neurogenesis” (GO:0022008) 
were selected from the NPC and neuronal data sets. For both these time points, the neurogenesis-
related genes affected by both an increase and a reduction of CYFIP1 were chosen for subsequent 
analysis (Fig. 5.2 A and B).  
This analysis revealed that, in the context of neurogenesis, the most substantial differences (highest 
fold changes and p-adjusted values) were observed at the NPC stage for the CYFIP1tg-control data 
set and at the neuronal stage for the CYIP1ko-control dataset. For both time points and datasets, 
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CYFIP1 and CYFIP2 transcripts were found to be significantly changed. They were upregulated in 
CYFIP1tg samples and downregulated in CYFIP1ko samples. In addition, WNT signalling genes, such 
as frizzled (FZD) receptors and WNT ligands, were highly represented in this data set, especially at 
the NPC stage. At the same stage, several Cadherins transcripts were also found to be altered 
(CDH1/2/4/11), as expected on the basis of the KEGG results. 
CYFIP1tg and CYFIP1ko NPCs showed opposite changes in many, but not all, genes expressed in the 
developing cortex. These included dopachrome tautomerase (DCT), expressed by VZ progenitors 
between E10.5 and E17.5 (Jiao et al., 2006), doublecortin (DCX), marking immature neuronal cells 
(Gleeson et al., 1999), LHX2, which is necessary for βCAT-driven cortical progenitor proliferation 
(Hsu et al., 2015) and forkhead box O3 (FOXO3), a downstream effector of PI3K-AKT that regulates 
proliferation and cell cycle exit of embryonic and adult neural stem cells (Paik et al., 2009; Renault 
et al., 2009; Vezzali et al., 2016). Strong upregulation of FOXG1 was also detected in CYFIP1tg NPCs 
(Fig. 5.2 A).  
At the neuronal time point, transcripts that were found to be significantly altered included many 
transcription factors involved in the fate specification of cortical neurons, Empty Spiracles 
Homeobox 1 (EMX1/2), Neurogenic differentiation 1/4 (NEUROD1/4), RELN, TBR1 and FEZF2 
(Martynoga et al., 2012; Mattar et al., 2008) (Fig. 5.2 B). Moreover, at this stage, DEGs related to 
synaptic maturation (Erb-B2 Receptor Tyrosine Kinase 4 or ERBB4, Discs Large MAGUK Scaffold 
Protein 4  or DLG4) and axonal growth and migration (Semaphorin 5A/B or SEMA5A/B) appeared 
to be also affected (El-Husseini et al. 2000; Li et al., 2007; Purohit et al., 2014; Yoshida, 2012). Finally, 
increased and decreased CYFIP1 levels also caused alterations in the expression  of several 
psychiatric disorder risk genes, such as CNTNAP2, NXRN3 , SHANK1/3 and TSC at the progenitor 
stage and NRXN1 and SHANK3 in neurons (Alarcón et al., 2008; Costales & Kolevzon, 2015; Curatolo 
et al., 2015; Gong & Wang, 2015; Reichelt et al., 2012). 
Importantly, a number of DEGs present in CYFIP1tg and CYFIP1ko datasets, such as WNT5A, FOXG1 
and CDH2, did not show the same direction of fold change. This is in part expected, as CYFIP1, 
contrarily to transcription factors, does not affect gene transcription directly. For instance, some of 
the observed changes could to be due to compensatory mechanisms activated by the cells, rather 
than being a direct consequence of CYFIP1 alterations. Nevertheless, variations in these genes 
prove the presence of a significant dysregulation of the pathways to which they belong.  
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Figure 5.2  Neurogenesis-related genes affected by abnormal CYFIP1 levels. 
Bar graphs illustrating the DEGs associated with the GO term “neurogenesis” (GO:0022008) for CYFIP1tg and 
CYFIP1ko NPCs (A) and neurons (B). The height of the bars is proportional to the gene expression fold change 
(FC) in respect to the appropriate control parental line. The colour represents the significance of the FC, 
expressed as -LOG10 of the p adjusted value (padj). 
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(II) Dysregulated Cadherin-Catenin signalling in CYFIP1tg and CYFIP1ko cells 
The analysis of the DEGs present in CYFIP1tg and CYFIP1ko data sets revealed a high representation 
of genes coding for members of the Cadherin family and genes related to WNT and PI3K-AKT 
pathways (Fig. 5.1 and 5.2). A point of convergence of these biological processes is represented by 
β-catenin (βCAT). The stabilisation of this protein in VZ progenitors requires the activation of WNT 
and AKT pathways and includes a strong contribution from NCAD, the levels of which correlate 
positively with βCAT activity (Zhang et al., 2010).  If affected, this mechanism could provide an 
explanation to the altered neurogenesis caused by CYFIP1 changes. To verify this, the amount of 
NCAD and βCAT, both active and primed for degradation, were analysed by western blot at three 
time points between the neural progenitor and neuronal stages.  
The levels of NCAD were increased in CYFIP1tg progenitors (day 18) and early neurons (day 35) 
compared to those derived from the parental line. Conversely, a lower amount of NCAD was 
detected in CYFIP1ko neural cells than in those derived from the parental line, at day 12 and 20. 
The differences in NCAD expression between CYFIP1tg or CYFIP1ko and their respective controls 
were visibly reduced at the last time point analysed (Fig. 5.3 A, B, E, F). Phosphorylation of βCAT by 
GSK3-β of the residues serine 33 and serine 37 (p-ser33/37) primes this protein for degradation, 
while phosphorylation of serine 552 (p-ser552) enhances its transcriptional activity (Fang et al., 
2007; Liu et al., 2002; Zhang et al., 2013). The amount of inactive βCAT, represented by the ratio 
between p-S33/37 βCAT over the total was reduced in CYFIP1tg early and late neurons compared 
to levels observed in the parental line (Fig. 5.3 A, C, E, G). Conversely, the quantity of active βCAT, 
expressed by the ratio between p-S552-βCAT/total βCAT was found to be generally higher in 
CYFIP1tg neural cells than in control ones. CYFIP1ko displayed overall an opposite pattern of βCAT 
phosphorylation, with a generally higher amount of p-S33/37-βCAT/ total βCAT and a lower ratio 
of active βCAT (p-ser552) in neurons of day 20 and 35 (Fig. 5.3 A, D, E, H).  Overall, these results are 
consistent with an increased activation of βCAT signalling in CYFIP1tg neural cells and a 
downregulation of βCAT signalling in CYFIP1ko cells, compared to their respective controls. 
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Figure 5.3 Western blot analysis of NCAD and βCAT in CYFIP1tg and CYFIP1ko. 
Western blots for NCAD, phosphorylated (p-S33/37 and p-S552), total βCAT and GAPDH in CYFIP1tg (A) and 
CYFIP1ko (E) cultures at three time points. These were defined as NPCs, early and mature neurons and 
corresponded to day 18, 35 and 45 for CYFIP1tg cells and to day 12, 25 and 35 for CYFIP1ko respectively. Bar 
graphs representing the quantification of NCAD (B, F), p-βCAT (S33/36) over the total βCAT (C, G) and p-βCAT 
(S552) over the total βCAT (D, H). The intensity of each band was measured with ImageJ and normalised to 
the intensity of GAPDH band on the same blot. Data represent the mean value ± SD from two technical 
replicates of two independent experiments. Expression values were compare via two-way ANOVA, followed 
by Tukey post-hoc test (*p<0.05). 
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(III) Manipulation of N-CADHERIN-mediated activation of β-catenin rescues the 
differentiation of CYFIP1tg progenitors 
The data presented above demonstrate a higher activation of the NCAD-βCAT signalling axis in 
CYFIP1tg neural cells than in those derived from the parental line H7. According to mouse 
developmental data, this alteration could be responsible for the abnormal expansion of PAX6+ 
progenitors in the overexpressing cultures. To verify this, late progenitors of day 30 CYFIP1tg and 
H7 cultures were exposed to several treatments aimed at reducing βCAT signalling activity and, 
ultimately, rescuing the delayed neurogenesis. These treatments included direct blockage of NCAD 
activity or, downstream of this, inhibition of WNT and AKT pathways, alone or in combination. The 
small molecules used for WNT and AKT inhibition were XAV939 and API2, respectively (Huang et 
al., 2009; Yang et al., 2004). NCAD blocking was achieved by incubating the cells with a specific anti-
NCAD antibody, which was used for the same purpose by several other studies on cultured mouse 
and human neural cells (Iefremova et al., 2017; Zhang et al., 2013). A control group exposed only 
to the vehicle DMSO was also included for both CYFIP1tg and H7 cells. After the treatments, the 
cells were left to mature for 5 additional days, before being fixed and stained for PAX6. The 
experimental scheme is illustrated in figure 5.4 A and B. 
The analysis of DMSO-treated cultures at the end of the experiment showed that 40% of NPCs in 
CYFIP1tg cultures were PAX6+, compared to less than 20% in the control, confirming previous results 
indicating an expansion of the PAX6+ fraction in CYFIP1tg cultures. The percentage of PAX6+ 
progenitors was still higher also in CYFIP1tg cells treated with XAV939 or API2, than in control cells 
exposed to the same molecules, showing that inhibition of WNT or AKT signalling alone had only a 
small effect on the delayed neurogenesis. However, the combination of these two treatments 
effectively lowered the number of PAX6+ CYFIP1tg NPCs to a level that was not statistically different 
from that obtained from control cells that had received the same inhibitors. Moreover, the 
percentage of PAX6+ cells present in overexpressing cultures treated with XAV939 and API2 was 
comparable to the amount of PAX6+ cells present in H7 cultures in control conditions. Finally, also 
the application of NCAD-blocking antibody resulted in a reduction of PAX6+ progenitors in CYFIP1tg 
cultures to below 30%, with no significant difference from the H7 cultures exposed to the same 
antibody (Fig. 5.4 C, D). In summary, the use of the NCAD-blocking antibody and of XAV939 and 
API2 together were the only two treatments able to normalise the levels of PAX6+ NPCs present in 
CYFIP1tg cultures, with the combination of WNT and AKT inhibition being the most successful.  
Dysregulation of the basal level of WNT signalling has been associated with an alteration of cells 
fate during in vitro differentiation, reflected in an imbalanced expression of dorsal and ventral 
telencephalic markers (Srikanth et al., 2015). Moreover, incubation of stem cells-derived neural 
92 
 
progenitors with the WNT inhibitor XAV939 is used by several protocols with the aim to ventralise 
cells during the derivation of GABAergic neurons  (Maroof et al., 2013; Nicoleau et al., 2013). 
Therefore, to ascertain that the observed reduction of PAX6+ cells was not due to a switch from 
dorsal to ventral cortical fate following XAV939 and API2 treatment, immunostaining for the 
neurotransmitter GABA was performed to quantify the number of inhibitory cells. No significant 
differences were found in the number of GABA+ cells in the vehicle treated control and CYFIP1tg 
cultures with or without WNT and AKT inhibition (Fig. 5.5).  
In conclusion, these data provide evidence that the inhibition of WNT and AKT signalling, can 
efficiently rescue the over-proliferation of PAX6+ cortical progenitors caused by high levels of 
CYFIP1, without altering the identity of the treated cells. 
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Figure 5.4 Reduction of βCAT activity downstream of NCAD rescues the delayed neurogenesis of 
CYFIP1tg cultures. 
(A) Scheme of βCAT stabilisation in VZ progenitors and the molecules used to modulate this signalling. NCAD 
stimulates AKT, which phosphorylates βCAT at the position S552, and WNT signalling, which blocks GSK3-β 
preventing its phosphorylation of βCAT. These pathways can be altered by blocking NCAD function with a 
specific antibody or by using AKT and WNT antagonists (API2 and XAV respectively). Image modified from 
Zhang et al., 2013. (B) Experimental scheme illustrating the application of the different treatments between 
day 30 and 33 of differentiation on CYFIP1tg and H7 control cultures. (C) PAX6 staining, in red, at day 38, 5 
days after the treatments, in each condition and cell line. Nuclei were counterstained with dapi (blue). (D) 
Quantification of the percentage of PAX6+ cells against the total of dapi+ nuclei. Data represent the mean 
value ± SD of three technical replicates from one experiment. The mean value for each treatment and cell line 
were compared with two-way ANOVA, followed by Tukey post-hoc test (*p<0.05, **p<0.01, ***p<0.001). 
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Figure 5.5 Quantification of GABAergic cells in CYFIP1tg and control cultures. 
(A) Staining for the neurotransmitter GABA at day 38, at the end of the rescue experiment. The staining was 
carried out in control cells in control condition (DMSO) and in CYFIP1tg cells exposed to control (DMSO) and 
XAV+API2 treatments. (B) Quantification of GABA+ cells in the same experimental conditions. Data represent 
the mean value ± SD of three technical replicates from one experiment.  No significant differences were found. 
 
5.2.3 Mitochondrial alterations in CYFIP1tg and CYFIP1ko neural cells 
(I) Mitochondria-related genes affected by CYFIP1 changes 
The KEGG pathway enrichment analysis presented in paragraph 5.2.1 highlighted a significant 
alteration of mitochondrial function in neural cells derived from CYFIP1tg and CYFIP1ko hESCs. To 
explore this aspect further, the DEGs related to mitochondrial function were analysed in more detail 
at the NPCs and neuronal stage.  
Many of the differentially expressed mitochondria-related genes, which were present in both the 
overexpression and knock-out datasets, code for enzymes forming the respiratory complexes. 
These include NADH dehydrogenase, also known as respiratory complex I (NDUFA genes), Succinate 
dehydrogenase complex subunit D (SDHD) that constitute part of Complex II, Ubiquinol-
Cytochrome C Reductase or Complex III (UQCR genes), the Cytochrome C oxydase or Complex IV 
A B 
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(COX genes) and the ATP synthase or Complex V (ATP genes). Most of these transcripts show 
opposite direction of FC in CYFIP1tg and CYFIP1ko at the NPCs stage (Fig 5.5 A), a pattern that was 
not maintained at a later time (Fig. 5.5 B).  The genes showing an opposite FC between CYFIP1tg 
and CYFIP1ko lines, at both time points, were the mitochondrial encoded genes MT-ND2/3/4/5, 
MT-CO2 and MT-APT6/8, which code for subunits of the respiratory complex I, II and V, respectively. 
Other transcripts that appeared to be affected by CYFIP1 levels were related to mitochondrial 
dynamics, such as fission, fusion and transport. These included genes for Fission, Mitochondrial 1 
(FIS1), Mitofusin 1/2 (MFN1/2), Misato 1 (MSTO1), Mitochondrial fission regulator 2 (MTFR2) and 
Mitochondrial dynamin like GTPase (OPA1). 
Together, these data show that the expression of many genes involved in the regulation of 
mitochondria metabolism and dynamics in neural cells is significantly affected by changes in CYFIP1 
levels. 
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Figure 5.6 Mitochondria-related genes affected by abnormal CYFIP1 levels. 
Bar graphs illustrating the DEGs associated with oxidative phosphorylation and mitochondria dynamics in 
CYFIP1tg and CYFIP1ko NPCs (A) and neurons (B). The height of the bars is proportional to the gene expression 
fold change (FC) in respect to the appropriate control parental line. The colour represents the significance of 
the FC, expressed as -LOG10 of the p adjusted value (padj). Genes were taken from the Human MitoCarta 2.0 
(Calvo et al., 2016). 
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(II) Disruption of mitochondrial dynamics in CYFIP1tg and CYFIP1ko neural cells 
Data presented above suggest the presence of significant changes in mitochondrial dynamics 
caused by altered levels of CYFIP1. To validate this, CYFIP1tg and CYFIP1ko NPCs and neurons were 
incubated with Mitotracker, a reagent that selectively labels the mitochondria (Cataldo et al., 2010; 
Leonard et al., 2015) (Fig. 5.6 A). The cells were then fixed and stained with Dapi and analysed on a 
high-content screening (HCS) platform for detection of intracellular “spots”, which represent 
Mitotracker-labelled mitochondria (Ghosh et al., 2005; Leonard et al., 2015). Representative images 
of Mitotracker-stained cells elaborated by the HCS software can be found in figure 5.6 B and C. This 
approach revealed the presence of significant differences in the number and size of spots. In 
particular, both the spots count and area in CYFIP1tg NPCs and neurons showed a tendency to be 
higher than those of the parental control cells, although statistical significance was only observed 
for the spots number at the progenitor stage (Fig. 5.6 D). Conversely, CYFIP1ko NPCs had less and 
smaller Mitotracker+ spots than the parental control group, but this difference was no longer 
detected in neuronal cells (Fig. 5.6 D).  
Moreover, the high-content analysis highlighted the presence of significant differences in the size 
of nuclei, with an opposite trend, in CYFIP1tg and CYFIP1ko cells compared to their respective 
controls. CYFIP1tg nuclei were significantly smaller than those of the parental control neuronal 
cells, while CYFIP1ko cell nuclei were smaller than the control at the NPCs stage but bigger at the 
neuronal stage. Overall, these results demonstrate significant alterations to mitochondrial 
dynamics and nuclear morphology in neural cells with abnormal CYFIP1 expression levels. 
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Figure 5.7 Alterations of mitochondria dynamics in CYFIP1tg and CYFIP1ko NPCs and neurons. 
(A) High magnification image of hESCs-derived NPCs stained with Mitotracker (red) and dapi, marking the 
nuclei (blue). (B) Representative field of mitotracker-stained cells elaborated by the HCS platform. Single nuclei 
are identified as primary object and the area surrounding each nucleus (delimited by green lines) is used for 
the detection of mitotracker+ spots. (C) Mitotracker+ spots (in yellow) detected in single cells. (D) 
Quantification of parameters relative to spots count, spots area and nuclei area, in arbitrary units provided 
by the HCS platform. Data are expressed as mean ± SD (N=3).  Significance was analysed by t-test (*p<0.05). 
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5.3 Discussion 
Whole-genome transcriptomic analysis was used to identify CYFIP1-mediated molecular changes in 
hESC-derived cortical cells with the aim to decipher the mechanisms responsible for the 
differentiation phenotype observed in CYFIP1tg and CYFIP1ko cells. However, the interpretation of 
these results should take into account the possibility that some gene changes may also reflect the 
different composition of the sample population, due to the altered differentiation kinetics of 
CYFIP1tg and CYFIP1ko lines presented in the previous chapter. A way to overcome this 
complication could be represented by sorting the cells samples prior to RNA-seq analysis, in order 
to separate progenitors and neuronal populations, or, after the RNA-seq, normalising mRNA 
changes to the expression levels of some stage-specific markers, such as Nestin and MAP2. Despite 
this, the transcriptomic analysis presented here helped to identify some important and novel 
pathways in which CYFIP1 is involved and provided important support to the phenotypic 
characterisation of CYFIP1-modified lines. 
First of all, CYFIP1 and CYFIP2 were the most significant DEGs, showing up- and downregulation in 
NPCs and neurons derived from CYFIP1tg and CYFIP1ko ESCs respectively. These results provided 
independent confirmation of the increased CYFIP1 levels in the overexpressing cells and of the 
decreased CYFIP1 expression in the knock-out ones, in line with the characterisation of these 
engineered lines reported in Chapter 3. With regard to CYFIP2, the regulation of its expression is 
not well characterised and previous studies report different results on the levels of this gene 
following knock-out or knock-down of CYFIP1. The reduction in CYFIP2 transcript levels in CYFIP1ko 
neural cells is in agreement with the results reported by Abekhoukh et al., showing a 
downregulation of Cyfip2 mRNA in mouse primary neurons with knock-down of Cyfip1 and in the 
blood of patients carrying 15q11.2 deletion (Abekhoukh et al., 2017). CYFIP2 has been reported to 
be one of the top-ranked FMRP targets, while CYFIP1 itself did not appear in the same list (Darnell 
et al., 2011). This suggests that CYFIP2 translation could be regulated by the FMRP-CYFIP1 complex 
and that changes in CYFIP2 transcript may be a consequence of alterations of its protein levels, as 
part of a feedback mechanism. However, other published studies did not find any change in CYFIP2 
expression following CYFIP1KD in human NPCs or in the brain of Cyfip1+/- mice (Bozdagi et al., 2012; 
Nebel et al., 2016). Future work on the regulatory network involving FMRP, CYFIP1 and CYFIP2 may 
help to explain these discrepancies. 
Another aspect providing additional support to the validity of our model is the significant 
enrichment for genes related to the regulation of actin cytoskeleton and axonal guidance in both 
CYFIP1tg and CYFIP1ko datasets (Fig. 5.1). Alterations to these pathways have also been reported 
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by other studies on in vitro and in vivo models of CYFIP1 alterations (Nebel et al., 2016; Oguro-Ando 
et al., 2014; Pathania et al., 2014). Other pathways highlighted by this analysis include the PI3K/AKT, 
cAMP and calcium signalling. PI3K/AKT alterations have been reported in FXS and SZ and are known 
to be important for dendritic branching, synaptogenesis and spine formation (Cuesto et al., 2011; 
Gross et al., 2010; Jaworski, 2005; Kalkman, 2006; Zheng et al., 2012). Moreover, modulation of this 
pathway has been proposed for pharmacological intervention for both ASD and SZ (Enriquez-
Barreto & Morales, 2016). Calcium and cAMP signalling are also fundamental in neuronal cells, 
especially in the regulation of synaptic activity and plasticity mechanisms (reviewed by Bading, 
2013). Together, these alterations confirm the relevance of the gene network affected by CYFIP1 
changes in the context of neurodevelopmental psychiatric disorders.  
In light of the phenotypic characterisation presented in Chapter 4, the signalling pathways involved 
in the regulation of neurogenesis were prioritised for a more in-depth investigation. Many of the 
DEGs affected by both the increase and loss of CYFIP1 included WNT signalling genes and adhesion 
molecules such as Cadherin proteins.  These, together with AKT, form an interconnected molecular 
system that has been previously shown to regulate the balance between proliferation and 
differentiation in the mouse cortex. According to this model, NCAD regulates βCAT stability by 
stimulating both WNT and AKT signalling, leading to an increase in βCAT-dependent transcriptional 
activation  (Zhang et al., 2010, 2013). The same signalling mechanism has been recently shown to 
be conserved in human cortex development using forebrain organoid differentiation from iPSCs 
derived from individuals with Miller-Dieker syndrome, which causes microcephaly and seizures 
amongst other symptoms (Iefremova et al., 2017). Defects in the distribution of NCAD at the 
ventricular surface and in the proliferation of NPCs in Miller-Dieker organoids were demonstrated 
to be specifically linked to decreased activity of the NCAD-βCAT signalling axis and could be rescued 
by treatment with a WNT agonist (Iefremova et al., 2017). The same pathways were found to be 
altered in CYFIP1tg and CYFIP1ko cells, as the phosphorylation pattern of βCAT by GSK3β and by 
AKT was consistent with a hyper-activation of βCAT in overexpressing cells and a downregulation 
in knock-outs. Moreover, treatment with a combination of WNT and AKT inhibitors was successful 
in rescuing the over-proliferation of PAX6 progenitors in CYFIP1tg cultures, confirming that this 
signalling cascade is specifically altered by the excess of CYFIP1.  
A likely mechanism by which CYFIP1 may be disturbing this pathway is through translational 
regulation of NCAD, AKT3 and GSK3-β that have all been reported to be FMRP targets (Darnell et 
al., 2011; La Fata et al., 2014). However, the fraction of transcriptionally active βCAT can also be 
affected by alterations to the actin cytoskeleton caused by malfunction of the WAVE complex of 
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which CYFIP1 is part. For instance, F-Actin accumulation in the nucleus has been shown to enhance 
the translocation of active βCAT to this cellular compartment (Yamazaki et al., 2016). 
Dysregulation of WNT signalling has been reported by several studies on in vitro models of 
psychiatric disorders, including ASD, SZ and BD (Brennand et al., 2011; Srikanth et al., 2015; Topol 
et al., 2015; P. Wang, Mokhtari, et al., 2015). Together with this, another aspect linking CYFIP1 
alterations to a broader spectrum of neurodevelopmental disorders is represented by changes in 
FOXG1 expression levels. FOXG1 plays a fundamental role in brain development and mutations in 
its locus are associated with severe mental retardation and microcephaly (reviewed by Florian, 
Bahi-Buisson & Bienvenu, 2012). In the context of in vitro models of psychiatric disorders, cells 
carrying DISC1 mutation were shown to have higher baseline WNT, together with downregulation 
of FOXG1 and downregulation of ventral forebrain markers (Srikanth et al., 2015). Conversely, 
upregulation of FOXG1 was reported  in cerebral organoids derived from ASD iPSCs, a defect 
specifically associated with a shift towards a more ventral identity of the differentiated cells 
(Mariani et al., 2015). Similarly, cortical progenitors with modified CYFIP1 levels showed an increase 
in the amount of FOXG1 transcript, a change that was stronger for the overexpressing line. 
However, this was not accompanied by differences in the percentage of FOXG1+ cells or changes in 
the dorso-ventral identity of the differentiated neurons, as the number of GABAergic cells in 
CYFIP1tg cultures was the same as in the controls. A reason for this may be that the increase 
observed in NPCs was only transient, as it was no longer present at the neuronal stage, when only 
a small but significant downregulation was detected by the RNA-seq analysis (data not shown).  
Finally, RNA-seq analysis revealed the presence of significant alterations in the expression of genes 
regulating mitochondria dynamics and oxidative phosphorylation. Overall, genes located in the 
nuclear DNA and coding for components of the respiratory chain showed similar levels and direction 
of FC, consistent with a co-regulation of their expression, a process controlled by signals originating 
from the mitochondria, such as the intracellular levels of Ca2+, reactive oxygen species (ROS) and 
ATP (Reinecke et al., 2009; van Waveren & Moraes, 2008).  
Changes in CYFIP1 levels seem to very specifically affect the expression of mitochondrially-encoded 
genes (MT-ATP6/8, MT-CO2, MT-ND2/3/4/5), as these show completely opposite FC pattern in 
overexpressing and knock-out cells at both the time points analysed. It has been suggested that the 
number of mitochondrial DNA (mtDNA) molecules per cell could play a role in regulating the 
transcription of mitochondrially-encoded genes. This indicates that the gene expression changes 
observed in CYFIP1tg and CYFIP1ko cells could be explained, at least in part, by different amounts 
of mitochondria or mtDNA (Reinecke et al. , 2009). Consistently with this, HCS analysis revealed 
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significant differences in several parameters related to the size and number of mitochondria 
between control NPCs and neurons and those with abnormal CYFIP1 levels.  
The mechanisms regulating the number of mitochondria or the number of mtDNA molecules are 
not well characterised (Lee & Wei, 2005; Reinecke et al., 2009). Nonetheless, it has been reported 
that mitochondrial dynamics play an important role during neural differentiation. In the mouse 
developing cortex, the commitment to neuronal differentiation is accompanied by mitochondrial 
fragmentation  and  by an increase in physiological levels of ROS, at the same time as the cells also 
undergo a metabolic switch from anaerobic to aerobic metabolism (Khacho et al., 2015). In 
addition, ROS levels have been shown to contribute to cellular signalling post-translationally, 
maintaining an appropriate level of PI3K-AKT and Notch activation, which are fundamental for self-
renewal of neural stem cells (Khacho et al., 2015; Le Belle et al., 2011). Therefore, the mitochondrial 
alterations present in CYFIP1tg and CYFIP1ko cells could contribute to the dysregulation of 
neurogenesis observed in these lines. 
Importantly, mitochondrial abnormalities were also reported in neurons derived from BD iPSCs, 
which displayed high membrane potential and decreased mitochondria size (Mertens et al., 2015) 
and in those from SZ iPSCs, which showed altered mitochondrial respiration and distribution 
(Robicsek et al., 2013). Mitochondrial homeostasis and metabolism were also affected in in vivo 
and in vitro models of tuberous sclerosis syndrome (Ebrahimi-Fakhari et al., 2016). This aspect 
represents another point of convergence between the phenotype caused by CYFIP1 mutations and 
other models of neurodevelopmental psychiatric disorders.  
Finally, the HCS analysis allowed the discovery of the presence of significant differences in the size 
of the nuclei in CYFIP1tg and CYFIP1ko NPCs and neurons. Similarly, Nebel and colleagues reported 
that nuclear size was affected also by CYFIP1KD, a phenotype that is consistent with alterations to 
the actin cytoskeleton (Jevtić et al., 2014; Nebel et al., 2016) 
In conclusion, the changes in gene expression revealed by the RNA-seq analysis confirmed the 
presence of a dysregulation of neurogenesis and supported a role for WNT and the NCAD/βCAT axis 
in the phenotype cause by CYFIP1 alterations. These, together with the changes in mitochondria 
dynamics, demonstrate the relevance of the phenotypes caused by CYFIP1 alterations in the 
context of neurodevelopmental psychiatric disorders. 
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6 General Discussion 
6.1 Summary of findings 
In this thesis, I investigated the role played by CYFIP1 during cortical differentiation of hESCs. 
CYFIP1tg and CYFIP1ko hESCs were derived to examine the consequences of increased and 
decreased levels of this gene, as both deletions and duplication of the genetic region where CYFIP1 
is located are found in psychiatric patients. NPCs derived from both lines showed deficits in the 
formation of neural rosettes and in the balance between proliferation and differentiation. In 
particular, the excess and loss of CYFIP1 had opposite consequences on this process. High levels of 
this gene were associated with an increased proliferative ability of the cortical progenitor pool, 
while the reduction of CYFIP1 was linked to premature exit from the cell cycle and neuronal 
differentiation. With the help of RNA-seq analysis, it was possible to confirm that the expression of 
a high number of genes involved in the regulation of neurogenesis was significantly affected in 
CYFIP1tg and CYFIP1ko cells. Follow up experiments, including analysis of the phosphorylation state 
of β-CAT and manipulation of the differentiation conditions, allowed to specifically link the 
neurogenesis phenotype with a malfunction of the NCAD-β-CAT signalling axis. In addition, the 
transcriptomic analysis revealed the presence of alterations to the oxidative phosphorylation 
system and to the regulation of mitochondria dynamics, which were confirmed using a platform for 
automated high-content screening. These findings uncovered a novel mechanism by which CYFIP1 
participates in the regulation of neuronal differentiation and revealed new biological functions in 
which this gene is involved. 
6.2 Convergent mechanisms in neurodevelopmental psychiatric disorders  
6.2.1 Cadherins- and Catenins-related signalling 
The analysis of the pathways dysregulated by altered levels of CYFIP1 provided interesting points 
of convergence with other in vitro and in vivo models of neurodevelopmental disorders. One of 
these aspects is represented by alterations to cadherin-dependent cell-cell adhesion. Mutations in 
genes of the Cadherins superfamily not only result in brain malformations, but they have also been 
found to increase the risk for several psychiatric diseases. For instance, deletions of the locus 
encoding CDH8 have been found in patients affected by ASD and learning disabilities (Pagnamenta 
et al., 2011) and SNPs in the proximity of CDH9 and CDH10 were identified in a ASD cohort by a 
GWAS study (Wang et al., 2009). In addition, SNPs within the sequence of CDH7 have been reported 
to increase the risk for SZ (Sklar et al., 2008; Soronen et al., 2010). These data have led, in the past, 
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to the formulation of a “cadherin hypothesis of schizophrenia”. According to this, the severe impact 
on brain development caused by alterations to the adhesion molecules system is responsible for an 
increased risk of psychiatric disorders (Yagi & Takeichi, 2000).  
As discussed in previous chapters, disruption of WNT signalling has also been reported by several 
in vitro-based studies on psychiatric disorders (Brennand et al., 2011; Srikanth et al., 2015; Topol et 
al., 2015). In addition, several in vivo models of neurodevelopmental disorders have shown an 
association between alterations in WNT signalling and the presence of behavioural defects typical 
of ASD.  A loss-of-function mutation in the dishevelled genes 1 and 3 (Dvl1-/-3-/+) in mice led to early 
differentiation of basal progenitors and expansion of deep cortical layers and resulted in the 
development of repetitive behaviour and abnormal social interaction later in life (Belinson et al., 
2016). Prenatal pharmacological activation of WNT signalling rescued both the structural and 
behavioural phenotypes (Belinson et al., 2016).  Alterations of the balance between proliferation 
and differentiation in the embryonic cortex have also been reported in another mouse model, in 
which the ASD risk gene CDH8 was knocked-down (Durak et al., 2016). Histological and 
transcriptomic analysis of this model demonstrated the presence of cell cycle and differentiation 
defects in the developing cortex. Adult mice showed decreased exploratory behaviour and 
sociability. These defects were demonstrated to be caused by a reduction of WNT activity, as 
introduction of a stabilised form of β-Catenin in the embryonic cortex completely rescued the 
phenotype (Durak et al., 2016).  
In humans, mutations involving WNT genes have been reported in a considerable number of 
psychiatric patients. These include SNPs in the sequence of WNT2 found in cohorts of ASD patients 
(Marui et al., 2010; Wassink et al., 2001) and CNVs involving the chromosomic locus containing 
FZD9, which are associated with serious developmental delay and ADHD (Merla et al., 2010; 
Sanders et al., 2011). A specific missense mutation in the WNT1 sequence, resulting in overactive 
WNT, has also been reported in ASD individuals (Martin et al., 2013). In addition, deleterious 
mutations of β-CAT have been found in SZ, ASD and ID patients (Levchenko et al., 2015; O’Roak et 
al., 2011; Tucci et al., 2014). Previous post-mortem studies also suggested alterations in the 
expression of WNT-related genes, such as WNT1 and β-CAT, in SZ brains (Cotter et al., 1998; 
Miyaoka, Seno, & Ishino, 1999). 
A number of studies showed evidence for AKT alterations in psychiatric patients. Genetic variants 
of the AKT1 gene were found to be associated with SZ in populations of various ethnicities (Bajestan 
et al., 2006; Emamian et al., 2004; Ikeda et al., 2004; Schwab et al., 2005) and specific reduction of 
AKT1 was observed in the hippocampus and cortex of SZ patients (Emamian et al., 2004). More 
105 
 
recently, SNPs in the AKT3 locus were also reported to be significantly associated with SZ in two 
recent GWAS studies (Ripke et al., 2014). 
Overall, the evidence from genetic and neuroanatomical studies, as well as from animal and in vitro 
models, converge to reinforce the hypothesis of the developmental origin of ASD and SZ and 
highlights the importance of WNT, AKT and Cadherin/Catenin signalling in their aetiology.   
6.2.2 Mitochondria alterations 
Mitochondria alterations represent another point of convergence between the phenotype 
observed in CYFIP1tg and CYFIP1ko neural cells and psychiatric disorders. Indeed, mitochondrial 
dysfunction has long been hypothesised to contribute to the pathology of ASD and SZ. 
Mitochondria-related phenotypes have been observed not only in several in vitro models of 
psychiatric disorders, as discussed in the previous chapter, but also in a number of animal models. 
For instance, two independent studies on a mouse model of Angelman syndrome showed abnormal 
levels of ROS and deficits in the structure of mitochondria, together with altered synaptic plasticity 
and performance in fear conditioning tasks (Santini et al., 2015; Su et al., 2011). Interestingly, the 
administration of a mitochondria-specific antioxidant in this model ameliorated both synaptic and 
memory phenotypes (Santini et al., 2015).  Moreover, a large body of evidence suggests that altered 
oxidative metabolism is also present in ASD patients. Lower levels of antioxidants were found in the 
urine, blood and lymphoblastoid cells of ASD subjects, when compared to control samples, and a 
recent post-mortem study detected a decreased expression of antioxidant enzymes in ASD patients’ 
brains compared to age-matched controls (Damodaran & Arumugam, 2011; Frustaci et al., 2012; 
Gu, Chauhan, & Chauhan, 2013; James et al., 2009).  In general, the prevalence of mitochondrial 
dysfunction in ASD has been estimated to be between 5% and 80%, depending on the measure 
used. Despite the variation, the level of prevalence is significantly higher than that of the general 
population (0.01%) (Giulivi et al., 2010; Rossignol & Frye, 2012). Moreover, the presence of 
mitochondrial disease in ASD patients correlates with the existence of other physiological 
abnormalities, such as motor delay and seizures (Rossignol & Frye, 2012). 
A popular theory for the aetiology of ASD is represented by the imbalance between the excitatory 
and inhibitory neuron activities in the affected brain (Canitano & Pallagrosi, 2017; Marín, 2012). 
Interestingly, mitochondrial deficits could affect the development and function of inhibitory 
interneurons more seriously than excitatory neurons. A recent study showed that, in the mouse 
embryonic cortex, pharmacological or genetic disruption of the oxidative phosphorylation process 
has very severe effects on the tangential migration of MGE-derived cortical interneurons, while the 
radial migration of developing pyramidal neurons was not significantly affected (Lin-Hendel et al., 
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2016). Moreover, fast-spiking parvalbumin+ interneurons are particularly rich in mitochondria and 
have high energy requirements, which are considered critical to sustain the typical high-frequency 
generation of action potentials (reviewed by Kann, Papageorgiou, & Draguhn, 2014). In line with 
this, deletion of the cytochrome oxidase gene in mice resulted in severe electrophysiological 
abnormalities in these cells consistent with increased excitatory activity in the circuit. These mice 
also displayed social and behavioural abnormalities, similar to those observed in other SZ and ASD 
models (Inan et al., 2016). 
Disruption of the excitation/inhibition balance has also been proposed to play an important role in 
the aetiology of SZ, making mitochondria dysfunction very relevant in the context of this disorder 
as well (Marín, 2012). In line with this, several post-mortem studies on SZ brains reported evidence 
of a reduction in mitochondrial number and/or functionality. The defects observed included a 
decreased number of mitochondria in layer 5/6 pyramidal neurons, altered expression of COX 
subunits in dopaminergic neurons and a significant alteration of mitochondria-related transcripts 
and proteins in the prefrontal cortex of SZ patients (Prabakaran et al., 2004; Rice et al., 2014; 
Roberts et al., 2015). Furthermore, evidence of decreased mitochondrial function has been found 
in the platelets of SZ subjects (Dror et al., 2002). In some cases, mitochondrial dysfunction could be 
secondary to other abnormalities, such as immune dysfunction or aberrant calcium homeostasis, 
nonetheless it represents a very common feature, present in a high number of ASD and SZ patients 
(Frye & Rossignol, 2011).  
In conclusion, the phenotypes caused by altered levels of CYFIP1 appear to have a significant degree 
of overlap with several mechanisms at the origin of psychiatric disorders, supporting the view that 
abnormal levels of CYFIP1 expression play a major role in the clinical manifestations observed in 
15q11.2 CNVs carriers. 
6.3 Future directions 
Disruption of the normal levels of CYFIP1 have been demonstrated to have a severe impact on the 
balance between proliferation and differentiation of cortical progenitor cells. However, alterations 
of the pathways regulating this process also have important implications at later stages of brain 
development, due to their involvement in neuronal migration and synapse formation. For instance, 
Cadherins are involved in synaptic adhesion and function. In particular, NCAD has been shown to 
be abundant at the contact sites between the filopodia, protruding from dendrites, and the axons 
(Hirano & Takeichi, 2012; Togashi et al., 2002). Moreover, NCAD-β-CAT complexes can bind to 
AMPA receptors in vivo and the amount of NCAD regulates the level of surface expression of these 
receptors (Nuriya & Huganir, 2006). In line with the strict connection between Cadherin-mediated 
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adhesion and WNT signalling, a number of WNT ligands has been demonstrated to be fundamental 
in the process of synaptogenesis, as well as for axonal and dendrite morphogenesis (Salinas & Zou, 
2008). Together, these aspects suggest that the analysis of morphological and electrophysiological 
properties of CYFIP1tg and CYFIP1ko neuronal cells is also necessary and could provide additional 
information about the contribution of this gene to the development of psychiatric symptoms. The 
need for this analysis is further supported by the presence of morphological and synaptic deficits in 
mice with Cyfip1 mutations (Oguro-Ando et al., 2014; Pathania et al., 2014). 
Another important aspect that should be examined using CYFIP1tg and CYFIP1ko hESCs is their 
differentiation into cortical inhibitory interneurons. Gene expression databases of mouse 
development show that CYFIP1 is expressed in the VZ of the MGE (Eurexpress.org), indicating that 
changes in the levels of this gene could potentially affect the development of this class of neurons. 
Moreover, as discussed above, cortical interneurons are more vulnerable to mitochondrial 
alterations, suggesting that the consequences of CYFIP1 loss- or gain-of function could be even 
more dramatic than those observed in pyramidal cells.  
Finally, to have a better understanding of CYFIP1’s role in the context of 15q11.2-related disorders, 
the investigation of neuronal cells derived from iPSCs carrying 15q11.2 CNVs is also necessary. 
Preliminary experiments on 15q11.2-deleted iPSCs showed that NIPA2 is expressed in developing 
neural cells and its level is reduced in neurons derived from 15q11.2del iPSCs. Therefore, NIPA2 
could potentially play a role in brain development. The importance of this and the other 15q11.2 
genes in the context of neurodevelopmental disorders can only be determined by analysing the 
phenotype of isogenic cell lines carrying mutations of one or multiple genes at a time.  Experiments 
addressing these questions, including transcriptomic characterisation of 15q11.2-deleted neural 
cells and generation of lentiviral vectors for the knock-out of the genes located in this region, are 
currently ongoing in our group. 
At the same time, we are carrying out an in-depth analysis of the RNA-seq data derived from 
CYFIP1tg and CYFIP1ko cells. This includes determining the degree of correlation between the 
transcriptome changes linked to CYFIP1 alterations and the network of genes affected by common 
variants in SZ patients, using the CLOZUK and SZ2 databases (Ripke et al., 2014). The same analysis 
will be done on the data set of DEGs found in 15q11.2-deleted neural progenitors and neurons. The 
comparison between the results obtained from patients’ iPSCs and CYFIP1 isogenic hESCs will 
provide significant information about the degree of CYFIP1 contribution towards the psychiatric 
phenotypes found in 15q11.2 CNVs carriers.  
Lastly, we will be able to compare the transcriptomic signature of the cells used in this study with 
those obtained from other in vitro models of neurodevelopmental disorders developed in our 
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group. These include iPSCs carrying 22q11.2 deletion, a mutation strongly associated with an 
increased risk of SZ (Murphy, Jones, & Owen, 1999; Stefansson et al., 2008), and hESCs with knock-
out of the Set Binding Protein 1 (SETBP1). Loss-of-function of this gene is strongly associated with 
ASD, intellectual disability and various congenital malformations (Coe et al., 2014; Roak et al., 
2012). The investigation of altered mechanisms shared between the different models will help, with 
time, to gain a deeper understanding of the link between genetic risk factors and psychiatric 
phenotypes. 
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